

Structure of an HIV gp120 envelope glycoprotein in complex with a neutralizing human antibody

Nature

393, 648-659

DOI: [10.1038/31405](https://doi.org/10.1038/31405)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Effect of Low-Profile Serine Substitutions in the V3 Loop of HIV-1 gp120 IIIIB/LAI on the Immunogenicity of the Envelope Protein. <i>Virology</i> , 1998, 251, 59-70.	1.1	1
2	Envelope's letters boxed into shape. <i>Nature</i> , 1998, 393, 630-631.	13.7	44
3	Thermal noise. <i>Nature</i> , 1998, 393, 631-631.	13.7	0
4	The antigenic structure of the HIV gp120 envelope glycoprotein. <i>Nature</i> , 1998, 393, 705-711.	13.7	1,152
5	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. <i>Nature Medicine</i> , 1998, 4, 1302-1307.	15.2	985
6	And the Best Picture is " the HIV gp120 envelope, please!. <i>Nature Structural and Molecular Biology</i> , 1998, 5, 671-674.	3.6	4
7	HIV gp120: double lock strategy foils host defences. <i>Structure</i> , 1998, 6, 945-949.	1.6	33
9	HIV Preparing for HIV vaccines that induce cytotoxic T lymphocytes. <i>Current Opinion in Immunology</i> , 1998, 10, 379-381.	2.4	4
10	Chemokine Receptors and their Crucial Role in Human Immunodeficiency Virus Infection: Major Breakthroughs in HIV Research. <i>Scandinavian Journal of Immunology</i> , 1998, 48, 339-346.	1.3	19
11	The envelope please. <i>Trends in Microbiology</i> , 1998, 6, 306.	3.5	3
12	NMR Studies on the Conformation of the CD4 36~59 Peptide Bound to HIV-1 gp120. <i>Biochemistry</i> , 1998, 37, 10616-10625.	1.2	13
13	The HIV-Inactivating Protein, Cyanovirin-N, Does Not Block gp120-Mediated Virus-to-Cell Binding. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 841-845.	1.0	33
14	Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 15613-15617.	3.3	507
15	Affinity Capillary Electrophoresis: From Binding Measurement to Combinatorial Library Screening. <i>Journal of the Chinese Chemical Society</i> , 1998, 45, 713-720.	0.8	6
16	Science, medicine, and the future: Infection with HIV-1. <i>BMJ: British Medical Journal</i> , 1998, 317, 1297-1301.	2.4	14
17	Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140. <i>Journal of Virology</i> , 1998, 72, 9656-9667.	1.5	36
18	A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1 α chemokine binding. <i>FASEB Journal</i> , 1999, 13, 503-511.	0.2	5
19	Primary Human Immunodeficiency Virus Type 2 (HIV-2) Isolates Infect CD4-Negative Cells via CCR5 and CXCR4: Comparison with HIV-1 and Simian Immunodeficiency Virus and Relevance to Cell Tropism In Vivo. <i>Journal of Virology</i> , 1999, 73, 7795-7804.	1.5	142

#	ARTICLE	IF	CITATIONS
20	Human Erythrocyte Glycosphingolipids as Alternative Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1) Entry: Evidence for CD4-Induced Interactions between HIV-1 gp120 and Reconstituted Membrane Microdomains of Glycosphingolipids (Gb3 and GM3). <i>Journal of Virology</i> , 1999, 73, 5244-5248.	1.5	133
21	Inhibition of Human Immunodeficiency Virus Type 1 Infectivity by the gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion. <i>Journal of Virology</i> , 1999, 73, 8578-8586.	1.5	80
22	Role Of Chemokine Receptors In Hiv-1 Infection And Pathogenesis. <i>Advances in Virus Research</i> , 1999, 52, 233-267.	0.9	27
24	Human Immunodeficiency Virus Type 1 Entry and Chemokine Receptors: A New Therapeutic Target. <i>Antiviral Chemistry and Chemotherapy</i> , 1999, 10, 53-62.	0.3	17
25	Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 13091-13096.	3.3	155
26	Enhanced Expression, Native Purification, and Characterization of CCR5, a Principal HIV-1 Coreceptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 28745-28750.	1.6	127
27	A Convenient Oxidation of Natural Glycosphingolipids to Their α -Ceramide Acids for Neoglycoconjugation. <i>Journal of Biological Chemistry</i> , 1999, 274, 20725-20732.	1.6	24
28	Evolutionary Conservation of the Membrane Fusion Machine. <i>IUBMB Life</i> , 1999, 48, 151-156.	1.5	6
29	Role of the HIV Type 1 Glycoprotein 120 V3 Loop in Determining Coreceptor Usage. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 731-743.	0.5	36
30	Extracellular Cysteines of CCR5 Are Required for Chemokine Binding, but Dispensable for HIV-1 Coreceptor Activity. <i>Journal of Biological Chemistry</i> , 1999, 274, 18902-18908.	1.6	104
31	Probability Analysis of Variational Crystallization and Its Application to gp120, The Exterior Envelope Glycoprotein of Type 1 Human Immunodeficiency Virus (HIV-1). <i>Journal of Biological Chemistry</i> , 1999, 274, 4115-4123.	1.6	106
32	The V3 Loop-Mimicking Pseudopeptide 5[K psi(CH2N)PR]- TASP Inhibits HIV Infection in Primary Macrophage Cultures. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 381-390.	0.5	17
34	Coreceptor Ligand Inhibition of Fetal Brain Cell Infection by HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 989-1000.	0.5	18
36	HIV-1 envelope determinants for cell tropism and chemokine receptor use. <i>Molecular Membrane Biology</i> , 1999, 16, 57-65.	2.0	100
37	Structural basis for membrane fusion by enveloped viruses. <i>Molecular Membrane Biology</i> , 1999, 16, 3-9.	2.0	349
38	A Critical Site in the Core of the CCR5 Chemokine Receptor Required for Binding and Infectivity of Human Immunodeficiency Virus Type 1. <i>Journal of Biological Chemistry</i> , 1999, 274, 1905-1913.	1.6	81
39	Constitutive cell surface association between CD4 and CCR5. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7496-7501.	3.3	169
40	Marked Increase in Anti-HIV Activity, as Well as Inhibitory Activity against HIV Entry Mediated by CXCR4, Linked to Enhancement of the Binding Ability of Tachyplesin Analogs to CXCR4. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 419-427.	0.5	44

#	ARTICLE	IF	CITATIONS
41	Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1157-1170.	1.9	11
42	Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: Therapeutic and prophylactic implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 4558-4562.	3.3	55
43	Metastability in the Inhibitory Mechanism of Human α_1 -Antitrypsin. <i>Journal of Biological Chemistry</i> , 1999, 274, 11072-11077.	1.6	59
44	Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 6359-6364.	3.3	256
45	Methods for X-ray diffraction analysis of macromolecular structures. <i>Current Opinion in Chemical Biology</i> , 1999, 3, 525-529.	2.8	10
46	Structural and functional characterization of an epitope in the conserved C-terminal region of HIV-1 gp120. <i>Chemical Biology and Drug Design</i> , 1999, 54, 32-42.	1.2	25
47	Copper(II) dipeptide complexes containing an acidic and a basic amino acid residue. Side chain effects on structures and stabilities. <i>Journal of Inorganic Biochemistry</i> , 1999, 73, 203-213.	1.5	30
48	The role of the viral glycoprotein in HIV-1 persistence. <i>Immunology Letters</i> , 1999, 65, 63-70.	1.1	5
49	Antibody neutralization of HIV-1 and the potential for vaccine design. <i>Immunology Letters</i> , 1999, 66, 143-149.	1.1	31
50	Use of cryoprotectants in combination with immiscible oils for flash cooling macromolecular crystals. <i>Journal of Applied Crystallography</i> , 1999, 32, 102-105.	1.9	32
51	A gentle vapor-diffusion technique for cross-linking of protein crystals for cryocrystallography. <i>Journal of Applied Crystallography</i> , 1999, 32, 106-112.	1.9	90
52	Interactions of HIV-1 with antigen-presenting cells. <i>Immunology and Cell Biology</i> , 1999, 77, 289-303.	1.0	9
53	Strategies used by human immunodeficiency virus that allow persistent viral replication. <i>Nature Medicine</i> , 1999, 5, 723-725.	15.2	58
54	Chemokine receptor trafficking and viral replication. <i>Immunological Reviews</i> , 1999, 168, 33-49.	2.8	73
55	A banner year for membranes. , 1999, 6, 1-2.		6
56	Solid-state NMR evidence for an antibody-dependent conformation of the V3 loop of HIV-1 gp120. <i>Nature Structural Biology</i> , 1999, 6, 141-145.	9.7	78
57	A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1 gp120 V3 peptide. <i>Nature Structural Biology</i> , 1999, 6, 331-335.	9.7	54
58	Structural and Functional Studies of the Measles Virus Hemagglutinin: Identification of a Novel Site Required for CD46 Interaction. <i>Virology</i> , 1999, 256, 142-151.	1.1	38

#	ARTICLE	IF	CITATIONS
59	Role of the Leukocyte Function Antigen-1 Conformational State in the Process of Human Immunodeficiency Virus Type 1-Mediated Syncytium Formation and Virus Infection. <i>Virology</i> , 1999, 257, 228-238.	1.1	33
60	Use of Site-Specific Mutagenesis and Monoclonal Antibodies to Map Regions of CD46 That Interact with Measles Virus H Protein. <i>Virology</i> , 1999, 258, 314-326.	1.1	27
61	Prediction of Three-Dimensional Structure and Mapping of Conformational Epitopes of Envelope Glycoprotein of Japanese Encephalitis Virus. <i>Virology</i> , 1999, 261, 31-42.	1.1	101
62	HIV-1 Evolves into a Nonsyncytium-Inducing Virus upon Prolonged Culture in Vitro. <i>Virology</i> , 1999, 263, 55-69.	1.1	20
63	Fatal Immunopathogenesis by SIV/HIV-1 (SHIV) Containing a Variant Form of the HIV-1sf33 env Gene in Juvenile and Newborn Rhesus Macaques. <i>Virology</i> , 1999, 263, 112-127.	1.1	47
64	KSHV strains: the origins and global spread of the virus. <i>Seminars in Cancer Biology</i> , 1999, 9, 187-199.	4.3	98
65	Characterization of Conformation-Dependent Anti-gp120 Murine Monoclonal Antibodies Produced by Immunization with Monomeric and Oligomeric Human Immunodeficiency Virus Type 1 Envelope Proteins. <i>Virology</i> , 1999, 254, 257-267.	1.1	18
66	Relationship between Productive HIV-1 Infection of Macrophages and CCR5 Utilization. <i>Virology</i> , 1999, 264, 278-288.	1.1	20
67	The protein data bank. Bridging the gap between the sequence and 3D structure world. <i>Genetica</i> , 1999, 106, 149-158.	0.5	35
68	Evolutionary Conservation of the Membrane Fusion Machine. <i>IUBMB Life</i> , 1999, 48, 151-156.	1.5	8
69	Crystal structure of two CD46 domains reveals an extended measles virus-binding surface. <i>EMBO Journal</i> , 1999, 18, 2911-2922.	3.5	143
70	Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection. <i>Advanced Drug Delivery Reviews</i> , 1999, 39, 63-80.	6.6	23
71	Transport, metabolism and elimination mechanisms of anti-HIV agents. <i>Advanced Drug Delivery Reviews</i> , 1999, 39, 81-103.	6.6	75
72	Towards the structure of the human immunodeficiency virus: divide and conquer?. <i>Current Opinion in Structural Biology</i> , 1999, 9, 231-243.	2.6	37
73	Development of Internet-based multimedia applications. <i>Trends in Biochemical Sciences</i> , 1999, 24, 321-324.	3.7	3
74	Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing Fabs. <i>Structure</i> , 1999, 7, 131-142.	1.6	145
75	Purification of receptor complexes of interleukin-10. Stoichiometry and the importance of deglycosylation in their crystallization. <i>FEBS Journal</i> , 1999, 262, 134-141.	0.2	12
76	Molecular dynamics study of the proposed β -hairpin form of the switch domain from HIV1 gp120 alone and complexed with an inhibitor of CD4 binding. , 1999, 34, 197-205.		5

#	ARTICLE	IF	CITATIONS
77	High-resolution structures of scytalone dehydratase-inhibitor complexes crystallized at physiological pH. , 1999, 35, 425-439.		35
78	Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides. <i>Proteins: Structure, Function and Bioinformatics</i> , 1999, 36, 217-227.	1.5	48
79	Active concentration measurements of recombinant biomolecules using biosensor technology. <i>Journal of Molecular Recognition</i> , 1999, 12, 300-309.	1.1	35
80	Lentivirus Replication and Regulation. <i>Annual Review of Genetics</i> , 1999, 33, 133-170.	3.2	105
81	Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 10842-10847.	3.3	90
83	Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing Adenoviridae. <i>Science</i> , 1999, 286, 1568-1571.	6.0	391
84	Structural Analysis of the Mechanism of Adenovirus Binding to Its Human Cellular Receptor, CAR. <i>Science</i> , 1999, 286, 1579-1583.	6.0	400
85	An Unusual HIV Type 1 env Sequence Embedded in a Mosaic Virus from Cameroon: Identification of a New env Clade. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1585-1589.	0.5	24
86	HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. <i>Molecular Membrane Biology</i> , 1999, 16, 49-55.	2.0	47
87	HIV-1 attachment: another look. <i>Trends in Microbiology</i> , 1999, 7, 144-149.	3.5	223
88	Inhibition of M-tropic HIV-1 infection by the fd phage-gene 3 protein with MIP-1 β -binding activity. <i>Molecular Immunology</i> , 1999, 36, 1249-1254.	1.0	6
89	Definition of the I β 2 region of HLA-DR molecules involved in CD4 binding. <i>Human Immunology</i> , 1999, 60, 273-281.	1.2	12
90	Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses. <i>Vaccine</i> , 1999, 17, 1425-1433.	1.7	19
91	A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. <i>Vaccine</i> , 1999, 17, 2392-2399.	1.7	14
92	AIDS and HIV vaccines. <i>Vaccine</i> , 1999, 17, S65-S70.	1.7	19
93	AIDS and the brain: is there a chemokine connection?. <i>Trends in Neurosciences</i> , 1999, 22, 471-479.	4.2	138
94	Targeting of HIV gp120 by oligonucleotide-photosensitizer conjugates. <i>FEBS Letters</i> , 1999, 462, 467-471.	1.3	6
95	Inhibiting HIV-1 Entry. <i>Cell</i> , 1999, 99, 103-115.	13.5	459

#	ARTICLE	IF	CITATIONS
96	Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry. <i>Cell</i> , 1999, 96, 667-676.	13.5	658
97	HIV-1 Entry Inhibitors in the Side Pocket. <i>Cell</i> , 1999, 99, 243-246.	13.5	94
98	STRUCTURAL BASIS OF T CELL RECOGNITION. <i>Annual Review of Immunology</i> , 1999, 17, 369-397.	9.5	488
99	Synthesis and Anti-HIV Activity of Cosalane Analogues with Substituted Benzoic Acid Rings Attached to the Pharmacophore through Methylene and Amide Linkers. <i>Journal of Organic Chemistry</i> , 1999, 64, 5858-5866.	1.7	14
100	Synthetic peptides as vaccines. <i>Laboratory Techniques in Biochemistry and Molecular Biology / Edited By T S Work [and] E Work</i> , 1999, , 281-317.	0.2	13
101	Conformational Changes of gp120 in Epitopes near the CCR5 Binding Site Are Induced by CD4 and a CD4 Mini-protein Mimetic. <i>Biochemistry</i> , 1999, 38, 9405-9416.	1.2	96
102	Trimerization Specificity in HIV-1 gp41: Analysis with a GCN4 Leucine Zipper Model. <i>Biochemistry</i> , 1999, 38, 5378-5385.	1.2	55
103	Characterization of the Noncovalent Complex of Human Immunodeficiency Virus Glycoprotein 120 with Its Cellular Receptor CD4 by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. <i>Biochemistry</i> , 1999, 38, 11734-11740.	1.2	38
104	CHEMOKINE RECEPTORS AS HIV-1 CORECEPTORS: Roles in Viral Entry, Tropism, and Disease. <i>Annual Review of Immunology</i> , 1999, 17, 657-700.	9.5	2,044
105	Structural biology of HIV 1 Edited by P. E. Wright. <i>Journal of Molecular Biology</i> , 1999, 285, 1-32.	2.0	351
106	The Crystal Structure of the SIV gp41 Ectodomain at 1.47 Å... Resolution. <i>Journal of Structural Biology</i> , 1999, 126, 131-144.	1.3	122
107	Binding of Soluble Recombinant HIV Envelope Glycoprotein, rgp120, Induces Conformational Changes in the Cellular Membrane-Anchored CD4 Molecule. <i>Biochemical and Biophysical Research Communications</i> , 1999, 265, 428-433.	1.0	12
108	Peptide T Blocks GP120/CCR5 Chemokine Receptor-Mediated Chemotaxis. <i>Clinical Immunology</i> , 1999, 93, 124-131.	1.4	33
109	BiP-binding Sequences in HIV gp160. <i>Journal of Biological Chemistry</i> , 1999, 274, 29850-29857.	1.6	49
110	Few Clues for AIDS Vaccines From Structural Data on gp120 and Its Receptors and Antibodies. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 315-316.	0.3	1
111	What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective. <i>Aids</i> , 1999, 13, 873-881.	1.0	88
112	Chemically Induced Infection of CD4-Negative HeLa Cells with HIV-1. <i>Microbiology and Immunology</i> , 1999, 43, 1077-1086.	0.7	3
113	Reconstitution of Sphingolipid-Cholesterol Plasma Membrane Microdomains for Studies of Virus-Glycolipid Interactions. <i>Methods in Enzymology</i> , 2000, 312, 495-506.	0.4	14

#	ARTICLE	IF	CITATIONS
114	Hijacked receptors. <i>Pharmacochemistry Library</i> , 2000, 31, 287-290.	0.1	0
115	Evolution of the Human Immunodeficiency Virus Type 1 Envelope during Infection Reveals Molecular Corollaries of Specificity for Coreceptor Utilization and AIDS Pathogenesis. <i>Journal of Virology</i> , 2000, 74, 11858-11872.	1.5	68
116	Sj-FABPc fatty-acid-binding protein of the human blood fluke <i>Schistosoma japonicum</i> : structural and functional characterization and unusual solvent exposure of a portal-proximal tryptophan residue. <i>Biochemical Journal</i> , 2000, 349, 377.	1.7	18
117	Sj-FABPc fatty-acid-binding protein of the human blood fluke <i>Schistosoma japonicum</i> : structural and functional characterization and unusual solvent exposure of a portal-proximal tryptophan residue. <i>Biochemical Journal</i> , 2000, 349, 377-384.	1.7	32
118	Assessment of HIV vaccine development: Past, present, and future. <i>Advances in Pharmacology</i> , 2000, 49, 263-314.	1.2	4
119	The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. <i>Aids</i> , 2000, 14, 931-938.	1.0	28
120	Detection of IgA-binding Sites on Human Immunodeficiency Virus Type-1 Envelope Glycoproteins, Gp120 and Gp41. <i>Microbiology and Immunology</i> , 2000, 44, 923-929.	0.7	4
121	Monoclonal antibody screening of a phage-displayed random peptide library reveals mimotopes of chemokine receptor CCR5: implications for the tertiary structure of the receptor and for an N-terminal binding site for HIV-1 gp120. <i>European Journal of Immunology</i> , 2000, 30, 1162-1171.	1.6	25
122	AIDS in an HIV-seronegative Ghanaian woman with intersubtype A/G recombinant HIV-1 infection. <i>Journal of Medical Virology</i> , 2000, 62, 1-8.	2.5	43
123	Evaluation of the Binding between Potential Anti-HIV DNA-Based Drugs and Viral Envelope Glycoprotein gp120 by Capillary Electrophoresis with Laser-Induced Fluorescence Detection. <i>Analytical Biochemistry</i> , 2000, 284, 334-341.	1.1	24
124	Helper T-cell Epitope Immunodominance Associated with Structurally Stable Segments of Hen Egg Lysozyme and HIV gp120. <i>Journal of Theoretical Biology</i> , 2000, 203, 189-201.	0.8	24
125	A new vector-search rotation function: image-seeking functions revisited in macromolecular crystallography. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2000, 56, 735-746.	2.5	1
126	A model of a gp120-fv3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints. <i>FEBS Journal</i> , 2000, 267, 767-779.	0.2	15
127	Engineering Novel Bioactive Mini-Proteins on Natural Scaffolds. <i>Tetrahedron</i> , 2000, 56, 9451-9460.	1.0	16
128	Selective and facile cyclization of N-chloroacetylated peptides from the C4 domain of HIV Gp120 in LiCl/DMF solvent systems. <i>Chemical Biology and Drug Design</i> , 2000, 56, 115-120.	1.2	10
129	Turning a corner on HIV neutralization?. <i>Microbes and Infection</i> , 2000, 2, 213-221.	1.0	10
130	Expression, purification and biological properties of the carboxyl half part of the HTLV-I surface envelope glycoprotein. <i>Biomedical Applications</i> , 2000, 737, 85-95.	1.7	1
131	Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?. <i>Nature Medicine</i> , 2000, 6, 123-125.	15.2	57

#	ARTICLE	IF	CITATIONS
132	Rational design of cytotoxic T-cell inhibitors. <i>Nature Biotechnology</i> , 2000, 18, 984-988.	9.4	7
133	New targets for inhibitors of HIV-1 replication. <i>Nature Reviews Molecular Cell Biology</i> , 2000, 1, 40-49.	16.1	158
134	HIV-1 entry – an expanding portal for drug discovery. <i>Drug Discovery Today</i> , 2000, 5, 183-194.	3.2	71
135	Maturation of HIV envelope glycoprotein precursors by cellular endoproteases. <i>BBA - Biomembranes</i> , 2000, 1469, 121-132.	7.9	118
136	A novel cell-free translation/glycosylation system prepared from insect cells. <i>Journal of Bioscience and Bioengineering</i> , 2000, 90, 508-514.	1.1	31
137	Extracellular iron: a signal that can be sensed and transduced in bacteria. <i>Trends in Biochemical Sciences</i> , 2000, 25, 643-644.	3.7	0
138	Reducing (oxidative) stress: structure and mechanism. <i>Trends in Biochemical Sciences</i> , 2000, 25, 643.	3.7	0
139	Synchrotron crystallography. <i>Trends in Biochemical Sciences</i> , 2000, 25, 637-643.	3.7	121
140	NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding. <i>Structure</i> , 2000, 8, 385-395.	1.6	56
141	Structures of HIV-1 gp120 Envelope Glycoproteins from Laboratory-Adapted and Primary Isolates. <i>Structure</i> , 2000, 8, 1329-1339.	1.6	358
142	Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis. , 2000, 86, 201-215.		24
143	Structure analysis of CCR5 from human and primates. <i>Computational and Theoretical Chemistry</i> , 2000, 505, 199-210.	1.5	5
144	Hijacked receptors. <i>Pharmaceutica Acta Helveticae</i> , 2000, 74, 287-290.	1.2	3
145	Research on anti-HIV-1 agents. Investigation on the CD4-Suradista binding mode through docking experiments. <i>Journal of Computer-Aided Molecular Design</i> , 2000, 14, 355-368.	1.3	7
146	Probing hydrogen bonds in the antibody-bound HIV-1 gp120 V3 loop by solid state NMR REDOR measurements. <i>Journal of Biomolecular NMR</i> , 2000, 16, 313-327.	1.6	26
147	Cell Recognition and Entry by Rhino- and Enteroviruses. <i>Virology</i> , 2000, 269, 239-247.	1.1	62
148	Entry of R5X4 and X4 Human Immunodeficiency Virus Type 1 Strains Is Mediated by Negatively Charged and Tyrosine Residues in the Amino-Terminal Domain and the Second Extracellular Loop of CXCR4. <i>Virology</i> , 2000, 271, 240-247.	1.1	54
149	Evaluation of Immune Responses Induced by HIV-1 gp120 in Rhesus Macaques: Effect of Vaccination on Challenge with Pathogenic Strains of Homologous and Heterologous Simian Human Immunodeficiency Viruses. <i>Virology</i> , 2000, 274, 149-164.	1.1	30

#	ARTICLE	IF	CITATIONS
150	CD46 as a Measles Receptor: Form Follows Function. <i>Virology</i> , 2000, 274, 5-10.	1.1	35
151	Rotavirus Infection of MA104 Cells Is Inhibited by Ricinus Lectin and Separately Expressed Single Binding Domains. <i>Virology</i> , 2000, 275, 89-97.	1.1	60
152	Inhibition of CCR5-Dependent HIV-1 Infection by Hairpin Ribozyme Gene Therapy against CC-Chemokine Receptor 5. <i>Virology</i> , 2000, 276, 271-278.	1.1	57
153	Beyond Receptor Expression: The Influence of Receptor Conformation, Density, and Affinity in HIV-1 Infection. <i>Virology</i> , 2000, 276, 229-237.	1.1	171
154	Distinct cellular receptor interactions in poliovirus and rhinoviruses. <i>EMBO Journal</i> , 2000, 19, 1207-1216.	3.5	118
155	Receptor recognition by a hepatitis B virus reveals a novel mode of high affinity virus-receptor interaction. <i>EMBO Journal</i> , 2000, 19, 1217-1227.	3.5	52
156	Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin. <i>Annual Review of Biochemistry</i> , 2000, 69, 531-569.	5.0	2,369
157	Sticky-finger interaction sites on cytosolic lipid-binding proteins?. <i>Cellular and Molecular Life Sciences</i> , 2000, 57, 1379-1387.	2.4	12
158	Analysis of the Interaction between the HIV-Inactivating Protein Cyanovirin-N and Soluble Forms of the Envelope Glycoproteins gp120 and gp41. <i>Molecular Pharmacology</i> , 2000, 58, 982-992.	1.0	68
159	Identification of gp120 Regions Targeted by a Highly Potent Neutralizing Antiserum Elicited in a Chimpanzee Inoculated with a Primary Human Immunodeficiency Virus Type 1 Isolate. <i>Journal of Virology</i> , 2000, 74, 9749-9754.	1.5	30
160	HIV Infections: The Global Epidemiology and Goals for Vaccine Research. <i>Molecular Medicine</i> , 2000, 6, 69-85.	1.9	4
161	Vaccines for HIV. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 1179-1188.	2.4	3
162	Immunogenicity of a Vaccine Preparation Representing the Variable Regions of the HIV Type 1 Envelope Glycoprotein. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 153-161.	0.5	22
163	Docking of Peptide-T onto the D1 Domain of the CD4 Receptor. <i>Journal of Biomolecular Structure and Dynamics</i> , 2000, 17, 725-733.	2.0	0
164	A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure. <i>Journal of Virology</i> , 2000, 74, 627-643.	1.5	503
165	Enhanced Binding of Antibodies to Neutralization Epitopes following Thermal and Chemical Inactivation of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2000, 74, 5802-5809.	1.5	21
166	Processing, Stability, and Receptor Binding Properties of Oligomeric Envelope Glycoprotein from a Primary HIV-1 Isolate. <i>Journal of Biological Chemistry</i> , 2000, 275, 35137-35145.	1.6	50
167	Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120. <i>Journal of Virology</i> , 2000, 74, 8358-8367.	1.5	714

#	ARTICLE	IF	CITATIONS
168	Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses. <i>Journal of Virology</i> , 2000, 74, 4562-4569.	1.5	194
169	The Binding of a Glycoprotein 120 V3 Loop Peptide to HIV-1 Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2000, 275, 36645-36652.	1.6	20
170	Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2000, 74, 1961-1972.	1.5	248
171	Selective Interactions of Polyanions with Basic Surfaces on Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2000, 74, 1948-1960.	1.5	285
172	Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 12794-12799.	3.3	61
173	Preparation and Crystallization of Dynamic NF- κ B Complexes. <i>Journal of Biological Chemistry</i> , 2000, 275, 32800-32806.	1.6	16
174	Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 5762-5767.	3.3	182
175	HIV-1 gp120 Induces IL-4 and IL-13 Release from Human Fc μ RI+ Cells Through Interaction with the VH3 Region of IgE. <i>Journal of Immunology</i> , 2000, 164, 589-595.	0.4	157
176	Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A. <i>Journal of Immunology</i> , 2000, 164, 4156-4161.	0.4	42
177	The plasma membrane as a combat zone in the HIV battlefield. <i>Genes and Development</i> , 2000, 14, 2677-2688.	2.7	210
178	Stimulus-specific Interaction between Activator-Coactivator Cognates Revealed with a Novel Complex-specific Antiserum. <i>Journal of Biological Chemistry</i> , 2000, 275, 8263-8266.	1.6	25
179	The Human Immunodeficiency Virus Type 1 gp120 V2 Domain Mediates gp41-Independent Intersubunit Contacts. <i>Journal of Virology</i> , 2000, 74, 4448-4455.	1.5	60
180	A biosensor assay for studying ligand-membrane receptor interactions: Binding of antibodies and HIV-1 Env to chemokine receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 11215-11220.	3.3	105
181	Critical Role of Enhanced CD4 Affinity in Laboratory Adaptation of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 871-882.	0.5	27
182	The use of Envelope for HIV therapeutics: from vaccines to co-receptors. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 423-437.	1.0	1
183	Higher Western Blot Immunoreactivity of Glycoprotein 120 from R5 HIV Type 1 Isolates Compared with X4 and X4R5 Isolates. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 765-775.	0.5	16
184	Solution Structure of an Antibody-Bound HIV-1IIIBV3 Peptide: A Cis Proline Turn Linking Two β -hairpin Strands. <i>Journal of Biomolecular Structure and Dynamics</i> , 2000, 17, 57-63.	2.0	1
185	Molecular Function of the CD4 D1 Domain in Coreceptor-Mediated Entry by HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1845-1854.	0.5	13

#	ARTICLE	IF	CITATIONS
186	Induction of High Levels of Epitope-Specific Antibodies by Epitope/Peptide Candidate Vaccines against Human Immunodeficiency Virus Type-1 (HIV-1). <i>Microbiology and Immunology</i> , 2000, 44, 105-110.	0.7	9
187	Innate Immune System Damage in Human Immunodeficiency Virus Type 1 Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 162, S141-S145.	2.5	10
188	Deletion of the GPG Motif in the HIV Type 1 V3 Loop Does Not Abrogate Infection in All Cells. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 37-48.	0.5	16
189	Short Communication: Fine Definition of a Conserved CCR5-Binding Region on the Human Immunodeficiency Virus Type 1 Glycoprotein 120. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 741-749.	0.5	155
190	Interaction between HIV Type 1 Glycoprotein 120 and CXCR4 Coreceptor Involves a Highly Conserved Arginine Residue in Hypervariable Region 3. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1821-1829.	0.5	10
191	HIV gp120 Plus Specific Peptides Are Recognized in a Similar Manner to Specific HLA Plus Peptide by HLA-Restricted Antigen-Specific T-Cell Lines. <i>Viral Immunology</i> , 2000, 13, 9-17.	0.6	9
192	The HB-19 Pseudopeptide 5[Kpsi(CH2N)PR]-TASP Inhibits Attachment of T Lymphocyte- and Macrophage-Tropic HIV to Permissive Cells. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 237-249.	0.5	25
193	Retroviral Vector Targeting to Human Immunodeficiency Virus Type 1-Infected Cells by Receptor Pseudotyping. <i>Journal of Virology</i> , 2000, 74, 4420-4424.	1.5	29
194	V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies. <i>Journal of Virology</i> , 2000, 74, 6769-6776.	1.5	151
195	Interactions between HIV-1 gp41 Core and Detergents and Their Implications for Membrane Fusion. <i>Journal of Biological Chemistry</i> , 2000, 275, 1839-1845.	1.6	34
196	Reevaluation of Amino Acid Variability of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein and Prediction of New Discontinuous Epitopes. <i>Journal of Virology</i> , 2000, 74, 4335-4350.	1.5	98
197	Expression, Purification, and Characterization of gp160e, the Soluble, Trimeric Ectodomain of the Simian Immunodeficiency Virus Envelope Glycoprotein, gp160. <i>Journal of Biological Chemistry</i> , 2000, 275, 34946-34953.	1.6	31
198	The N-Terminal V3 Loop Glycan Modulates the Interaction of Clade A and B Human Immunodeficiency Virus Type 1 Envelopes with CD4 and Chemokine Receptors. <i>Journal of Virology</i> , 2000, 74, 11008-11016.	1.5	95
199	Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits. <i>Journal of Virology</i> , 2000, 74, 5091-5100.	1.5	106
200	Involvement of both the V2 and V3 Regions of the CCR5-Tropic Human Immunodeficiency Virus Type 1 Envelope in Reduced Sensitivity to Macrophage Inflammatory Protein 1 α . <i>Journal of Virology</i> , 2000, 74, 1787-1793.	1.5	73
201	Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2000, 74, 5716-5725.	1.5	169
202	Tat Protein Is an HIV-1-Encoded β -Chemokine Homolog That Promotes Migration and Up-Regulates CCR3 Expression on Human Fc μ RI+ Cells. <i>Journal of Immunology</i> , 2000, 165, 7171-7179.	0.4	67
203	Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo. <i>Journal of Virology</i> , 2000, 74, 11955-11962.	1.5	58

#	ARTICLE	IF	CITATIONS
204	A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry. <i>Journal of Biological Chemistry</i> , 2000, 275, 33516-33521.	1.6	138
205	Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex. <i>Journal of Virology</i> , 2000, 74, 11427-11436.	1.5	116
206	A Human Milk Factor Susceptible to Cathepsin D Inhibitors Enhances Human Immunodeficiency Virus Type 1 Infectivity and Allows Virus Entry into a Mammary Epithelial Cell Line. <i>Journal of Virology</i> , 2000, 74, 1004-1007.	1.5	26
207	Energetics of the HIV gp120-CD4 binding reaction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 9026-9031.	3.3	399
208	Human Immunodeficiency Virus Type 1 Subtype E Envelope Recombinant Peptides Containing Naturally Immunogenic Epitopes. <i>Journal of Infectious Diseases</i> , 2000, 182, 442-450.	1.9	4
209	Influenza virus infection of desialylated cells. <i>Glycobiology</i> , 2000, 10, 649-658.	1.3	110
210	Current Evidence and Future Directions for Targeting HIV Entry. <i>JAMA - Journal of the American Medical Association</i> , 2000, 284, 215.	3.8	87
211	Properties of the Naturally Occurring Soluble Surface Glycoprotein of Ecotropic Murine Leukemia Virus: Binding Specificity and Possible Conformational Change after Binding to Receptor. <i>Journal of Virology</i> , 2000, 74, 1815-1826.	1.5	12
212	A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex. <i>Journal of Virology</i> , 2000, 74, 4183-4191.	1.5	46
213	Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120. <i>Journal of Virology</i> , 2000, 74, 326-333.	1.5	135
214	Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution. <i>Journal of Virology</i> , 2000, 74, 4746-4754.	1.5	148
215	Coreceptor-Dependent Inhibition of the Cell Fusion Activity of Simian Immunodeficiency Virus Env Proteins. <i>Journal of Virology</i> , 2000, 74, 6217-6222.	1.5	8
216	Cooperation of Multiple CCR5 Coreceptors Is Required for Infections by Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2000, 74, 7005-7015.	1.5	231
217	Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M. <i>Journal of Virology</i> , 2000, 74, 7096-7107.	1.5	137
218	Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees. <i>Journal of Virology</i> , 2000, 74, 7699-7707.	1.5	12
219	Heterogeneous Spectrum of Coreceptor Usage among Variants within a Dualtropic Human Immunodeficiency Virus Type 1 Primary-Isolate Quasispecies. <i>Journal of Virology</i> , 2000, 74, 10229-10235.	1.5	50
220	Envelope Glycoprotein Determinants of Increased Fusogenicity in a Pathogenic Simian-Human Immunodeficiency Virus (SHIV-KB9) Passaged In Vivo. <i>Journal of Virology</i> , 2000, 74, 4433-4440.	1.5	101
221	Accessibility of the High-Mannose Glycans of Glycoprotein gp120 from Human Immunodeficiency Virus Type 1 Probed by in Vitro Interaction with Mannose-Binding Lectins. <i>Biochemical and Biophysical Research Communications</i> , 2000, 274, 455-460.	1.0	24

#	ARTICLE	IF	CITATIONS
222	Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization 1 Edited by I. Wilson. <i>Journal of Molecular Biology</i> , 2000, 302, 359-375.	2.0	52
223	Sequence similarity between the envelope surface unit (SU) glycoproteins of primate and small ruminant lentiviruses. <i>Virus Research</i> , 2000, 69, 47-54.	1.1	19
224	Chimeras between the human immunodeficiency virus (HIV-1) Env and vaccinia virus immunogenic proteins p14 and p39 generate in mice broadly reactive antibodies and specific activation of CD8+ T cell responses to Env. <i>Vaccine</i> , 2000, 18, 3123-3133.	1.7	6
225	HIV-1 and its causal relationship to immunosuppression and nervous system disease in AIDS: A review. <i>Human Pathology</i> , 2000, 31, 1274-1298.	1.1	17
226	Interaction of the third helix of Antennapedia homeodomain and a phospholipid monolayer, studied by ellipsometry and PM-IRRAS at the air-water interface. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2000, 1467, 131-143.	1.4	82
227	DC-SIGN, a Dendritic Cell-Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells. <i>Cell</i> , 2000, 100, 587-597.	13.5	2,214
229	The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. <i>FEBS Letters</i> , 2000, 477, 123-128.	1.3	32
230	Structure of Murine CTLA-4 and Its Role in Modulating T Cell Responsiveness. <i>Science</i> , 2000, 290, 816-819.	6.0	140
231	Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 981-994.	0.5	76
232	Pertussis Toxin Enhances Human Immunodeficiency Virus Type 1 Replication. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 373-379.	0.5	4
233	Anti-CD4-Binding Domain Antibodies Complexed with HIV Type 1 Glycoprotein 120 Inhibit CD4+T Cell-Proliferative Responses to Glycoprotein 120. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 893-905.	0.5	21
234	Mass Spectrometric Characterization of the Glycosylation Pattern of HIV-gp120 Expressed in CHO Cells. <i>Biochemistry</i> , 2000, 39, 11194-11204.	1.2	223
235	Helical Interactions in the HIV-1 gp41 Core Reveal Structural Basis for the Inhibitory Activity of gp41 Peptides. <i>Biochemistry</i> , 2000, 39, 1634-1642.	1.2	74
236	Buried Polar Interactions and Conformational Stability in the Simian Immunodeficiency Virus (SIV) gp41 Core. <i>Biochemistry</i> , 2000, 39, 676-685.	1.2	34
237	HIV VACCINES FOR PREVENTION OF INFECTION AND DISEASE IN HUMANS. <i>Infectious Disease Clinics of North America</i> , 2000, 14, 1001-1016.	1.9	9
238	Immunization with Recombinant Canarypox Vectors Expressing Membrane-Anchored Glycoprotein 120 Followed by Glycoprotein 160 Boosting Fails to Generate Antibodies That Neutralize R5 Primary Isolates of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 2019-2035.	0.5	146
239	Crystal Structure of Rabbit Phosphoglucose Isomerase, a Glycolytic Enzyme That Moonlights as Neuroleukin, Autocrine Motility Factor, and Differentiation Mediator. <i>Biochemistry</i> , 2000, 39, 955-964.	1.2	136
240	Electron Cryomicroscopy and Computer Image Processing Techniques: Use in Structure-Function Studies of Rotavirus. , 2000, 34, 9-31.		12

#	ARTICLE	IF	CITATIONS
241	Mechanisms of Viral Membrane Fusion and Its Inhibition. <i>Annual Review of Biochemistry</i> , 2001, 70, 777-810.	5.0	1,209
242	Dysregulation of the IgE/Fc ϵ R1 network in HIV-1 infection. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 22-30.	1.5	26
243	The Potent Anti-HIV Protein Cyanovirin-N Contains Two Novel Carbohydrate Binding Sites That Selectively Bind to Man8D1D3 and Man9with Nanomolar Affinity: A Implications for Binding to the HIV Envelope Protein gp120. <i>Journal of the American Chemical Society</i> , 2001, 123, 3892-3902.	6.6	131
244	The Membrane-Proximal Tryptophan-Rich Region of the HIV Glycoprotein, gp41, Forms a Well-Defined Helix in Dodecylphosphocholine Micelles. <i>Biochemistry</i> , 2001, 40, 9570-9578.	1.2	168
245	GP120: Biologic Aspects of Structural Features. <i>Annual Review of Immunology</i> , 2001, 19, 253-274.	9.5	226
246	Living in oblivion: HIV immune evasion. <i>Seminars in Immunology</i> , 2001, 13, 51-57.	2.7	30
247	Formation of HIV-1 Envelope-Hepatitis B Core Antigen Hybrids with High Affinity for CD4. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 639-643.	1.0	3
248	Thermodynamics of trimer-of-hairpins formation by the SIV gp41 envelope protein. Edited by I. B. Holland. <i>Journal of Molecular Biology</i> , 2001, 307, 637-656.	2.0	42
249	Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. <i>Vaccine</i> , 2001, 19, 2210-2215.	1.7	17
250	Folding of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum. <i>Biochimie</i> , 2001, 83, 783-790.	1.3	80
251	Expression of deletion mutants of the hepatitis B virus protein HBx in <i>E. coli</i> and characterization of their RNA binding activities. <i>Virus Research</i> , 2001, 74, 59-73.	1.1	14
252	HIV gp120 V1/V2 and C2-V3 domains glycoprotein compatibility is required for viral replication. <i>Virus Research</i> , 2001, 79, 91-101.	1.1	12
253	Human mast cells and basophils in HIV-1 infection. <i>Trends in Immunology</i> , 2001, 22, 229-232.	2.9	49
254	Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2001, 1536, 116-122.	1.8	66
255	Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor HveA. <i>Molecular Cell</i> , 2001, 8, 169-179.	4.5	349
256	Insights from the structure of the yeast cytochrome bc ₁ complex: crystallization of membrane proteins with antibody fragments. <i>FEBS Letters</i> , 2001, 504, 126-132.	1.3	40
257	Structure of Pumilio Reveals Similarity between RNA and Peptide Binding Motifs. <i>Cell</i> , 2001, 105, 281-289.	13.5	237
258	Structural Features of HIV Envelope Defined by Antibody Escape Mutant Analysis. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1205-1209.	0.5	17

#	ARTICLE	IF	CITATIONS
259	Expression, Purification, and Characterization of Recombinant HIV gp140. <i>Journal of Biological Chemistry</i> , 2001, 276, 39577-39585.	1.6	71
260	Solid-State Nuclear Magnetic Resonance Evidence for an Extended β^2 Strand Conformation of the Membrane-Bound HIV-1 Fusion Peptide. <i>Biochemistry</i> , 2001, 40, 8126-8137.	1.2	113
261	Short Peptides with Induced β^2 -Turn Inhibit the Interaction between HIV-1 gp120 and CD4. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1356-1363.	2.9	14
262	Antibody 17b Binding at the Coreceptor Site Weakens the Kinetics of the Interaction of Envelope Glycoprotein gp120 with CD4. <i>Biochemistry</i> , 2001, 40, 1662-1670.	1.2	46
263	Virology: The efficacy of a new single post-exposure treatment of rabies in mice without vaccination. <i>Veterinary Quarterly</i> , 2001, 23, 187-190.	3.0	1
264	A Minimal Peptide Scaffold for β^2 -Turn Display: Optimizing a Strand Position in Disulfide-Cyclized β^2 -Hairpins. <i>Journal of the American Chemical Society</i> , 2001, 123, 625-632.	6.6	140
265	Correlation of Anti-HIV Activity with Anion Spacing in a Series of Cosalane Analogues with Extended Polycarboxylate Pharmacophores. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 703-714.	2.9	26
266	Polar Interactions with Aromatic Side Chains in β^2 -Helical Peptides: $\text{C}^{\alpha}\text{H}\cdots\text{O}$ H-Bonding and Cation- π Interactions. <i>Journal of the American Chemical Society</i> , 2001, 123, 6451-6452.	6.6	64
267	Inhibition of Human Immunodeficiency Virus Type 1 gp120 Presentation to CD4 T Cells by Antibodies Specific for the CD4 Binding Domain of gp120. <i>Journal of Virology</i> , 2001, 75, 10950-10957.	1.5	26
268	Chemokine Receptors as Anti-Retroviral Targets. <i>Current Drug Targets</i> , 2001, 2, 21-39.	1.0	7
270	HIV-1 entry and how to block it. <i>Aids</i> , 2001, 15, S3-S11.	1.0	12
271	The potential for HIV fusion inhibition. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 13-16.	1.3	15
272	Role of V3 Independent Domains on a Dualtropic Human Immunodeficiency Virus Type 1 (HIV-1) Envelope gp120 in CCR5 Coreceptor Utilization and Viral Infectivity. <i>Microbiology and Immunology</i> , 2001, 45, 521-530.	0.7	14
273	Uterocalin, a lipocalin provisioning the preattachment equine conceptus: fatty acid and retinol binding properties, and structural characterization. <i>Biochemical Journal</i> , 2001, 356, 369-376.	1.7	50
274	Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics*. <i>Annals of Internal Medicine</i> , 2001, 134, 978.	2.0	114
275	Incorporation of Long CDR3s into V Domains: Implications for the Structural Evolution of the Antibody-Combining Site. <i>Experimental and Clinical Immunogenetics</i> , 2001, 18, 176-198.	1.4	42
276	Peptides Derived from Salivary Thrombospondin-1 Replicate Its Anti-HIV Effect: Potential Role in Microbicide Development. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 27, 91-93.	0.9	5
277	Immunogenicity of Recombinant Envelope Glycoproteins Derived From T-Cell Line-Adapted Isolates or Primary HIV Isolates. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2001, 26, 413-422.	0.9	4

#	ARTICLE	IF	CITATIONS
278	Mechanisms for HIV-1 entry: Current strategies to interfere with this step. <i>Current Infectious Disease Reports</i> , 2001, 3, 93-99.	1.3	19
279	Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tail of a neutralizing antibody escape mutant of human immunodeficiency virus type 1. <i>Archives of Virology</i> , 2001, 146, 157-166.	0.9	14
280	Envelope gp120 of HIV-1 binds to and activates human basophils. <i>Rendiconti Lincei</i> , 2001, 12, 117-131.	1.0	0
281	Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1III _B gp120. <i>Immunology Letters</i> , 2001, 79, 209-213.	1.1	19
282	From receptor recognition mechanisms to bioinspired mimetic antagonists in HIV-1/cell docking. <i>Biomedical Applications</i> , 2001, 753, 327-335.	1.7	5
283	Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. <i>BMC Infectious Diseases</i> , 2001, 1, 17.	1.3	79
284	Phage randomization in a charybdotoxin scaffold leads to CD4-mimetic recognition motifs that bind HIV-1 envelope through non-aromatic sequences. <i>Chemical Biology and Drug Design</i> , 2001, 57, 507-518.	1.2	20
285	Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution. <i>FEBS Journal</i> , 2001, 268, 2620-2628.	0.2	23
286	Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies. <i>FEBS Journal</i> , 2001, 268, 2856-2866.	0.2	21
287	Role of human FcepsilonRI+ cells in HIV-1 infection. <i>Immunological Reviews</i> , 2001, 179, 128-138.	2.8	24
288	Structure of an anti-HIV monoclonal Fab antibody fragment specific to a gp120 C-4 region peptide. <i>Proteins: Structure, Function and Bioinformatics</i> , 2001, 45, 281-282.	1.5	3
289	Peptide T revisited: conformational mimicry of epitopes of anti-HIV proteins. <i>Journal of Peptide Science</i> , 2001, 7, 197-207.	0.8	5
290	Antibodies raised to short synthetic peptides with sequences derived from HIV-1 SF2 gp120 can both neutralize and enhance HIV-1 SF13: A later variant isolated from the same host. <i>Journal of Medical Virology</i> , 2001, 64, 207-216.	2.5	11
291	Ab initio modeling of small, medium, and large loops in proteins. <i>Biopolymers</i> , 2001, 60, 153-168.	1.2	43
292	Revealing and utilizing receptor recognition mechanisms in a high-throughput world. <i>Journal of Cellular Biochemistry</i> , 2001, 84, 126-135.	1.2	2
293	Crystallization of macromolecular complexes: combinatorial complex crystallization. <i>Journal of Crystal Growth</i> , 2001, 232, 573-579.	0.7	12
294	Role of Human Immunodeficiency Virus (HIV) Type 1 Envelope in the Anti-HIV Activity of the Betulinic Acid Derivative IC9564. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 60-66.	1.4	88
295	Potent Broad Cross-Neutralizing Sera Inhibit Attachment of Primary HIV-1 Isolates (Groups M and O) to Peripheral Blood Mononuclear Cells. <i>Virology</i> , 2001, 281, 305-314.	1.1	14

#	ARTICLE	IF	CITATIONS
296	Evidence for Positive Selection Driving the Evolution of HIV-1 env under Potent Antiviral Therapy. <i>Virology</i> , 2001, 284, 250-258.	1.1	42
297	Adaptation to Blockade of Human Immunodeficiency Virus Type 1 Entry Imposed by the Anti-CCR5 Monoclonal Antibody 2D7. <i>Virology</i> , 2001, 287, 382-390.	1.1	41
298	HIV-1 replication. <i>Somatic Cell and Molecular Genetics</i> , 2001, 26, 13-33.	0.7	174
299	Structure of a malaria parasite antigenic determinant displayed on filamentous bacteriophage determined by NMR spectroscopy: Implications for the structure of continuous peptide epitopes of proteins. <i>Protein Science</i> , 2001, 10, 1150-1159.	3.1	21
300	Cloning and expression of the external-glycoprotein gene mutant from HIV-2 in the methylotrophic yeast <i>Pichia pastoris</i> and identification of the glycoprotein. <i>Biotechnology and Applied Biochemistry</i> , 2001, 34, 1.	1.4	34
301	Virus receptors in the human central nervous system. <i>Journal of NeuroVirology</i> , 2001, 7, 187-195.	1.0	34
302	The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface. <i>EMBO Journal</i> , 2001, 20, 19-26.	3.5	62
303	Isolation of primary HIV-1 that target CD8+ T Lymphocytes using CD8 as a receptor. <i>Nature Medicine</i> , 2001, 7, 65-72.	15.2	88
304	Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. <i>Nature Medicine</i> , 2001, 7, 1225-1231.	15.2	73
305	Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. <i>Nature</i> , 2001, 410, 604-608.	13.7	323
306	Challenges and opportunities for development of an AIDS vaccine. <i>Nature</i> , 2001, 410, 1002-1007.	13.7	177
307	The leucine zipper motif of the envelope glycoprotein ectodomain of human immunodeficiency virus type 1 contains conformationally flexible regions as revealed by NMR and circular dichroism studies in different media. <i>Chemical Biology and Drug Design</i> , 2001, 57, 234-239.	1.2	2
308	HIV fusion and its inhibition. <i>Antiviral Research</i> , 2001, 50, 95-115.	1.9	102
309	Solution Structure of a Cyanovirin-N:Man α 1-2Man α Complex. <i>Structure</i> , 2001, 9, 931-940.	1.6	130
310	An algorithm for mapping positively selected members of quasispecies-type viruses. <i>BMC Bioinformatics</i> , 2001, 2, 1.	1.2	22
311	The leucine zipper motif of the envelope glycoprotein ectodomain of human immunodeficiency virus type 1 contains conformationally flexible regions as revealed by NMR and circular dichroism studies in different media. <i>Chemical Biology and Drug Design</i> , 2001, 57, 234-239.	1.2	2
312	Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 4113-4118.	3.3	72
313	Early Intermediates in HIV-1 Envelope Glycoprotein-mediated Fusion Triggered by CD4 and Co-receptor Complexes. <i>Journal of Biological Chemistry</i> , 2001, 276, 30335-30341.	1.6	45

#	ARTICLE	IF	CITATIONS
314	The Stoichiometry of Trimeric SIV Glycoprotein Interaction with CD4 Differs from That of Anti-envelope Antibody Fab Fragments. <i>Journal of Biological Chemistry</i> , 2001, 276, 42667-42676.	1.6	27
315	Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 664-672.	1.4	89
316	Relationships between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein. <i>Journal of Virology</i> , 2001, 75, 5230-5239.	1.5	135
317	Structural Flexibility and Functional Valence of CD4-IgG2 (PRO 542): Potential for Cross-Linking Human Immunodeficiency Virus Type 1 Envelope Spikes. <i>Journal of Virology</i> , 2001, 75, 6682-6686.	1.5	36
318	Antigenically Distinct Conformations of CXCR4. <i>Journal of Virology</i> , 2001, 75, 8957-8967.	1.5	147
319	Evidence for Similar Recognition of the Conserved Neutralization Epitopes of Human Immunodeficiency Virus Type 1 Envelope gp120 in Humans and Macaques. <i>Journal of Virology</i> , 2001, 75, 9287-9296.	1.5	12
320	Conservation of Human Immunodeficiency Virus Type 1 gp120 Inner-Domain Sequences in Lentivirus and Type A and B Retrovirus Envelope Surface Glycoproteins. <i>Journal of Virology</i> , 2001, 75, 2014-2018.	1.5	17
321	Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate. <i>Journal of Virology</i> , 2001, 75, 3568-3580.	1.5	63
322	Ability of the V3 Loop of Simian Immunodeficiency Virus To Serve as a Target for Antibody-Mediated Neutralization: Correlation of Neutralization Sensitivity, Growth in Macrophages, and Decreased Dependence on CD4. <i>Journal of Virology</i> , 2001, 75, 3903-3915.	1.5	98
323	Cooperation of the V1/V2 and V3 Domains of Human Immunodeficiency Virus Type 1 gp120 for Interaction with the CXCR4 Receptor. <i>Journal of Virology</i> , 2001, 75, 5457-5464.	1.5	64
324	Binding of Human Immunodeficiency Virus Type 1 gp120 to CXCR4 Induces Mitochondrial Transmembrane Depolarization and Cytochrome c-Mediated Apoptosis Independently of Fas Signaling. <i>Journal of Virology</i> , 2001, 75, 7637-7650.	1.5	109
325	Secretory IgA Specific for a Conserved Epitope on gp41 Envelope Glycoprotein Inhibits Epithelial Transcytosis of HIV-1. <i>Journal of Immunology</i> , 2001, 166, 6257-6265.	0.4	179
326	Antibody Binding and Neutralization of Primary and T-Cell Line-Adapted Isolates of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2001, 75, 2741-2752.	1.5	55
327	Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12. <i>Journal of Virology</i> , 2001, 75, 6692-6699.	1.5	85
328	Tryptophan zippers: Stable, monomeric \hat{A} -hairpins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 5578-5583.	3.3	687
329	Receptors and Entry Cofactors for Retroviruses Include Single and Multiple Transmembrane-Spanning Proteins as well as Newly Described Glycophosphatidylinositol-Anchored and Secreted Proteins. <i>Microbiology and Molecular Biology Reviews</i> , 2001, 65, 371-389.	2.9	165
330	Are Mast Cells MASTers in HIV-1 Infection?. <i>International Archives of Allergy and Immunology</i> , 2001, 125, 89-95.	0.9	29
331	An overview of the determinants of CCR5 and CXCR4 co-receptor function. <i>Journal of General Virology</i> , 2001, 82, 1807-1814.	1.3	119

#	ARTICLE	IF	CITATIONS
332	Immunogenicity of Recombinant Envelope Glycoproteins Derived From T-Cell Line-Adapted Isolates or Primary HIV Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 26, 413-422.	0.9	9
333	Peptides Derived from Salivary Thrombospondin-1 Replicate Its Anti-HIV Effect: Potential Role in Microbicide Development. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 91-93.	0.9	10
334	Neuroimmune and neurovirological aspects of human immunodeficiency virus infection. <i>Advances in Virus Research</i> , 2001, 56, 389-433.	0.9	31
335	HIV Type 1 Molecular Clones Able to Use the Bonzo/STRL-33 Coreceptor for Virus Entry. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 217-227.	0.5	18
336	Protection of Neutralization Epitopes in the V3 Loop of Oligomeric Human Immunodeficiency Virus Type 1 Glycoprotein 120 by N-Linked Oligosaccharides in the V1 Region. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1067-1076.	0.5	50
337	The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region. <i>Journal of Virology</i> , 2001, 75, 5526-5540.	1.5	213
338	Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. <i>Science</i> , 2001, 293, 1155-1159.	6.0	870
339	A Defined Conformational Epitope from the C4 Domain of HIV Type 1 Glycoprotein 120: Anti-Cyclic C4 Antibodies from HIV-Positive Donors Magnify Glycoprotein 120 Suppression of Interleukin 2 Produced by T Cells. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 533-541.	0.5	4
340	Phosphatidylglycerol Participates in Syncytium Formation Induced by HTLV Type 1-Bearing Cells. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 125-135.	0.5	10
341	Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10799-10804.	3.3	215
342	Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen. <i>Journal of Virology</i> , 2001, 75, 2087-2096.	1.5	119
343	Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques. <i>Journal of Virology</i> , 2001, 75, 5879-5890.	1.5	64
344	The role of the third \hat{A} strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 15227-15232.	3.3	32
345	Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development. <i>Journal of Virology</i> , 2001, 75, 5721-5729.	1.5	108
346	Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity. <i>Journal of Biological Chemistry</i> , 2001, 276, 29485-29489.	1.6	88
347	CD4-Independent Use of Rhesus CCR5 by Human Immunodeficiency Virus Type 2 Implicates an Electrostatic Interaction between the CCR5 N Terminus and the gp120 C4 Domain. <i>Journal of Virology</i> , 2001, 75, 10766-10778.	1.5	22
348	Membrane-Fusing Capacity of the Human Immunodeficiency Virus Envelope Proteins Determines the Efficiency of CD4 + T-Cell Depletion in Macaques Infected by a Simian-Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2001, 75, 5646-5655.	1.5	75
349	Ligand Binding Characteristics of CXCR4 Incorporated into Paramagnetic Proteoliposomes. <i>Journal of Biological Chemistry</i> , 2001, 276, 38433-38440.	1.6	86

#	ARTICLE	IF	CITATIONS
350	Allocation of Helper T-cell Epitope Immunodominance According to Three-dimensional Structure in the Human Immunodeficiency Virus Type I Envelope Glycoprotein gp120. <i>Journal of Biological Chemistry</i> , 2001, 276, 41913-41920.	1.6	51
351	Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the Position of the gp120 V1/V2 Variable Loops. <i>Journal of Virology</i> , 2001, 75, 3435-3443.	1.5	162
352	HIV-1 receptors and cell tropism. <i>British Medical Bulletin</i> , 2001, 58, 43-59.	2.7	141
353	Replacement of the V3 Region of gp120 with SDF-1 Preserves the Infectivity of T-Cell Line-Tropic Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2001, 75, 4258-4267.	1.5	12
354	Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the Coreceptor. <i>Journal of Virology</i> , 2001, 75, 8605-8614.	1.5	184
355	Improved Elicitation of Neutralizing Antibodies against Primary Human Immunodeficiency Viruses by Soluble Stabilized Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , 2001, 75, 1165-1171.	1.5	189
356	Simian Immunodeficiency Virus Replicates to High Levels in Naturally Infected African Green Monkeys without Inducing Immunologic or Neurologic Disease. <i>Journal of Virology</i> , 2001, 75, 2262-2275.	1.5	228
357	N-Linked Glycosylation Sites Adjacent to and within the V1/V2 and the V3 Loops of Dualtropic Human Immunodeficiency Virus Type 1 Isolate DH12 gp120 Affect Coreceptor Usage and Cellular Tropism. <i>Journal of Virology</i> , 2001, 75, 5998-6006.	1.5	128
358	Antibody-Mediated Neutralization of Primary Human Immunodeficiency Virus Type 1 Isolates: Investigation of the Mechanism of Inhibition. <i>Journal of Virology</i> , 2001, 75, 2235-2245.	1.5	29
359	Adaptive Mutations in the V3 Loop of gp120 Enhance Fusogenicity of Human Immunodeficiency Virus Type 1 and Enable Use of a CCR5 Coreceptor That Lacks the Amino-Terminal Sulfated Region. <i>Journal of Virology</i> , 2001, 75, 12266-12278.	1.5	42
360	Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course. <i>Journal of Virology</i> , 2001, 75, 2246-2252.	1.5	68
361	Mapping the Determinants of the CCR5 Amino-Terminal Sulfopeptide Interaction with Soluble Human Immunodeficiency Virus Type 1 gp120-CD4 Complexes. <i>Journal of Virology</i> , 2001, 75, 5541-5549.	1.5	132
362	Human Immunodeficiency Virus Type 1 Env Sequences from Calcutta in Eastern India: Identification of Features That Distinguish Subtype C Sequences in India from Other Subtype C Sequences. <i>Journal of Virology</i> , 2001, 75, 10479-10487.	1.5	90
363	Increased Neutralization Sensitivity of CD4-Independent Human Immunodeficiency Virus Variants. <i>Journal of Virology</i> , 2001, 75, 2041-2050.	1.5	168
364	Antigenic Variation within the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120: Effects on Chemokine Receptor Utilization. <i>Journal of Virology</i> , 2001, 75, 5593-5603.	1.5	8
365	Envelope Glycoprotein Determinants of Neutralization Resistance in a Simian-Human Immunodeficiency Virus (SHIV-HXBc2P 3.2) Derived by Passage in Monkeys. <i>Journal of Virology</i> , 2001, 75, 4208-4218.	1.5	55
366	Glial cells as targets of viral infection in the human central nervous system. <i>Progress in Brain Research</i> , 2001, 132, 721-735.	0.9	7
367	Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 1245-1252.	2.4	24

#	ARTICLE	IF	CITATIONS
368	Antigenic variation in trypanosomes: Enhanced phenotypic variation in a eukaryotic parasite. <i>Advances in Parasitology</i> , 2001, 49, 1-70.	1.4	260
369	Human Immunodeficiency Virus Type 1-Mediated Syncytium Formation Is Compatible with Adenovirus Replication and Facilitates Efficient Dispersion of Viral Gene Products and De Novo-Synthesized Virus Particles. <i>Human Gene Therapy</i> , 2001, 12, 2155-2165.	1.4	45
370	A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1757-1765.	0.5	470
371	CD4-Independent Infection of Human B Cells with HIV Type 1: Detection of Unintegrated Viral DNA. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1585-1598.	0.5	18
372	Isolation and Characterization of an Infectious HIV Type 1 Molecular Clone from a Patient with Primary Infection. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1127-1133.	0.5	10
373	Long-Term Treatment with Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily Living. <i>AIDS Patient Care and STDs</i> , 2002, 16, 327-335.	1.1	35
374	The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 685-693.	0.5	187
375	Local Structural Properties of the V3 Loop of Thailand HIV-1 Isolate. <i>Journal of Biomolecular Structure and Dynamics</i> , 2002, 19, 973-989.	2.0	19
376	Characterization of CD4-Induced Epitopes on the HIV Type 1 gp120 Envelope Glycoprotein Recognized by Neutralizing Human Monoclonal Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1207-1217.	0.5	142
377	Solution Structure of the Viral Receptor Domain of Tva and Its Implications in Viral Entry. <i>Journal of Virology</i> , 2002, 76, 2848-2856.	1.5	25
378	CD4 Independence of Simian Immunodeficiency Virus Envs Is Associated with Macrophage Tropism, Neutralization Sensitivity, and Attenuated Pathogenicity. <i>Journal of Virology</i> , 2002, 76, 2595-2605.	1.5	122
379	HIV-1 gp41 Envelope Residues 650-685 Exposed on Native Virus Act as a Lectin to Bind Epithelial Cell Galactosyl Ceramide. <i>Journal of Biological Chemistry</i> , 2002, 277, 25649-25659.	1.6	115
380	Antibody-Mediated Enhancement of Human Immunodeficiency Virus Type 1 Infectivity Is Determined by the Structure of gp120 and Depends on Modulation of the gp120-CCR5 Interaction. <i>Journal of Virology</i> , 2002, 76, 2827-2834.	1.5	23
381	Purification and Characterization of Oligomeric Envelope Glycoprotein from a Primary R5 Subtype B Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2002, 76, 2835-2847.	1.5	104
382	Enfuvirtide. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 1837-1843.	1.9	36
383	High Mannose Glycans and Sialic Acid on gp120 Regulate Binding of Mannose-Binding Lectin (MBL) to HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 1311-1317.	0.5	50
384	Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2002, 76, 8875-8889.	1.5	424
385	The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. <i>Journal of Virology</i> , 2002, 76, 7293-7305.	1.5	528

#	ARTICLE	IF	CITATIONS
386	Envelope Glycoprotein Incorporation, Not Shedding of Surface Envelope Glycoprotein (gp120/SU), Is the Primary Determinant of SU Content of Purified Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2002, 76, 5315-5325.	1.5	260
387	Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein. <i>Journal of Virology</i> , 2002, 76, 7760-7776.	1.5	150
389	Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2002, 17, 69-76.	2.5	51
390	Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci. <i>Journal of Immunology</i> , 2002, 169, 595-605.	0.4	61
391	Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13813-13818.	3.3	22
392	Inhibitors of Protein-Disulfide Isomerase Prevent Cleavage of Disulfide Bonds in Receptor-bound Glycoprotein 120 and Prevent HIV-1 Entry. <i>Journal of Biological Chemistry</i> , 2002, 277, 50579-50588.	1.6	176
393	Coreceptor Usage and Biological Phenotypes of HIV-1 Isolates. <i>Clinical Chemistry and Laboratory Medicine</i> , 2002, 40, 911-7.	1.4	3
395	Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2002, 76, 2606-2616.	1.5	133
396	Variability in the Human Immunodeficiency Virus Type 1 gp120 Env Protein Linked to Phenotype-Associated Changes in the V3 Loop. <i>Journal of Virology</i> , 2002, 76, 3852-3864.	1.5	151
397	Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex. <i>Journal of Biological Chemistry</i> , 2002, 277, 12891-12900.	1.6	15
398	Chemokine receptors in the brain: their role in HIV infection and pathogenesis. <i>Aids</i> , 2002, 16, 1709-1730.	1.0	44
399	Monoclonal antibodies and human sera directed to the secreted glycoprotein G of herpes simplex virus type 2 recognize type-specific antigenic determinants. <i>Journal of General Virology</i> , 2002, 83, 157-165.	1.3	24
400	Structure and Function of Viral Glycoproteins in Membrane Fusion. , 2002, , 25-54.		1
401	Chronic immune activation and inflammation in the pathogenesis of aids and cancer. <i>Advances in Cancer Research</i> , 2002, 84, 231-276.	1.9	142
402	Mutagenic Stabilization and/or Disruption of a CD4-Bound State Reveals Distinct Conformations of the Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein. <i>Journal of Virology</i> , 2002, 76, 9888-9899.	1.5	177
403	Segregation of CD4 and CXCR4 into Distinct Lipid Microdomains in T Lymphocytes Suggests a Mechanism for Membrane Destabilization by Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2002, 76, 1802-1815.	1.5	129
404	Identification of Conserved and Variable Structures in the Human Immunodeficiency Virus gp120 Glycoprotein of Importance for CXCR4 Binding. <i>Journal of Virology</i> , 2002, 76, 10791-10800.	1.5	75
405	Quaternary Structure of Coronavirus Spikes in Complex with Carcinoembryonic Antigen-related Cell Adhesion Molecule Cellular Receptors. <i>Journal of Biological Chemistry</i> , 2002, 277, 19727-19734.	1.6	59

#	ARTICLE	IF	CITATIONS
406	A Replication-Competent, Neutralization-Sensitive Variant of Simian Immunodeficiency Virus Lacking 100 Amino Acids of Envelope. <i>Journal of Virology</i> , 2002, 76, 2075-2086.	1.5	79
407	HIV-1 Envelope gp41 Peptides Promote Migration of Human FcγRI+ Cells and Inhibit IL-13 Synthesis Through Interaction with Formyl Peptide Receptors. <i>Journal of Immunology</i> , 2002, 169, 4559-4567.	0.4	39
408	Comparison of Predicted Scaffold-Compatible Sequence Variation in the Triple-Hairpin Structure of Human Immunodeficiency Virus Type 1 gp41 with Patient Data. <i>Journal of Virology</i> , 2002, 76, 7595-7606.	1.5	5
409	Human Immunodeficiency Virus Envelope (gp120) Binding to DC-SIGN and Primary Dendritic Cells Is Carbohydrate Dependent but Does Not Involve 2G12 or Cyanovirin Binding Sites: Implications for Structural Analyses of gp120-DC-SIGN Binding. <i>Journal of Virology</i> , 2002, 76, 12855-12865.	1.5	90
410	Analysis of Antigenicity and Topology of E2 Glycoprotein Present on Recombinant Hepatitis C Virus-Like Particles. <i>Journal of Virology</i> , 2002, 76, 7672-7682.	1.5	134
411	Effect of the V3 Loop Deletion of Envelope Glycoprotein on Cellular Responses and Protection against Challenge with Recombinant Vaccinia Virus Expressing gp160 of Primary Human Immunodeficiency Virus Type 1 Isolates. <i>Journal of Virology</i> , 2002, 76, 4222-4232.	1.5	18
412	Biochemical and Biological Characterization of a Dodecameric CD4-Ig Fusion Protein. <i>Journal of Biological Chemistry</i> , 2002, 277, 11456-11464.	1.6	71
413	Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6913-6918.	3.3	203
414	Rapid Progression to Simian AIDS Can Be Accompanied by Selection of CD4-Independent gp120 Variants with Impaired Ability To Bind CD4. <i>Journal of Virology</i> , 2002, 76, 7903-7909.	1.5	30
415	Blockade of HIV-1 Infection of New World Monkey Cells Occurs Primarily at the Stage of Virus Entry. <i>Journal of Experimental Medicine</i> , 2002, 196, 431-445.	4.2	44
416	The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of 1±1±2 Mannose Residues on the Outer Face of gp120. <i>Journal of Virology</i> , 2002, 76, 7306-7321.	1.5	664
418	Structural and Thermodynamic Correlates of T Cell Signaling. <i>Annual Review of Biophysics and Biomolecular Structure</i> , 2002, 31, 121-149.	18.3	101
419	Progress in Clinical Neurosciences: The Neuropathogenesis of HIV Infection: Host-Virus Interaction and the Impact of Therapy. <i>Canadian Journal of Neurological Sciences</i> , 2002, 29, 19-32.	0.3	56
420	DNA vaccines encoding human immunodeficiency virusâ€™1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. <i>Blood</i> , 2002, 100, 1153-1159.	0.6	127
421	Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody Response. <i>Journal of Virology</i> , 2002, 76, 4199-4211.	1.5	103
422	A Rational Design Approach for Developing Immunomodulators Based on CD4 and CD8. <i>Biotechnology and Genetic Engineering Reviews</i> , 2002, 19, 175-204.	2.4	0
423	Î²-Turn Phe in HIV-1 Env Binding Site of CD4 and CD4 Mimetic Mini-protein Enhances Env Binding Affinity but Is Not Required for Activation of Co-Receptor/17b Site. <i>Biochemistry</i> , 2002, 41, 7038-7046.	1.2	26
424	Prospects for an HIV Vaccine: Conventional Approaches and DNA Immunization. <i>Biotechnology and Genetic Engineering Reviews</i> , 2002, 19, 205-244.	2.4	0

#	ARTICLE	IF	CITATIONS
425	Interhelical Interactions in the gp41 Core: Implications for Activation of HIV-1 Membrane Fusion. <i>Biochemistry</i> , 2002, 41, 7283-7292.	1.2	47
426	Characterization of the Tertiary Structure of Soluble CD4 Bound to Glycosylated Full-Length HIVgp120 by Chemical Modification of Arginine Residues and Mass Spectrometric Analysis. <i>Biochemistry</i> , 2002, 41, 1759-1766.	1.2	33
427	High level production of functional antibody fab fragments in an oxidizing bacterial cytoplasm. Edited by J. Karn. <i>Journal of Molecular Biology</i> , 2002, 315, 1-8.	2.0	82
428	Role of CD4 Hinge Region in GP120 Utilization by Immunoglobulin Domain 1. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 449-455.	1.0	4
429	Discovery of a Stable Dimeric Mutant of Cyanovirin-N (CV-N) from a T7 Phage-Displayed CV-N Mutant Library. <i>Biochemical and Biophysical Research Communications</i> , 2002, 292, 1036-1043.	1.0	24
430	Expression, Purification, and Isotope Labeling of a gp120 V3 Peptide and Production of a Fab from a HIV-1 Neutralizing Antibody for NMR Studies. <i>Protein Expression and Purification</i> , 2002, 24, 374-383.	0.6	23
431	Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins. <i>Journal of Virology</i> , 2002, 76, 3511-3521.	1.5	88
432	Viral Persistence: HIV's Strategies of Immune System Evasion. <i>Annual Review of Medicine</i> , 2002, 53, 499-518.	5.0	179
433	Insight into β -hairpin stability: a structural and thermodynamic study of diastereomeric β -hairpin mimetics. Electronic supplementary information (ESI) available: temperature and concentration-dependent chemical shifts and melting curves of the investigated molecules in different solvents and details of the X-ray analysis. See http://www.rsc.org/suppdata/nj/b1/b111241d/ . <i>New Journal of Chemistry</i> , 2002, 26, 834-843.	1.4	22
434	Structural basis of macromolecular recognition. <i>Advances in Protein Chemistry</i> , 2002, 61, 9-73.	4.4	147
435	Molecular Modeling and Simulation. <i>Interdisciplinary Applied Mathematics</i> , 2002, , .	0.2	416
436	Influence of gp41 Fusion Peptide on the Kinetics of Poly(ethylene glycol)-Mediated Model Membrane Fusion. <i>Biochemistry</i> , 2002, 41, 10866-10876.	1.2	43
437	Monte carlo simulation of HIV-1 evolution in response to selection by antibodies. , 2002, , .		3
438	Insertion of carrier proteins into hydrophilic loops of the Escherichia coli lactose permease. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2002, 1564, 38-46.	1.4	25
439	Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility. <i>Journal of Molecular Biology</i> , 2002, 319, 9-18.	2.0	246
440	Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. <i>Protein Expression and Purification</i> , 2002, 26, 42-49.	0.6	41
441	Structure of the Epstein-Barr Virus gp42 Protein Bound to the MHC Class II Receptor HLA-DR1. <i>Molecular Cell</i> , 2002, 9, 375-385.	4.5	138
442	HIV entry inhibitors in clinical development. <i>Current Opinion in Pharmacology</i> , 2002, 2, 523-528.	1.7	31

#	ARTICLE	IF	CITATIONS
443	Picornavirusâ€™receptor interactions. Trends in Microbiology, 2002, 10, 324-331.	3.5	201
444	Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine, 2002, 20, 1169-1180.	1.7	30
445	Understanding the basis of CD4+ T-cell depletion in macaques infected by a simianâ€™human immunodeficiency virus. Vaccine, 2002, 20, 1934-1937.	1.7	15
446	Development of an oral primeâ€™boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine, 2002, 20, 1968-1974.	1.7	37
447	An approach to increased polyplex gene delivery by peptides selected from a phage display library. Journal of Proteomics, 2002, 52, 31-43.	2.4	12
448	HIV-1 entry and entry inhibitors as therapeutic agents. Clinics in Laboratory Medicine, 2002, 22, 681-701.	0.7	28
449	PROSPECTS FOR VACCINE PROTECTION AGAINST HIV-1 INFECTION AND AIDS. Annual Review of Immunology, 2002, 20, 73-99.	9.5	173
450	Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation. Journal of Virology, 2002, 76, 8757-8768.	1.5	241
451	The Role of Chemokine Receptors in the Promotion of Viral Infections. , 2002, 10, 210-231.		5
452	Fusion Mediated by the HIV-1 Envelope Protein. , 2000, 34, 457-481.		4
453	Molecular modeling as a powerful technique for understanding smallâ€™large molecules interactions. Il Farmaco, 2002, 57, 153-165.	0.9	19
454	A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains. Antiviral Research, 2002, 56, 233-251.	1.9	37
455	Prospects for immunotherapeutic proteolytic antibodies. Journal of Immunological Methods, 2002, 269, 257-268.	0.6	24
456	Protein recognition by cell surface receptors: physiological receptors versus virus interactions. Trends in Biochemical Sciences, 2002, 27, 122-126.	3.7	69
457	Grafting Segments from the Extracellular Surface of CCR5 onto a Bacteriorhodopsin Transmembrane Scaffold Confers HIV-1 Coreceptor Activity. Structure, 2002, 10, 515-525.	1.6	13
458	Crystal Structure of a Human Rhinovirus that Displays Part of the HIV-1 V3 Loop and Induces Neutralizing Antibodies against HIV-1. Structure, 2002, 10, 999-1011.	1.6	30
459	Crystallisation of membrane proteins mediated by antibody fragments. Current Opinion in Structural Biology, 2002, 12, 503-508.	2.6	180
460	Reductionism and the search for structure-function relationships in antibody molecules. Journal of Molecular Recognition, 2002, 15, 240-247.	1.1	70

#	ARTICLE	IF	CITATIONS
461	Crystal structures of human antibodies: a detailed and unfinished tapestry of immunoglobulin gene products. <i>Journal of Molecular Recognition</i> , 2002, 15, 248-259.	1.1	29
462	Cyclosporin A as a model antigen: immunochemical and structural studies. <i>Journal of Molecular Recognition</i> , 2002, 15, 277-285.	1.1	10
463	Structural features of prions explored by sequence analysis. <i>Sequence data. Cellular and Molecular Life Sciences</i> , 2002, 59, 1366-1376.	2.4	11
464	Detection of orientation-specific anti-gp120 antibodies by a new N-glycanase protection assay. <i>Apmis</i> , 2002, 110, 123-131.	0.9	3
465	Human retroviruses after 20 years: a perspective from the past and prospects for their future control. <i>Immunological Reviews</i> , 2002, 185, 236-265.	2.8	56
466	CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 677-679.	1.0	32
467	Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. <i>BMC Infectious Diseases</i> , 2002, 2, 6.	1.3	60
468	Surrogacy in antiviral drug development. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 75-80.	1.1	3
469	Solution structure of the HIV gp120 C5 Domain. <i>FEBS Journal</i> , 2002, 269, 4860-4867.	0.2	21
470	HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. <i>Nature</i> , 2002, 420, 678-682.	13.7	832
471	Asymmetric inheritance of centrosomally localized mRNAs during embryonic cleavages. <i>Nature</i> , 2002, 420, 682-686.	13.7	212
472	Conformational camouflage. <i>Nature</i> , 2002, 420, 623-624.	13.7	12
473	Structural mechanisms of costimulation. <i>Nature Immunology</i> , 2002, 3, 427-434.	7.0	123
474	Shc: a dominant player after ten seasons. <i>Nature Immunology</i> , 2002, 3, 710-711.	7.0	5
475	HIV entry: are all receptors created equal?. <i>Nature Immunology</i> , 2002, 3, 709-710.	7.0	7
476	Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. <i>Nature Medicine</i> , 2002, 8, 673-680.	15.2	236
477	New hope for an aids vaccine. <i>Nature Reviews Immunology</i> , 2002, 2, 239-250.	10.6	132
478	The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?. <i>Nature Reviews Immunology</i> , 2002, 2, 283-291.	10.6	126

#	ARTICLE	IF	CITATIONS
479	Design, synthesis and evaluation of peptide libraries as potential anti-HIV compounds, via inhibition of gp120/cell membrane interactions, using the gp120/cd4/fab17 crystal structure. <i>European Journal of Medicinal Chemistry</i> , 2002, 37, 883-890.	2.6	15
480	Induction of Secreted Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Factors in CD4-Positive T Lymphocytes by Attenuated HIV-1 Infection. <i>Virology</i> , 2002, 294, 1-12.	1.1	19
481	The N-linked Glycan g15 within the V3 Loop of the HIV-1 External Glycoprotein gp120 Affects Coreceptor Usage, Cellular Tropism, and Neutralization. <i>Virology</i> , 2002, 304, 70-80.	1.1	77
482	Title is missing!. <i>Molecular Biology</i> , 2002, 36, 517-521.	0.4	6
483	Structure and Conformational Properties of the HIVThailand gp120 Immunodominant Epitope. <i>Molecular Biology</i> , 2002, 36, 567-574.	0.4	3
484	Antibody proteases: induction of catalytic response. <i>Biochemistry (Moscow)</i> , 2002, 67, 1168-1179.	0.7	8
485	A Proposal for a Shorter Post-Exposure Prophylaxis of HIV Infection to Prevent Adverse Secondary Reactions. <i>Journal of Infection</i> , 2002, 45, 65.	1.7	0
486	HIV Receptors and Cellular Tropism. <i>IUBMB Life</i> , 2002, 53, 201-205.	1.5	35
487	Neutralizing Antibody Responses to HIV-1 Infection. <i>IUBMB Life</i> , 2002, 53, 197-199.	1.5	9
488	Crystal structure of murine sCEACAM1a[1,4]: a coronavirus receptor in the CEA family. <i>EMBO Journal</i> , 2002, 21, 2076-2086.	3.5	102
489	Discovery of 4-Benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-gp120 Interactions. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 4236-4239.	2.9	206
490	Immunogenicity and Ability of Variable Loop-Deleted Human Immunodeficiency Virus Type 1 Envelope Glycoproteins to Elicit Neutralizing Antibodies. <i>Virology</i> , 2003, 305, 124-137.	1.1	57
491	HADDOCK: A Protein-Protein Docking Approach Based on Biochemical or Biophysical Information. <i>Journal of the American Chemical Society</i> , 2003, 125, 1731-1737.	6.6	2,642
492	Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2003, 40, 209-294.	2.7	793
493	Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies. <i>Journal of Molecular Modeling</i> , 2003, 9, 329-336.	0.8	38
494	Alternative Conformations of HIV-1 V3 Loops Mimic β^2 Hairpins in Chemokines, Suggesting a Mechanism for Coreceptor Selectivity. <i>Structure</i> , 2003, 11, 225-236.	1.6	145
495	Picking the Lock with a Hairpin. <i>Structure</i> , 2003, 11, 129-130.	1.6	4
496	Enhancing Protein Crystallization through Precipitant Synergy. <i>Structure</i> , 2003, 11, 1061-1070.	1.6	75

#	ARTICLE	IF	CITATIONS
497	Cross-reactivity between caprine arthritis-encephalitis virus and type 1 human immunodeficiency virus. Archives of Medical Research, 2003, 34, 362-366.	1.5	11
498	Role of the gp120 inner domain \hat{I}^2 -sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Virology, 2003, 313, 117-125.	1.1	55
499	Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology, 2003, 313, 387-400.	1.1	158
500	Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. Virology, 2003, 315, 292-302.	1.1	17
501	Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology, 2003, 315, 124-134.	1.1	76
502	Caprine arthritis-encephalitis virus-infected goats can generate human immunodeficiency virus-gp120 cross-reactive antibodies11We dedicate this article to the memory of Angeline Douvas.. Virology, 2003, 315, 217-223.	1.1	3
503	Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Virology, 2003, 315, 159-173.	1.1	48
504	A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny. Virology, 2003, 315, 362-372.	1.1	23
505	Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. Virology, 2003, 316, 17-28.	1.1	21
506	New gene-based approaches for an AIDS vaccine. Comparative Immunology, Microbiology and Infectious Diseases, 2003, 26, 357-372.	0.7	7
507	CD4 dependence of gp120IIIB-CXCR4 interaction is cell-type specific. Journal of Neuroimmunology, 2003, 140, 1-12.	1.1	20
508	The potential molecular targets of marine sulfated polymannuroguronate interfering with HIV-1 entryInteraction between SPMG and HIV-1 rgp120 and CD4 molecule. Antiviral Research, 2003, 59, 127-135.	1.9	71
509	Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 2663-2676.	1.4	117
510	Antigenic variations in the CD4 induced sites of the CCR5-tropic, pathogenic SHIVsf162p3 gp120 variants. Journal of Medical Primatology, 2003, 32, 211-217.	0.3	13
511	Assembling atomic resolution views of the immunological synapse. Current Opinion in Immunology, 2003, 15, 286-293.	2.4	5
512	Structural evidence for common functions and ancestry of the reovirus and adenovirus attachment proteins. Reviews in Medical Virology, 2003, 13, 123-132.	3.9	29
513	Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nature Biotechnology, 2003, 21, 71-76.	9.4	182
514	The structural biology of type I viral membrane fusion. Nature Reviews Molecular Cell Biology, 2003, 4, 309-319.	16.1	408

#	ARTICLE	IF	CITATIONS
515	HIV-1 entry inhibitors: new targets, novel therapies. <i>Immunology Letters</i> , 2003, 85, 113-118.	1.1	26
516	Is green tea good for HIV-1 infection?. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 851-853.	1.5	55
517	Turn stability in β -hairpin peptides: Investigation of peptides containing 3:5 type I G1 bulge turns. <i>Protein Science</i> , 2003, 12, 237-247.	3.1	56
518	Structure and Polymorphism of the Principal Neutralization Site of Thailand HIV-1 Isolate. <i>Journal of Biomolecular Structure and Dynamics</i> , 2003, 20, 603-613.	2.0	19
519	Synthesis, Enhanced Fusogenicity, and Solid State NMR Measurements of Cross-Linked HIV-1 Fusion Peptides. <i>Biochemistry</i> , 2003, 42, 3527-3535.	1.2	35
520	Is the V3 Loop Involved in HIV Binding to CD4? <i>Biochemistry</i> , 2003, 42, 9007-9012.	1.2	11
521	Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. <i>Trends in Molecular Medicine</i> , 2003, 9, 468-473.	3.5	43
522	The Mapping and Reconstitution of a Conformational Discontinuous B-cell Epitope of HIV-1. <i>Journal of Molecular Biology</i> , 2003, 334, 87-101.	2.0	89
523	Structure-Function Analysis of Reovirus Binding to Junctional Adhesion Molecule 1. <i>Journal of Biological Chemistry</i> , 2003, 278, 48434-48444.	1.6	67
524	Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate. <i>Biochemical and Biophysical Research Communications</i> , 2003, 312, 1047-1052.	1.0	9
525	Antibacterial activity of peptides derived from envelope glycoproteins of HIV-1. <i>FEBS Letters</i> , 2003, 535, 195-199.	1.3	7
526	Tyrosine Sulfation of Human Antibodies Contributes to Recognition of the CCR5 Binding Region of HIV-1 gp120. <i>Cell</i> , 2003, 114, 161-170.	13.5	186
527	The HIV Env-mediated fusion reaction. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1614, 36-50.	1.4	338
528	HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1614, 51-61.	1.4	66
529	Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. <i>Vaccine</i> , 2003, 21, 1213-1218.	1.7	19
530	Prospects and challenges for prophylactic and therapeutic HIV vaccines. <i>Vaccine</i> , 2003, 21, 616-619.	1.7	4
531	Neutralization epitopes of the HIV-1 primary isolate DH012. <i>Vaccine</i> , 2003, 21, 3301-3306.	1.7	5
532	Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120?CD4 complex in transgenic mice that produce human immunoglobulins. <i>Vaccine</i> , 2003, 21, 4421-4429.	1.7	21

#	ARTICLE	IF	CITATIONS
533	Vaccine for AIDS and Ebola virus infection. <i>Virus Research</i> , 2003, 92, 213-217.	1.1	16
534	Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies. <i>Protein Expression and Purification</i> , 2003, 29, 291-303.	0.6	8
535	Structure of Rab Escort Protein-1 in Complex with Rab Geranylgeranyltransferase. <i>Molecular Cell</i> , 2003, 11, 483-494.	4.5	116
536	Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2'F-RNA Aptamers. <i>Journal of Virology</i> , 2003, 77, 12692-12698.	1.5	167
537	Parasitic Infection and the Polarized Th2 Immune Response Can Alter a Vaccine-Induced Immune Response. <i>DNA and Cell Biology</i> , 2003, 22, 421-430.	0.9	15
538	Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion. <i>Journal of Virology</i> , 2003, 77, 5829-5836.	1.5	64
539	Retrocyclin, an Antiretroviral Î-Defensin, Is a Lectin. <i>Journal of Immunology</i> , 2003, 170, 4708-4716.	0.4	187
540	Multiple Interactions across the Surface of the gp120 Core Structure Determine the Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2003, 77, 8061-8071.	1.5	18
541	Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. <i>Journal of General Virology</i> , 2003, 84, 361-368.	1.3	49
542	Macrophage-Tropic Simian/Human Immunodeficiency Virus Chimeras Use CXCR4, Not CCR5, for Infections of Rhesus Macaque Peripheral Blood Mononuclear Cells and Alveolar Macrophages. <i>Journal of Virology</i> , 2003, 77, 13042-13052.	1.5	37
543	Access of Antibody Molecules to the Conserved Coreceptor Binding Site on Glycoprotein gp120 Is Sterically Restricted on Primary Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2003, 77, 10557-10565.	1.5	343
544	Protein-disulfide Isomerase-mediated Reduction of Two Disulfide Bonds of HIV Envelope Glycoprotein 120 Occurs Post-CXCR4 Binding and Is Required for Fusion. <i>Journal of Biological Chemistry</i> , 2003, 278, 3131-3136.	1.6	140
545	Caprine Arthritis-Encephalitis Virus Envelope Surface Glycoprotein Regions Interacting with the Transmembrane Glycoprotein: Structural and Functional Parallels with Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2003, 77, 11578-11587.	1.5	17
546	Crystal Structure of an Intact Human IgG: Antibody Asymmetry, Flexibility, and a Guide for HIV-1 Vaccine Design. <i>Advances in Experimental Medicine and Biology</i> , 2003, 535, 55-66.	0.8	32
547	Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions. <i>Journal of Virology</i> , 2003, 77, 10528-10536.	1.5	166
548	Effect of Amino Acid Substitution of the V3 and Bridging Sheet Residues in Human Immunodeficiency Virus Type 1 Subtype C gp120 on CCR5 Utilization. <i>Journal of Virology</i> , 2003, 77, 3832-3837.	1.5	38
549	Identification of gp120 Binding Sites on CXCR4 by Using CD4-Independent Human Immunodeficiency Virus Type 2 Env Proteins. <i>Journal of Virology</i> , 2003, 77, 931-942.	1.5	52
550	Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. <i>FASEB Journal</i> , 2003, 17, 1-20.	0.2	28

#	ARTICLE	IF	CITATIONS
551	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2003, 77, 642-658.	1.5	237
552	Neutralization of Human Immunodeficiency Virus Type 1 by sCD4-17b, a Single-Chain Chimeric Protein, Based on Sequential Interaction of gp120 with CD4 and Coreceptor. <i>Journal of Virology</i> , 2003, 77, 2859-2865.	1.5	69
553	Functional Evolution of the HIV-1 Envelope Glycoprotein 120 Association Site of Glycoprotein 41. <i>Journal of Biological Chemistry</i> , 2003, 278, 42149-42160.	1.6	34
554	Cytoplasmic Tail of Moloney Murine Leukemia Virus Envelope Protein Influences the Conformation of the Extracellular Domain: Implications for Mechanism of Action of the R Peptide. <i>Journal of Virology</i> , 2003, 77, 1281-1291.	1.5	70
555	Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions. <i>Journal of Virology</i> , 2003, 77, 5678-5684.	1.5	135
556	CD4 Binding Site Antibodies Inhibit Human Immunodeficiency Virus gp120 Envelope Glycoprotein Interaction with CCR5. <i>Journal of Virology</i> , 2003, 77, 713-718.	1.5	26
557	Turnover of env Variable Region 1 and 2 Genotypes in Subjects with Late-Stage Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2003, 77, 6811-6822.	1.5	49
558	Structural Analysis of the Kaposi's Sarcoma-Associated Herpesvirus K1 Protein. <i>Journal of Virology</i> , 2003, 77, 8072-8086.	1.5	51
559	Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes. <i>Journal of Virology</i> , 2003, 77, 12782-12794.	1.5	22
560	Structural Consequences of Target Epitope-directed Functional Alteration of an Antibody. <i>Journal of Biological Chemistry</i> , 2003, 278, 24929-24936.	1.6	15
561	The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4+T cell-depleted rhesus monkeys. <i>Journal of Leukocyte Biology</i> , 2003, 74, 772-780.	1.5	44
562	Concordant Modulation of Neutralization Resistance and High Infectivity of the Primary Human Immunodeficiency Virus Type 1 MN Strain and Definition of a Potential gp41 Binding Site in gp120. <i>Journal of Virology</i> , 2003, 77, 560-570.	1.5	23
563	A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11013-11018.	3.3	339
564	Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. <i>Journal of Leukocyte Biology</i> , 2003, 74, 676-682.	1.5	114
565	Antibody Fragment Mediated Crystallization of Membrane Proteins. , 2003, , 205-l.		3
566	Increased Mucosal Transmission but Not Enhanced Pathogenicity of the CCR5-Tropic, Simian AIDS-Inducing Simian/Human Immunodeficiency Virus SHIV SF162P3 Maps to Envelope gp120. <i>Journal of Virology</i> , 2003, 77, 989-998.	1.5	79
567	Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design. <i>Journal of Virology</i> , 2003, 77, 5889-5901.	1.5	126
568	Synthetic Combinatorial Libraries as an Alternative Strategy for the Development of Novel Treatments for Infectious Diseases. <i>Methods in Enzymology</i> , 2003, 369, 322-344.	0.4	11

#	ARTICLE	IF	CITATIONS
569	Conservation of the Human Immunodeficiency Virus Type 1 gp120 V1/V2 Stem/Loop Structure in the Equine Infectious Anemia Virus (EIAV) gp90. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 923-924.	0.5	15
570	An HIV Type 1 Subtype B Founder Effect in Korea: gp160 Signature Patterns Infer Circulation of CTL-Escape Strains at the Population Level. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 631-641.	0.5	16
571	Atomic Force Microscopy Investigation of Human Immunodeficiency Virus (HIV) and HIV-Infected Lymphocytes. <i>Journal of Virology</i> , 2003, 77, 11896-11909.	1.5	103
572	Evolution of Cell Recognition by Viruses: A Source of Biological Novelty with Medical Implications. <i>Advances in Virus Research</i> , 2003, 62, 19-111.	0.9	58
573	Conformational Changes in Enveloped Virus Surface Proteins During Cell Entry. <i>Advances in Protein Chemistry</i> , 2003, 64, 325-362.	4.4	6
574	Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15812-15817.	3.3	344
575	Development of a Cell-Based Enzyme-Linked Immunosorbent Assay for High-Throughput Screening of HIV Type 1 Entry Inhibitors Targeting the Coreceptor CXCR4. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 947-955.	0.5	14
576	A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12. <i>Journal of Virology</i> , 2003, 77, 6965-6978.	1.5	67
577	Distinct Mechanisms of Neutralization by Monoclonal Antibodies Specific for Sites in the N-Terminal or C-Terminal Domain of Murine Leukemia Virus SU. <i>Journal of Virology</i> , 2003, 77, 3993-4003.	1.5	19
578	The entry of entry inhibitors: A fusion of science and medicine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10598-10602.	3.3	259
579	Structural Basis for Variation in Adenovirus Affinity for the Cellular Coxsackievirus and Adenovirus Receptor. <i>Journal of Biological Chemistry</i> , 2003, 278, 26208-26215.	1.6	24
580	Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2003, 77, 5863-5876.	1.5	100
581	Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate. <i>Journal of Virology</i> , 2003, 77, 11244-11259.	1.5	144
582	Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region. <i>Journal of Virology</i> , 2003, 77, 2310-2320.	1.5	116
583	Crystal structure of human junctional adhesion molecule 1: Implications for reovirus binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5366-5371.	3.3	144
584	Blocking the docking of HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10581-10582.	3.3	16
585	Contrasting Use of CCR5 Structural Determinants by R5 and R5X4 Variants within a Human Immunodeficiency Virus Type 1 Primary Isolate Quasispecies. <i>Journal of Virology</i> , 2003, 77, 12057-12066.	1.5	9
586	HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. <i>Journal of Leukocyte Biology</i> , 2003, 74, 1117-1124.	1.5	38

#	ARTICLE	IF	CITATIONS
587	The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. <i>Protein Engineering, Design and Selection</i> , 2003, 16, 311-317.	1.0	42
588	CD4-dependent and CD4-independent HIV-2. <i>Aids</i> , 2003, 17, 291-300.	1.0	37
589	A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. <i>Aids</i> , 2003, 17, 691-698.	1.0	130
590	Anticancer and Antiviral Sulfonamides. <i>Current Medicinal Chemistry</i> , 2003, 10, 925-953.	1.2	646
591	Progress in the development of an HIV vaccine. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 37-45.	1.0	13
592	Bioorganic Approaches Towards HIV Vaccine Design. <i>Current Pharmaceutical Design</i> , 2003, 9, 1771-1787.	0.9	16
593	Subunit Protein Vaccines: Theoretical and Practical Considerations for HIV-1. <i>Current Molecular Medicine</i> , 2003, 3, 243-263.	0.6	7
594	CD4-independent infection of HIV and SIV. <i>Aids</i> , 2003, 17, S35-S43.	1.0	39
595	Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. <i>Aids</i> , 2003, 17, 685-689.	1.0	47
596	Clustering of Th Cell Epitopes on Exposed Regions of HIV Envelope Despite Defects in Antibody Activity. <i>Journal of Immunology</i> , 2003, 171, 4140-4148.	0.4	42
597	Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS. <i>Journal of Virology</i> , 2003, 77, 12336-12345.	1.5	149
598	Prospects for an AIDS vaccine. <i>Clinical Medicine</i> , 2003, 3, 269-272.	0.8	7
599	Determination of Epitopes by Mass Spectrometry. , 2004, 94, 109-120.		4
601	Glycoprotein gp120-mediated astrocytic dysfunction. <i>Advances in Molecular and Cell Biology</i> , 2003, 31, 921-949.	0.1	0
602	Hybrid Vigor: Hybrid Methods In Viral Structure Determination. <i>Advances in Protein Chemistry</i> , 2003, 64, 37-91.	4.4	6
603	Immunogenicity and protective efficacy of orally administered recombinant <i>Lactococcus lactis</i> expressing surface-bound HIV Env. <i>Blood</i> , 2003, 102, 223-228.	0.6	131
604	Structural Folds of Viral Proteins. <i>Advances in Protein Chemistry</i> , 2003, 64, 125-196.	4.4	40
605	Î²â€™hairpin polypeptides by design and selection. <i>Spectroscopy</i> , 2003, 17, 213-230.	0.8	4

#	ARTICLE	IF	CITATIONS
606	HIV Vaccine Development: Lessons from the Past and Promise for the Future. <i>Current HIV Research</i> , 2003, 1, 101-120.	0.2	53
607	Replication of lentiviruses. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, s156-174.	3.0	9
608	Vaccines and Vaccine Strategies Against HIV. <i>Current Drug Targets</i> , 2004, 5, 71-88.	1.0	22
609	Three-Dimensional Visualizations in Teaching Genomics and Bioinformatics: Mutations in HIV Envelope Proteins and Their Consequences for Vaccine Design. <i>Journal of Microbiology and Biology Education</i> , 2004, 5, 3-12.	0.2	3
610	Interactions of HIV-1 Proteins gp120 and Nef with Cellular Partners Define a Novel Allosteric Paradigm. <i>Current Protein and Peptide Science</i> , 2004, 5, 1-8.	0.7	33
612	Glycosylation of Immunodominant Linear Epitopes in the Carboxy-Terminal Region of the Caprine Arthritis-Encephalitis Virus Surface Envelope Enhances Vaccine-Induced Type-Specific and Cross-Reactive Neutralizing Antibody Responses. <i>Journal of Virology</i> , 2004, 78, 9190-9202.	1.5	13
613	Virus Attachment and Entry Offer Numerous Targets for Antiviral Therapy. <i>Current Pharmaceutical Design</i> , 2004, 10, 3701-3712.	0.9	54
614	Recent Advances in Understanding the Molecular Mechanisms of HIV-1 Entry and Fusion: Revisiting Current Targets and Considering New Options for Therapeutic Intervention. <i>Current HIV Research</i> , 2004, 2, 223-234.	0.2	49
615	Can HIV be Cured? Mechanisms of HIV Persistence and Strategies to Combat It. <i>Current HIV Research</i> , 2004, 2, 99-111.	0.2	82
616	An Inducible HIV Type 1 gp41 HR-2 Peptide-Binding Site on HIV Type 1 Envelope gp120. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 836-845.	0.5	42
617	Structural Similarities in the Cellular Receptors Used by Adenovirus and Reovirus. <i>Viral Immunology</i> , 2004, 17, 129-143.	0.6	32
618	Migration of Antigen-Specific T Cells Away from CXCR4-Binding Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2004, 78, 5184-5193.	1.5	29
619	Inhibition of respiratory syncytial virus by RhoA-derived peptides: implications for the development of improved antiviral agents targeting heparin-binding viruses. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 54, 299-302.	1.3	14
620	A Single Injection of Recombinant Measles Virus Vaccines Expressing Human Immunodeficiency Virus (HIV) Type 1 Clade B Envelope Glycoproteins Induces Neutralizing Antibodies and Cellular Immune Responses to HIV. <i>Journal of Virology</i> , 2004, 78, 146-157.	1.5	128
621	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. <i>Journal of General Virology</i> , 2004, 85, 911-919.	1.3	206
622	Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins. <i>Journal of Virology</i> , 2004, 78, 10617-10627.	1.5	94
623	G-Protein Coupled Receptors as Allosteric Machines. <i>Receptors and Channels</i> , 2004, 10, 51-60.	1.1	10
624	Influence of Random Genetic Drift on Human Immunodeficiency Virus Type 1 env Evolution During Chronic Infection. <i>Genetics</i> , 2004, 166, 1155-1164.	1.2	65

#	ARTICLE	IF	CITATIONS
625	Mannose-Specific Plant Lectins from the Amaryllidaceae Family Qualify as Efficient Microbicides for Prevention of Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3858-3870.	1.4	147
626	CD4-Induced T-20 Binding to Human Immunodeficiency Virus Type 1 gp120 Blocks Interaction with the CXCR4 Coreceptor. <i>Journal of Virology</i> , 2004, 78, 5448-5457.	1.5	58
627	DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade. <i>Clinical Microbiology Reviews</i> , 2004, 17, 370-389.	5.7	82
628	Determinants of Human Immunodeficiency Virus Type 1 Baseline Susceptibility to the Fusion Inhibitors Enfuvirtide and T-649 Reside outside the Peptide Interaction Site. <i>Journal of Virology</i> , 2004, 78, 7582-7589.	1.5	64
629	Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2004, 78, 12975-12986.	1.5	65
630	The Raft-Promoting Property of Virion-Associated Cholesterol, but Not the Presence of Virion-Associated Brij 98 Rafts, Is a Determinant of Human Immunodeficiency Virus Type 1 Infectivity. <i>Journal of Virology</i> , 2004, 78, 10556-10565.	1.5	59
631	N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies. <i>Journal of Virology</i> , 2004, 78, 3279-3295.	1.5	146
632	Role of Hydrophobic Residues in the Central Ectodomain of gp41 in Maintaining the Association between Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Subunits gp120 and gp41. <i>Journal of Virology</i> , 2004, 78, 4921-4926.	1.5	37
633	Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission. <i>Science</i> , 2004, 303, 2019-2022.	6.0	572
634	Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 2706-2711.	3.3	278
635	CD4 Receptor Localized to Non-raft Membrane Microdomains Supports HIV-1 Entry. <i>Journal of Biological Chemistry</i> , 2004, 279, 704-712.	1.6	106
636	Evolutionary Dynamics of the Glycan Shield of the Human Immunodeficiency Virus Envelope during Natural Infection and Implications for Exposure of the 2G12 Epitope. <i>Journal of Virology</i> , 2004, 78, 12625-12637.	1.5	68
637	G-Protein Coupled Receptors as Allosteric Machines. <i>Receptors and Channels</i> , 2004, 10, 51-60.	1.1	42
638	CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. <i>Aids</i> , 2004, 18, 2115-2125.	1.0	67
639	Antiviral Sulfonamide Derivatives. <i>Mini-Reviews in Medicinal Chemistry</i> , 2004, 4, 189-200.	1.1	103
640	Characterization of the Conformational State and Flexibility of HIV-1 Glycoprotein gp120 Core Domain. <i>Journal of Biological Chemistry</i> , 2004, 279, 30523-30530.	1.6	29
641	Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker. <i>Journal of Virology</i> , 2004, 78, 5651-5657.	1.5	27
642	Localized Changes in the gp120 Envelope Glycoprotein Confer Resistance to Human Immunodeficiency Virus Entry Inhibitors BMS-806 and #155. <i>Journal of Virology</i> , 2004, 78, 3742-3752.	1.5	126

#	ARTICLE	IF	CITATIONS
643	Development of a homology model for clade A human immunodeficiency virus type 1 gp120 to localize temporal substitutions arising in recently infected women. <i>Journal of General Virology</i> , 2004, 85, 1479-1484.	1.3	0
644	Bifunctional Anti-Human Immunodeficiency Virus Type 1 Small Molecules with Two Novel Mechanisms of Action. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 663-665.	1.4	47
645	Naturally Occurring Proteolytic Antibodies. <i>Journal of Biological Chemistry</i> , 2004, 279, 39611-39619.	1.6	77
646	The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection. <i>Journal of Virology</i> , 2004, 78, 5205-5215.	1.5	236
647	A Chimeric Protein of Simian Immunodeficiency Virus Envelope Glycoprotein gp140 and <i>Escherichia coli</i> Aspartate Transcarbamoylase. <i>Journal of Virology</i> , 2004, 78, 4508-4516.	1.5	15
648	Use of CD134 As a Primary Receptor by the Feline Immunodeficiency Virus. <i>Science</i> , 2004, 303, 1192-1195.	6.0	170
649	Effects of Human Immunodeficiency Virus Type 1 Infection on CCR5 and CXCR4 Coreceptor Expression on CD4 T Lymphocyte Subsets in Infants and Adolescents. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 305-313.	0.5	18
650	Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. <i>Protein Engineering, Design and Selection</i> , 2004, 17, 749-758.	1.0	54
651	Substitution of HIV Type-1 Non-B env Genes in C2, a Subtype B Cassette System, Results in Functional Chimeric Viruses. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 964-971.	0.5	1
652	Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor. <i>Journal of Virology</i> , 2004, 78, 2790-2807.	1.5	195
653	Impact of Mutations in the Coreceptor Binding Site on Human Immunodeficiency Virus Type 1 Fusion, Infection, and Entry Inhibitor Sensitivity. <i>Journal of Virology</i> , 2004, 78, 5476-5485.	1.5	111
654	Superallergens: a novel mechanism of IgE-mediated activation of human basophils and mast cells. <i>Clinical and Experimental Allergy Reviews</i> , 2004, 4, 64-75.	0.3	5
655	The brightening future of HIV therapeutics. <i>Nature Immunology</i> , 2004, 5, 867-871.	7.0	33
656	Genetic, cellular and immune approaches to disease therapy: past and future. <i>Nature Medicine</i> , 2004, 10, 135-141.	15.2	74
657	Identifying epitopes of HIV-1 that induce protective antibodies. <i>Nature Reviews Immunology</i> , 2004, 4, 199-210.	10.6	292
658	Virus entry: molecular mechanisms and biomedical applications. <i>Nature Reviews Microbiology</i> , 2004, 2, 109-122.	13.6	504
659	Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. <i>Gene Therapy</i> , 2004, 11, 1068-1080.	2.3	34
660	Structural Rationale for the Broad Neutralization of HIV-1 by Human Monoclonal Antibody 447-52D. <i>Structure</i> , 2004, 12, 193-204.	1.6	185

#	ARTICLE	IF	CITATIONS
661	Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. <i>Journal of Immunological Methods</i> , 2004, 287, 49-65.	0.6	33
662	Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. <i>Journal of Virological Methods</i> , 2004, 116, 177-180.	1.0	61
663	Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. <i>Virology</i> , 2004, 318, 493-506.	1.1	27
664	Neutralization sensitivity of a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2N) isolated from an infected rhesus macaque with neurological disease. <i>Virology</i> , 2004, 322, 168-181.	1.1	10
665	Atomic force microscopy investigation of wild-type Moloney murine leukemia virus particles and virus particles lacking the envelope protein. <i>Virology</i> , 2004, 323, 189-196.	1.1	33
666	HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. <i>Virology</i> , 2004, 324, 90-102.	1.1	19
667	Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. <i>Virology</i> , 2004, 324, 525-530.	1.1	19
668	A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. <i>Virology</i> , 2004, 326, 299-309.	1.1	13
669	Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. <i>Virology</i> , 2004, 328, 74-88.	1.1	49
670	Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. <i>Virology</i> , 2004, 329, 465-476.	1.1	24
671	Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. <i>Virology</i> , 2004, 330, 233-248.	1.1	56
672	Inhibition of certain strains of HIV-1 by cell surface polyanions in the form of cholesterol-labeled oligonucleotides. <i>Virology</i> , 2004, 330, 50-61.	1.1	10
673	Interaction of sulfonated anionic porphyrins with HIV glycoprotein gp120: photodamages revealed by inhibition of antibody binding to V3 and C5 domains. <i>Antiviral Research</i> , 2004, 61, 37-47.	1.9	21
674	A novel peptide that inhibits HIV-1 entry. <i>Science Bulletin</i> , 2004, 49, 2110.	1.7	0
675	How Viruses Enter Animal Cells. <i>Science</i> , 2004, 304, 237-242.	6.0	671
676	The HF-SCF energy of HIV-1 MNgp120 V3 hairpin loop conformers. <i>Journal of Molecular Modeling</i> , 2004, 10, 367-372.	0.8	4
677	The quantity and diversity of infectious viruses in various tissues of SHIV-infected monkeys at the early and AIDS stages. <i>Archives of Virology</i> , 2004, 149, 943-955.	0.9	10
678	Complestatin synthetic studies. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 1697-1702.	1.0	14

#	ARTICLE	IF	CITATIONS
679	Adsorption of a Novel Recombinant Glycoprotein from HIV (Env gp120dV2 SF162) to Anionic PLG Microparticles Retains the Structural Integrity of the Protein, Whereas Encapsulation in PLG Microparticles Does Not. <i>Pharmaceutical Research</i> , 2004, 21, 2148-2152.	1.7	49
680	Linkage of Amino Acid Variation and Evolution of Human Immunodeficiency Virus Type 1 gp120 Envelope Glycoprotein (Subtype B) with Usage of the Second Receptor. <i>Journal of Molecular Evolution</i> , 2004, 58, 333-340.	0.8	16
681	Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 55, 582-593.	1.5	39
682	Domain swapping of CD4 upon dimerization. <i>Proteins: Structure, Function and Bioinformatics</i> , 2004, 57, 205-212.	1.5	18
683	Prospects of HIV-1 entry inhibitors as novel therapeutics. <i>Reviews in Medical Virology</i> , 2004, 14, 255-270.	3.9	68
684	Structure of apo acyl carrier protein and a proposal to engineer protein crystallization through metal ions. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1545-1554.	2.5	43
685	<i>Punica granatum</i> (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide. <i>BMC Infectious Diseases</i> , 2004, 4, 41.	1.3	53
686	Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). , 2004, 1, 10.		97
687	A Peptidomimetic HIV-Entry Inhibitor Directed against the CD4 Binding Site of the Viral Glycoprotein gp120. <i>Angewandte Chemie - International Edition</i> , 2004, 43, 2937-2940.	7.2	19
688	Cross-strand disulphides in cell entry proteins: poised to act. <i>BioEssays</i> , 2004, 26, 73-79.	1.2	61
690	Characterize dynamic conformational space of human CCR5 extracellular domain by molecular modeling and molecular dynamics simulation. <i>Computational and Theoretical Chemistry</i> , 2004, 673, 133-143.	1.5	9
691	Characterization of glycopeptides from HIV-ISF2 gp120 by liquid chromatography mass spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2004, 15, 1545-1555.	1.2	67
692	Thrombin activates envelope glycoproteins of HIV type 1 and enhances fusion. <i>Microbes and Infection</i> , 2004, 6, 414-420.	1.0	10
693	Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. <i>Current Opinion in Immunology</i> , 2004, 16, 470-476.	2.4	53
694	Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2673-2676.	1.0	10
696	Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. <i>Organic and Biomolecular Chemistry</i> , 2004, 2, 483.	1.5	63
697	Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. <i>Journal of Virology</i> , 2004, 78, 13232-13252.	1.5	665
698	Native HIV Type 1 Virion Surface Structures: Relationships between Antibody Binding and Neutralization or Lessons from the Viral Capture Assay. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 435-441.	0.5	18

#	ARTICLE	IF	CITATIONS
699	MOLECULAR MAKEUP OF HIV-1 ENVELOPE PROTEIN. International Reviews of Immunology, 2004, 23, 383-411.	1.5	8
700	3D Structure Model of the Principal Neutralizing Epitope of Minnesota HIV-1 Isolate. Journal of Biomolecular Structure and Dynamics, 2004, 21, 577-590.	2.0	15
701	Dual Spatial Folds and Different Local Structures of the HIV-1 Immunogenic Crown in Various Virus Isolates. Journal of Biomolecular Structure and Dynamics, 2004, 22, 159-170.	2.0	15
702	Inhibition of HIV-1 Envelope-Mediated Fusion by Synthetic Batzelladine Analogues. Journal of Natural Products, 2004, 67, 1319-1324.	1.5	47
703	Solid-State NMR Yields Structural Constraints on the V3 Loop from HIV-1 Gp120 Bound to the 447-52D Antibody Fv Fragment. Journal of the American Chemical Society, 2004, 126, 4979-4990.	6.6	49
704	Synthetic Bivalent CD4-Mimetic Miniproteins Show Enhanced Anti-HIV Activity over the Monovalent Miniprotein. Bioconjugate Chemistry, 2004, 15, 783-789.	1.8	20
705	Mode of Action for Linear Peptide Inhibitors of HIV-1 gp120 Interactions. Biochemistry, 2004, 43, 1928-1938.	1.2	51
706	Crystal Structure of the Broadly Cross-Reactive HIV-1-Neutralizing Fab X5 and Fine Mapping of Its Epitope,. Biochemistry, 2004, 43, 1410-1417.	1.2	50
707	Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology, 2004, , .	1.1	0
708	Introduction to Retroviruses. , 2004, , 57-93.		0
709	Discovery and Development of New HIV Medicines. , 2004, , 855-866.		1
710	A novel and conserved pocket of human \hat{I}^e -Fab fragments: Design, synthesis, and verification of directed affinity ligands. Protein Science, 2004, 13, 1476-1488.	3.1	11
711	gp340 (SAG) Binds to the V3 Sequence of gp120 Important for Chemokine Receptor Interaction. AIDS Research and Human Retroviruses, 2004, 20, 600-607.	0.5	35
712	Brownian Adhesive Dynamics (BRAD) for Simulating the Receptor-Mediated Binding of Viruses. Biophysical Journal, 2004, 86, 3359-3372.	0.2	36
713	Enfuvirtide (T-20): Potentials and Challenges. Journal of the Association of Nurses in AIDS Care, 2004, 15, 65-71.	0.4	5
714	Early steps of retrovirus replicative cycle. Retrovirology, 2004, 1, 9.	0.9	139
715	Inferring Property Selection Pressure from Positional Residue Conservation. Applied Bioinformatics, 2004, 3, 167-179.	1.7	4
716	A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Review of Vaccines, 2004, 3, S105-S117.	2.0	36

#	ARTICLE	IF	CITATIONS
717	The Many Mechanisms of Viral Membrane Fusion Proteins. <i>Current Topics in Microbiology and Immunology</i> , 2004, 285, 25-66.	0.7	326
718	The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. <i>Current Opinion in Pharmacology</i> , 2004, 4, 447-452.	1.7	47
719	HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications. <i>Drug Resistance Updates</i> , 2004, 7, 89-95.	6.5	38
720	The use of recombinant methods and molecular engineering in protein crystallization. <i>Methods</i> , 2004, 34, 354-363.	1.9	141
721	HIV-1 entry inhibitor entrances. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 117-120.	4.0	16
722	Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein. <i>Peptides</i> , 2004, 25, 551-561.	1.2	5
723	Physical methods for structure, dynamics and binding in immunological research. <i>Trends in Immunology</i> , 2004, 25, 700-707.	2.9	29
724	Improved Breadth and Potency of an HIV-1-Neutralizing Human Single-chain Antibody by Random Mutagenesis and Sequential Antigen Panning. <i>Journal of Molecular Biology</i> , 2004, 335, 209-219.	2.0	68
725	New Carbohydrate Specificity and HIV-1 Fusion Blocking Activity of the Cyanobacterial Protein MVL: NMR, ITC and Sedimentation Equilibrium Studies. <i>Journal of Molecular Biology</i> , 2004, 339, 901-914.	2.0	56
726	Cyclam complexes and their applications in medicine. <i>Chemical Society Reviews</i> , 2004, 33, 246.	18.7	289
727	Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. <i>Aids</i> , 2004, 18, 329-331.	1.0	24
728	HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. <i>Aids</i> , 2004, 18, 1769-1779.	1.0	57
729	Synthesis and Biological Evaluation of Peptide Mimics Derived from First Extracellular Loop of CCR5 toward HIV-1. <i>Chemical and Pharmaceutical Bulletin</i> , 2004, 52, 1479-1482.	0.6	0
730	Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. <i>Blood</i> , 2005, 105, 2802-2811.	0.6	44
731	HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation. <i>Blood</i> , 2005, 105, 4693-4699.	0.6	58
732	A high-throughput fluorescence polarization assay specific to the CD4 binding site of HIV-1 glycoproteins based on a fluorescein-labelled CD4 mimic. <i>Biochemical Journal</i> , 2005, 390, 29-39.	1.7	22
733	Characteristics of HIV-1 env1 V3 loop sequences for subtype A1 variant spread in Eastern Europe. <i>Infection, Genetics and Evolution</i> , 2005, 5, 45-53.	1.0	10
734	Solubilization, stabilization, and purification of chemokine receptors using biosensor technology. <i>Analytical Biochemistry</i> , 2005, 339, 271-281.	1.1	90

#	ARTICLE	IF	CITATIONS
735	Punica granatum (Pomegranate) Juice Provides an HIV-1 Entry Inhibitor and Candidate Topical Microbicide. <i>Annals of the New York Academy of Sciences</i> , 2005, 1056, 311-327.	1.8	67
736	Polyvalent Interactions of HIV-gp120 Protein and Nanostructures of Carbohydrate Ligands. <i>Nanobiotechnology</i> , 2005, 1, 201-210.	1.2	12
737	Engineering and functional evaluation of a single-chain antibody against HIV-1 external glycoprotein gp120. <i>Clinical and Experimental Immunology</i> , 2005, 141, 72-80.	1.1	9
738	Structure of an unliganded simian immunodeficiency virus gp120 core. <i>Nature</i> , 2005, 433, 834-841.	13.7	483
739	Refolding the envelope. <i>Nature</i> , 2005, 433, 815-816.	13.7	34
740	HIV entry inhibitors: a new generation of antiretroviral drugs. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 1165-1173.	2.8	20
741	HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. <i>Brain Research Reviews</i> , 2005, 50, 14-26.	9.1	97
742	Cell-based and biochemical screening approaches for the discovery of novel HIV-1 inhibitors. <i>Antiviral Research</i> , 2005, 67, 121-140.	1.9	43
744	Keynote review: Progress in targeting HIV-1 entry. <i>Drug Discovery Today</i> , 2005, 10, 1085-1094.	3.2	101
745	Modification of a viral envelope glycoprotein cell-cell fusion assay by utilizing plasmid encoded bacteriophage RNA polymerase. <i>Journal of Virological Methods</i> , 2005, 128, 135-142.	1.0	9
746	Determining the Structure of an Unliganded and Fully Glycosylated SIV gp120 Envelope Glycoprotein. <i>Structure</i> , 2005, 13, 197-211.	1.6	67
747	Scorpion-Toxin Mimics of CD4 in Complex with Human Immunodeficiency Virus gp120. <i>Structure</i> , 2005, 13, 755-768.	1.6	107
748	Proteins that bind high-mannose sugars of the HIV envelope. <i>Progress in Biophysics and Molecular Biology</i> , 2005, 88, 233-282.	1.4	87
749	Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. <i>Virology</i> , 2005, 331, 20-32.	1.1	54
750	Multiple domains of the SIV Env protein determine virus replication efficiency and neutralization sensitivity. <i>Virology</i> , 2005, 332, 89-101.	1.1	23
751	Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers. <i>Virology</i> , 2005, 332, 369-383.	1.1	19
752	Substitutions of conserved amino acids in the receptor-binding domain of the spike glycoprotein affect utilization of murine CEACAM1a by the murine coronavirus MHV-A59. <i>Virology</i> , 2005, 334, 98-110.	1.1	13
753	Neutralization sensitivity of HIV-1 Env-pseudotyped virus clones is determined by co-operativity between mutations which modulate the CD4-binding site and those that affect gp120-gp41 stability. <i>Virology</i> , 2005, 337, 136-148.	1.1	6

#	ARTICLE	IF	CITATIONS
754	Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). <i>Virology</i> , 2005, 338, 182-199.	1.1	152
755	Mutations increasing exposure of a receptor binding site epitope in the soluble and oligomeric forms of the caprine arthritis-encephalitis lentivirus envelope glycoprotein. <i>Virology</i> , 2005, 339, 261-272.	1.1	8
756	Identification of N-phenyl-N ^ε -(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. <i>Virology</i> , 2005, 339, 213-225.	1.1	212
757	Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. <i>European Journal of Immunology</i> , 2005, 35, 2541-2551.	1.6	30
758	Strategies for Targeting Protein-Protein Interactions With Synthetic Agents. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 4130-4163.	7.2	422
759	High Thermal Stability Imparted by a Designed Tandem Arg-Trp Stretch in an α -Helical Coiled Coil. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 6180-6183.	7.2	47
762	Broadly distributed nucleophilic reactivity of proteins coordinated with specific ligand binding activity. <i>Journal of Molecular Recognition</i> , 2005, 18, 295-306.	1.1	17
763	Antibodies as defensive enzymes. <i>Seminars in Immunopathology</i> , 2005, 26, 485-503.	4.0	31
764	Highly conserved β 16/ β 17 β 2-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding. <i>Journal of Molecular Medicine</i> , 2005, 83, 542-552.	1.7	9
765	Sequence analysis on biological active peptides using electrospray ionization-Fourier transform ion cyclotron resonance mass spectrometer. <i>Science Bulletin</i> , 2005, 50, 853-857.	1.7	1
766	A conserved structural motif shared by EIAV gp90 and HIV gp120. <i>Science Bulletin</i> , 2005, 50, 2393-2394.	1.7	0
767	Cloning, expression, purification, crystallization and preliminary crystallographic study of the protein module (BIV2-Helix) in the fusion core of bovine immunodeficiency-like virus (BIV) gp40. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2005, 61, 249-251.	0.7	0
769	HIV vaccine development. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2064.	3.0	5
770	Tetraspanins in Viral Infections: a Fundamental Role in Viral Biology?. <i>Journal of Virology</i> , 2005, 79, 10839-10851.	1.5	94
771	HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway. <i>International Immunology</i> , 2005, 17, 729-736.	1.8	32
772	HIV-1 gp120 V3 Loop for Structure-Based Drug Design. <i>Current Protein and Peptide Science</i> , 2005, 6, 413-422.	0.7	59
773	Highly Active Antiretroviral Therapy: Current State of the Art, New Agents and Their Pharmacological Interactions Useful for Improving Therapeutic Outcome. <i>Current Pharmaceutical Design</i> , 2005, 11, 1805-1843.	0.9	222
774	Conformational Properties of HIV-1 gp120/V3 Immunogenic Domains. <i>Current Medicinal Chemistry</i> , 2005, 12, 1551-1538.	1.2	18

#	ARTICLE	IF	CITATIONS
775	A conserved structural motif shared by EIAV gp90 and HIV. <i>Science Bulletin</i> , 2005, 50, 2393.	1.7	0
776	Induction of Humoral Immune Responses following Vaccination with Envelope-Containing, Formaldehyde-Treated, Thermally Inactivated Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 4927-4935.	1.5	34
777	Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor. <i>Journal of Virology</i> , 2005, 79, 5996-6004.	1.5	46
778	Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Entry Inhibitors That Target the gp120-Binding Domain of CD4. <i>Journal of Virology</i> , 2005, 79, 6122-6133.	1.5	47
779	Crystal Structures of the HIV-1 Inhibitory Cyanobacterial Protein MVL Free and Bound to Man3GlcNAc2. <i>Journal of Biological Chemistry</i> , 2005, 280, 29269-29276.	1.6	58
780	Structure of a V3-Containing HIV-1 gp120 Core. <i>Science</i> , 2005, 310, 1025-1028.	6.0	696
781	Variants of Human Immunodeficiency Virus Type 1 That Efficiently Use CCR5 Lacking the Tyrosine-Sulfated Amino Terminus Have Adaptive Mutations in gp120, Including Loss of a Functional N-Glycan. <i>Journal of Virology</i> , 2005, 79, 4357-4368.	1.5	26
782	Receptor-Induced Conformational Changes in the SU Subunit of the Avian Sarcoma/Leukosis Virus A Envelope Protein: Implications for Fusion Activation. <i>Journal of Virology</i> , 2005, 79, 3488-3499.	1.5	18
783	Interaction of tSNARE Syntaxin 18 with the Papillomavirus Minor Capsid Protein Mediates Infection. <i>Journal of Virology</i> , 2005, 79, 6723-6731.	1.5	67
784	Comprehensive Analysis of Ebola Virus GP1 in Viral Entry. <i>Journal of Virology</i> , 2005, 79, 4793-4805.	1.5	144
785	Single-Molecule Analysis of Human Immunodeficiency Virus Type 1 gp120-Receptor Interactions in Living Cells. <i>Journal of Virology</i> , 2005, 79, 14748-14755.	1.5	71
786	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. <i>Journal of Experimental Medicine</i> , 2005, 201, 1407-1419.	4.2	296
787	Resistance of Human Immunodeficiency Virus Type 1 to the High-Mannose Binding Agents Cyanovirin N and Concanavalin A. <i>Journal of Virology</i> , 2005, 79, 7777-7784.	1.5	89
788	Soluble Mimetics of Human Immunodeficiency Virus Type 1 Viral Spikes Produced by Replacement of the Native Trimerization Domain with a Heterologous Trimerization Motif: Characterization and Ligand Binding Analysis. <i>Journal of Virology</i> , 2005, 79, 9954-9969.	1.5	67
789	Identification of Two N-Linked Glycosylation Sites within the Core of the Simian Immunodeficiency Virus Glycoprotein Whose Removal Enhances Sensitivity to Soluble CD4. <i>Journal of Virology</i> , 2005, 79, 12575-12583.	1.5	30
790	Complex Determinants in Human Immunodeficiency Virus Type 1 Envelope gp120 Mediate CXCR4-Dependent Infection of Macrophages. <i>Journal of Virology</i> , 2005, 79, 13250-13261.	1.5	39
791	Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. <i>Journal of Virology</i> , 2005, 79, 8454-8469.	1.5	76
792	Viral Membrane Proteins: Structure, Function, and Drug Design. , 2005, , .		9

#	ARTICLE	IF	CITATIONS
793	Role of Neutralizing Antibodies in Protective Immunity Against HIV. <i>Hum Vaccin</i> , 2005, 1, 45-60.	2.4	40
794	Production and characterization of a phage-display recombinant antibody against carrageenans: evidence for the recognition of a secondary structure of carrageenan chains present in red algae tissues. <i>Glycobiology</i> , 2005, 15, 849-860.	1.3	11
795	Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120. <i>Journal of Biological Chemistry</i> , 2005, 280, 41005-41014.	1.6	108
796	Steric Accessibility of the HIV-1 gp41 N-trimer Region. <i>Journal of Biological Chemistry</i> , 2005, 280, 12567-12572.	1.6	68
797	HIV-2 Infection and Chemokine Receptors Usage - Clues to Reduced Virulence of HIV-2. <i>Current HIV Research</i> , 2005, 3, 3-16.	0.2	15
798	A Conservative Domain Shared by HIV gp120 and EIAV gp90: Implications for HIV Vaccine Design. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 1057-1059.	0.5	8
799	New Insights into Human Immunodeficiency Virus Type 1 Replication. <i>Biotechnology and Biotechnological Equipment</i> , 2005, 19, 3-15.	0.5	1
800	Short Communication:HIV Type 1 Phenotype, Tropism, and Sequence Patterns: Association and Preference. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 234-238.	0.5	8
801	The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor. <i>Molecular Pharmacology</i> , 2005, 67, 1268-1282.	1.0	283
802	Design, Expression, and Immunogenicity of a Soluble HIV Trimeric Envelope Fragment Adopting a Prefusion gp41 Configuration. <i>Journal of Biological Chemistry</i> , 2005, 280, 23138-23146.	1.6	24
803	Retrovirus envelope protein complex structure in situ studied by cryo-electron tomography. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 4729-4734.	3.3	299
804	Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120. <i>Journal of Biological Chemistry</i> , 2005, 280, 11259-11273.	1.6	206
805	Functional Mimicry of a Human Immunodeficiency Virus Type 1 Coreceptor by a Neutralizing Monoclonal Antibody. <i>Journal of Virology</i> , 2005, 79, 6068-6077.	1.5	34
806	Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines. <i>Journal of Virology</i> , 2005, 79, 6089-6101.	1.5	123
807	Marked Depletion of Glycosylation Sites in HIV-1 gp120 under Selection Pressure by the Mannose-Specific Plant Lectins of <i>Hippeastrum Hybrid</i> and <i>Galanthus nivalis</i> . <i>Molecular Pharmacology</i> , 2005, 67, 1556-1565.	1.0	62
808	Comparing Antigenicity and Immunogenicity of Engineered gp120. <i>Journal of Virology</i> , 2005, 79, 12148-12163.	1.5	96
809	Interaction with CD4 and Antibodies to CD4-Induced Epitopes of the Envelope gp120 from a Microglial Cell-Adapted Human Immunodeficiency Virus Type 1 Isolate. <i>Journal of Virology</i> , 2005, 79, 6703-6713.	1.5	18
810	A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14759-14764.	3.3	136

#	ARTICLE	IF	CITATIONS
811	Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles. <i>Journal of Virology</i> , 2005, 79, 5232-5237.	1.5	142
812	Inhibition of Coreceptor-Independent Cell-to-Cell Human Immunodeficiency Virus Type 1 Transmission by a CD4-Immunoglobulin G2 Fusion Protein. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4296-4304.	1.4	22
813	N-Linked Glycosylation in C2 Region of HIV-1 Envelope Reduces Sensitivity to Neutralizing Antibodies. <i>Viral Immunology</i> , 2005, 18, 343-353.	0.6	22
815	Thermochemistry of Binary and Ternary Protein Interactions Measured by Titration Calorimetry: Complex Formation of CD4, HIV gp120, and Anti-gp120. , 2005, , 147-163.		3
816	Virion Envelope Content, Infectivity, and Neutralization Sensitivity of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2005, 79, 12455-12463.	1.5	49
817	Functional Chimeras of Human Immunodeficiency Virus Type 1 gp120 and Influenza A Virus (H3) Hemagglutinin. <i>Journal of Virology</i> , 2005, 79, 6459-6471.	1.5	2
818	Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains. <i>Journal of Virology</i> , 2005, 79, 6957-6968.	1.5	80
819	The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner. <i>Journal of Virology</i> , 2005, 79, 9069-9080.	1.5	107
820	Ternary Complex Formation of Human Immunodeficiency Virus Type 1 Env, CD4, and Chemokine Receptor Captured as an Intermediate of Membrane Fusion. <i>Journal of Virology</i> , 2005, 79, 11161-11169.	1.5	53
821	Structure of the Fab Fragment of F105, a Broadly Reactive Anti-Human Immunodeficiency Virus (HIV) Antibody That Recognizes the CD4 Binding Site of HIV Type 1 gp120. <i>Journal of Virology</i> , 2005, 79, 13060-13069.	1.5	30
822	Evidence for Heterogeneous Selective Pressures in the Evolution of the env Gene in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Virology</i> , 2005, 79, 1836-1841.	1.5	34
823	A Genomics Approach to the Detection of Positive Selection in Cattle:. <i>Genetics</i> , 2005, 170, 1189-1196.	1.2	20
824	An Aptamer That Neutralizes R5 Strains of Human Immunodeficiency Virus Type 1 Blocks gp120-CCR5 Interaction. <i>Journal of Virology</i> , 2005, 79, 13806-13810.	1.5	80
825	Alanine Scanning Mutants of the HIV gp41 Loop. <i>Journal of Biological Chemistry</i> , 2005, 280, 27284-27288.	1.6	45
826	The Distal Short Consensus Repeats 1 and 2 of the Membrane Cofactor Protein CD46 and Their Distance from the Cell Membrane Determine Productive Entry of Species B Adenovirus Serotype 35. <i>Journal of Virology</i> , 2005, 79, 10013-10022.	1.5	46
827	Probing Sequence Variation in the Receptor-Targeting Domain of Feline Leukemia Virus Envelope Proteins with Peptide Display Libraries. <i>Journal of Virology</i> , 2005, 79, 1463-1469.	1.5	19
828	An Unrelated Monoclonal Antibody Neutralizes Human Immunodeficiency Virus Type 1 by Binding to an Artificial Epitope Engineered in a Functionally Neutral Region of the Viral Envelope Glycoproteins. <i>Journal of Virology</i> , 2005, 79, 5616-5624.	1.5	49
829	The Molecular Targets of Anti-HIV-1 Triterpenes, An Update. <i>Medicinal Chemistry Reviews Online</i> , 2005, 2, 423-427.	0.1	4

#	ARTICLE	IF	CITATIONS
830	CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV Infection. <i>Antiviral Chemistry and Chemotherapy</i> , 2005, 16, 339-354.	0.3	106
831	Antibody vs. HIV in a clash of evolutionary titans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14943-14948.	3.3	268
832	Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga <i>Griffithsia</i> sp.. <i>Journal of Biological Chemistry</i> , 2005, 280, 9345-9353.	1.6	381
833	Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 Loop Library. <i>Journal of Biological Chemistry</i> , 2005, 280, 30083-30090.	1.6	31
834	Mechanism of Membrane Fusion by Viral Envelope Proteins. <i>Advances in Virus Research</i> , 2005, 64, 231-261.	0.9	162
835	Regulation of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail. <i>Journal of Virology</i> , 2005, 79, 12231-12241.	1.5	115
836	Macromolecular crystallization with microfluidic free-interface diffusion. <i>Expert Review of Proteomics</i> , 2005, 2, 165-172.	1.3	22
837	Quantitative Evaluation of HIV and SIV Co-Receptor Use With GHOST(3) Cell Assay. , 2005, 304, 333-342.		10
838	Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 726-731.	4.6	94
839	Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 1199-1212.	1.9	26
840	Conformational Changes in HIV-1 gp41 in the Course of HIV-1 Envelope Glycoprotein-Mediated Fusion and Inactivation. <i>Biochemistry</i> , 2005, 44, 12471-12479.	1.2	59
841	Computational Study of the Dynamics of Mannose Disaccharides Free in Solution and Bound to the Potent Anti-HIV Virucidal Protein Cyanovirin. <i>Journal of Physical Chemistry B</i> , 2005, 109, 3639-3647.	1.2	22
842	Induced Fit in HIV-Neutralizing Antibody Complexes: Evidence for Alternative Conformations of the gp120 V3 Loop and the Molecular Basis for Broad Neutralization. <i>Biochemistry</i> , 2005, 44, 7250-7258.	1.2	62
843	Structure and Dynamics of Micelle-Associated Human Immunodeficiency Virus gp41 Fusion Domain. <i>Biochemistry</i> , 2005, 44, 16167-16180.	1.2	124
844	Conformational Preferences of the HIV-1 Principal Neutralizing Determinant. <i>Journal of Biomolecular Structure and Dynamics</i> , 2005, 23, 267-282.	2.0	5
845	Chemoenzymatic Synthesis of HIV-1 V3 Glycopeptides Carrying Two N-Glycans and Effects of Glycosylation on the Peptide Domain. <i>Journal of Organic Chemistry</i> , 2005, 70, 9990-9996.	1.7	82
846	Protein Minimization of the gp120 Binding Region of Human CD4. <i>Biochemistry</i> , 2005, 44, 16192-16202.	1.2	30
847	V3: HIV's Switch-Hitter. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 171-189.	0.5	260

#	ARTICLE	IF	CITATIONS
848	CD4 Binding Partially Locks the Bridging Sheet in gp120 but Leaves the $\hat{I}^{2/3}$ Strands Flexible. <i>Journal of Molecular Biology</i> , 2005, 350, 514-527.	2.0	24
849	Restricted Variable Residues in the C-terminal Segment of HIV-1 V3 Loop Regulate the Molecular Anatomy of CCR5 Utilization. <i>Journal of Molecular Biology</i> , 2005, 350, 699-712.	2.0	37
850	Mannose binding lectin (MBL) and HIV. <i>Molecular Immunology</i> , 2005, 42, 145-152.	1.0	126
851	HIV-1 neutralization by chimeric CD4-CG10 polypeptides fused to human IgG1. <i>Molecular Immunology</i> , 2005, 42, 1099-1109.	1.0	7
852	Enfuvirtide nursing guidelines: A report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide. <i>Journal of the Association of Nurses in AIDS Care</i> , 2005, 16, 2-12.	0.4	1
853	Basics of the virology of HIV-1 and its replication. <i>Journal of Clinical Virology</i> , 2005, 34, 233-244.	1.6	109
854	Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41. <i>Immunity</i> , 2005, 22, 163-173.	6.6	410
855	Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. <i>Clinical Immunology</i> , 2005, 115, 26-32.	1.4	32
856	Entropy Calculation of HIV-1 Env gp120, its Receptor CD4, and their Complex: An Analysis of Configurational Entropy Changes upon Complexation. <i>Biophysical Journal</i> , 2005, 88, 15-24.	0.2	60
857	The Effect of Cellular Receptor Diffusion on Receptor-Mediated Viral Binding Using Brownian Adhesive Dynamics (BRAD) Simulations. <i>Biophysical Journal</i> , 2005, 88, 1666-1675.	0.2	27
858	A Preamble to Aglycone Reconstruction for Membrane-Presented Glycolipid Mimics. , 2005, , 761-779.		3
860	Comparison of HIV Type 1 ADA gp120 Monomers versus gp140 Trimers as Immunogens for the Induction of Neutralizing Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 58-67.	0.5	70
861	Introduction: Proteomics and Protein-Protein Interactions: Biology, Chemistry, Bioinformatics, and Drug Design. , 2005, , 1-18.		7
862	GP120: Target for Neutralizing HIV-1 Antibodies. <i>Annual Review of Immunology</i> , 2006, 24, 739-769.	9.5	404
864	Attachment Factors. <i>Advances in Experimental Medicine and Biology</i> , 2006, 790, 1-23.	0.8	29
865	Recent Progress and Prospects on Plant-Derived Anti-HIV Agents and Analogs. , 2006, , 357-397.		4
868	Conformation of Glycopeptides and Glycoproteins. , 2006, , 187-251.		28
869	A Rationally Designed Synthetic Mimic of the Discontinuous CD4-Binding Site of HIV-1 gp120. <i>Journal of Receptor and Signal Transduction Research</i> , 2006, 26, 453-460.	1.3	15

#	ARTICLE	IF	CITATIONS
870	Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding. <i>Journal of Virology</i> , 2006, 80, 8695-8704.	1.5	232
871	Dihedral-Angle Information Entropy as a Gauge of Secondary Structure Propensity. <i>Biophysical Journal</i> , 2006, 91, 4014-4023.	0.2	4
872	Binding of Full-Length HIV-1 gp120 to CD4 Induces Structural Reorientation around the gp120 Core. <i>Biophysical Journal</i> , 2006, 91, L69-L71.	0.2	9
873	Synthesis and optimization of peptidomimetics as HIV entry inhibitors against the receptor protein CD4 using STD NMR and ligand docking. <i>Organic and Biomolecular Chemistry</i> , 2006, 4, 3259.	1.5	17
875	Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. <i>Retrovirology</i> , 2006, 3, 39.	0.9	26
876	A reflection on HIV/AIDS research after 25 years. <i>Retrovirology</i> , 2006, 3, 72.	0.9	70
877	Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein. <i>Retrovirology</i> , 2006, 3, 84.	0.9	19
878	Targeting protein-protein interactions by rational design: mimicry of protein surfaces. <i>Journal of the Royal Society Interface</i> , 2006, 3, 215-233.	1.5	151
879	HIV VACCINES. <i>Annual Review of Immunology</i> , 2006, 24, 227-255.	9.5	257
880	How Can (âˆ—)-Epigallocatechin Gallate from Green Tea Prevent HIV-1 Infection? Mechanistic Insights from Computational Modeling and the Implication for Rational Design of Anti-HIV-1 Entry Inhibitors. <i>Journal of Physical Chemistry B</i> , 2006, 110, 2910-2917.	1.2	61
881	Thermodynamics of Binding of a Low-Molecular-Weight CD4 Mimetic to HIV-1 gp120. <i>Biochemistry</i> , 2006, 45, 10973-10980.	1.2	151
882	Macromolecular crystallography and medicine. , 2006, , 10-25.		1
883	A conserved molecular action of native and recombinant Epap-1 in inhibition of HIV-1 gp120 mediated viral entry. <i>Archives of Biochemistry and Biophysics</i> , 2006, 456, 79-92.	1.4	4
884	Cryo-EM Reconstruction of Dengue Virus in Complex with the Carbohydrate Recognition Domain of DC-SIGN. <i>Cell</i> , 2006, 124, 485-493.	13.5	277
885	Virus Entry: Open Sesame. <i>Cell</i> , 2006, 124, 729-740.	13.5	1,016
886	Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro. <i>Journal of Clinical Virology</i> , 2006, 36, 249-257.	1.6	26
887	Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs. <i>Journal of Molecular Biology</i> , 2006, 357, 82-99.	2.0	21
888	Mapping a Neutralizing Epitope on the SARS Coronavirus Spike Protein: Computational Prediction Based on Affinity-selected Peptides. <i>Journal of Molecular Biology</i> , 2006, 359, 190-201.	2.0	32

#	ARTICLE	IF	CITATIONS
889	High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. <i>Molecular Immunology</i> , 2006, 43, 2119-2123.	1.0	14
890	Progress towards an HIV-1 subtype C vaccine. <i>Vaccine</i> , 2006, 24, 391-401.	1.7	11
891	Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope. <i>Vaccine</i> , 2006, 24, 4995-5002.	1.7	32
892	Structural studies of human HIV-1 V3 antibodies. <i>Human Antibodies</i> , 2006, 14, 73-80.	0.6	14
893	Studies of the Structure of Caprine Arthritis-Encephalitis Virus Surface Envelope Glycoprotein. , 2006, , 391-403.		0
894	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. <i>Human Antibodies</i> , 2006, 14, 59-67.	0.6	142
895	High frequencies of antibody responses to CD4 induced epitopes in HIV infected patients started on HAART during acute infection. <i>Human Antibodies</i> , 2006, 14, 115-121.	0.6	26
896	The Nucleic Acid Database (NDB). , 2006, , 657-662.		0
898	Carbohydrate-Based Vaccines against HIV/AIDS. <i>ACS Symposium Series</i> , 2006, , 133-160.	0.5	4
899	Sources of Variation in Ancestral Sequence Reconstruction for HIV-1 Envelope Genes. <i>Evolutionary Bioinformatics</i> , 2006, 2, 117693430600200.	0.6	1
901	The Protein Data Bank, 1999â€“. , 2006, , 675-684.		120
902	Insights into neutralizing antibodies and HIV Envelope. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 301-308.	1.5	1
903	A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication. <i>Aids</i> , 2006, 20, 975-980.	1.0	22
904	Application of protein engineering to improve crystal properties. , 2006, , 100-110.		1
905	Images from the surface of HIV. <i>Nature</i> , 2006, 441, 817-818.	13.7	8
906	Oxygen breaks into carbon world. <i>Nature</i> , 2006, 441, 818-819.	13.7	126
907	Progress and obstacles in the development of an AIDS vaccine. <i>Nature Reviews Immunology</i> , 2006, 6, 930-939.	10.6	148
908	Determination of structurally conservative amino acids of the HIV-1 protein gp120 V3 loop as promising targets for drug design by protein engineering approaches. <i>Biochemistry (Moscow)</i> , 2006, 71, 906-914.	0.7	10

#	ARTICLE	IF	CITATIONS
909	Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. <i>Nature</i> , 2006, 439, 38-44.	13.7	374
910	Distribution and three-dimensional structure of AIDS virus envelope spikes. <i>Nature</i> , 2006, 441, 847-852.	13.7	675
911	HIV and the chemokine system: 10 years later. <i>EMBO Journal</i> , 2006, 25, 447-456.	3.5	185
912	Restraining the conformation of HIV-1 gp120 by removing a flexible loop. <i>EMBO Journal</i> , 2006, 25, 5026-5035.	3.5	23
913	Real-time analysis of human immunodeficiency virus type 1 Env-mediated membrane fusion by fluorescence resonance energy transfer. <i>Microbes and Infection</i> , 2006, 8, 520-532.	1.0	9
914	Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2006, 1764, 766-772.	1.1	39
915	Crystal structures, spectroscopic characterization and theoretical calculations of the guanidinium and ammonium salts of the insulin-enhancing anion [VO ₂ (dipic)] ³⁻ . <i>Polyhedron</i> , 2006, 25, 2920-2928.	1.0	39
916	Biology of CCR5 and Its Role in HIV Infection and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 815.	3.8	219
917	Selection and characterization of an HIV-1 gp120-binding affibody ligand. <i>Biotechnology and Applied Biochemistry</i> , 2006, 45, 93.	1.4	26
918	Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology. <i>Journal of NeuroVirology</i> , 2006, 12, 73-89.	1.0	18
919	CCR5 interactions with the variable 3 loop of gp120. <i>Journal of Molecular Modeling</i> , 2006, 13, 29-41.	0.8	16
920	Combination DNA plus protein HIV vaccines. <i>Seminars in Immunopathology</i> , 2006, 28, 255-265.	4.0	39
921	Current advances and challenges in HIV-1 vaccines. <i>Current HIV/AIDS Reports</i> , 2006, 3, 39-47.	1.1	12
922	Construction and characterization of an infectious molecular clone of HIV-1 subtype A of Indian origin. <i>Virology</i> , 2006, 345, 328-336.	1.1	15
923	Functional impact of HIV coreceptor-binding site mutations. <i>Virology</i> , 2006, 351, 226-236.	1.1	30
924	Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein. <i>Virology</i> , 2006, 352, 74-85.	1.1	7
925	Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. <i>Virology</i> , 2006, 352, 131-144.	1.1	23
926	Specific interaction of CXCR4 with CD4 and CD8 β : Functional analysis of the CD4/CXCR4 interaction in the context of HIV-1 envelope glycoprotein-mediated membrane fusion. <i>Virology</i> , 2006, 353, 52-67.	1.1	17

#	ARTICLE	IF	CITATIONS
927	Viral evolution in macaques coinfecting with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies. <i>Virology</i> , 2006, 355, 138-151.	1.1	17
928	Inhibition of HIV entry by carbohydrate-binding proteins. <i>Antiviral Research</i> , 2006, 71, 237-247.	1.9	147
929	A New Tool in Peptide Engineering: A Photoswitchable Stilbene-type β -Hairpin Mimetic. <i>Chemistry - A European Journal</i> , 2006, 12, 403-412.	1.7	36
930	Dynamic tradeoffs in the raft-mediated entry of human immunodeficiency virus type 1 into cells. <i>Biotechnology and Bioengineering</i> , 2006, 93, 246-257.	1.7	6
931	Cryoelectron Tomography Shows 3D Structure of Surface Spikes. <i>Imaging & Microscopy</i> , 2006, 8, 30-32.	0.1	0
932	Preparing recombinant proteins for X-ray crystallography. , 2006, , 65-80.		0
933	Perspectives for the future. , 2006, , 26-43.		0
934	Design of Miniproteins by the Transfer of Active Sites Onto Small-Size Scaffolds. , 2006, 340, 113-150.		7
935	Characterization of the Multiple Conformational States of Free Monomeric and Trimeric Human Immunodeficiency Virus Envelope Glycoproteins after Fixation by Cross-Linker. <i>Journal of Virology</i> , 2006, 80, 6725-6737.	1.5	75
936	Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity. <i>Journal of Virology</i> , 2006, 80, 9586-9598.	1.5	267
937	Deletion of the V1/V2 Region Does Not Increase the Accessibility of the V3 Region of Recombinant gp125. <i>Current HIV Research</i> , 2006, 4, 229-237.	0.2	5
938	Extreme Sequence Divergence but Conserved Ligand-Binding Specificity in <i>Streptococcus pyogenes</i> M Protein. <i>PLoS Pathogens</i> , 2006, 2, e47.	2.1	56
939	HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. <i>Journal of Leukocyte Biology</i> , 2006, 80, 965-972.	1.5	73
940	HIV-1 Entry Inhibitors: Classes, Applications and Factors Affecting Potency. <i>Current HIV Research</i> , 2006, 4, 387-400.	0.2	14
941	Advances in HIV-1 Entry Inhibitors: Strategies to Interfere with Receptor and CoReceptor Engagement. <i>Current Pharmaceutical Design</i> , 2006, 12, 1105-1119.	0.9	18
942	Cellular Entry of HIV: Evaluation of Therapeutic Targets. <i>Current Pharmaceutical Design</i> , 2006, 12, 1963-1973.	0.9	27
943	Novel Anti-Viral Therapy: Drugs that Block HIV Entry at Different Target Sites. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 557-562.	1.1	4
944	Inhibitors of HIV Infection via the Cellular CD4 Receptor. <i>Current Medicinal Chemistry</i> , 2006, 13, 731-743.	1.2	22

#	ARTICLE	IF	CITATIONS
945	HIV gp120-induced Interaction between CD4 and CCR5 Requires Cholesterol-rich Microenvironments Revealed by Live Cell Fluorescence Resonance Energy Transfer Imaging. <i>Journal of Biological Chemistry</i> , 2006, 281, 35446-35453.	1.6	39
946	Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry Events. <i>Journal of Virology</i> , 2006, 80, 4017-4025.	1.5	108
947	HIV entry inhibitors: mechanisms of action and resistance pathways. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 619-627.	1.3	156
948	Infectious Molecular Clones from a Simian Immunodeficiency Virus-Infected Rapid-Progressor (RP) Macaque: Evidence of Differential Selection of RP-Specific Envelope Mutations In Vitro and In Vivo. <i>Journal of Virology</i> , 2006, 80, 1463-1475.	1.5	27
949	Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes. <i>Journal of Virology</i> , 2006, 80, 8411-8421.	1.5	93
950	Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant. <i>Journal of Virology</i> , 2006, 80, 835-844.	1.5	271
951	Differential Utilization of CD134 as a Functional Receptor by Diverse Strains of Feline Immunodeficiency Virus. <i>Journal of Virology</i> , 2006, 80, 3386-3394.	1.5	45
952	Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen. <i>Journal of Virology</i> , 2006, 80, 6745-6756.	1.5	62
953	Simian Immunodeficiency Virus Engrafted with Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Epitopes: Replication, Neutralization, and Survey of HIV-1-Positive Plasma. <i>Journal of Virology</i> , 2006, 80, 3030-3041.	1.5	72
954	Novel Envelope Determinants for CCR3 Use by Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2006, 80, 10884-10889.	1.5	15
955	Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2006, 80, 4758-4770.	1.5	156
956	Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques. <i>Journal of Virology</i> , 2006, 80, 999-1014.	1.5	55
957	Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120. <i>FASEB Journal</i> , 2006, 20, 1762-1774.	0.2	34
958	Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity. <i>Journal of Virology</i> , 2006, 80, 6093-6105.	1.5	113
959	Histatin 5-Derived Peptide with Improved Fungicidal Properties Enhances Human Immunodeficiency Virus Type 1 Replication by Promoting Viral Entry. <i>Journal of Virology</i> , 2006, 80, 9236-9243.	1.5	26
960	HIV-1 Adapts to a Retrocyclin with Cationic Amino Acid Substitutions That Reduce Fusion Efficiency of gp41. <i>Journal of Immunology</i> , 2006, 176, 6900-6905.	0.4	45
961	An Immunoglobulin Fusion Protein Based on the gp120-CD4 Receptor Complex Potently Inhibits Human Immunodeficiency Virus Type 1 In Vitro. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 477-490.	0.5	11
962	Purified Feline and Canine Transferrin Receptors Reveal Complex Interactions with the Capsids of Canine and Feline Parvoviruses That Correspond to Their Host Ranges. <i>Journal of Virology</i> , 2006, 80, 8482-8492.	1.5	56

#	ARTICLE	IF	CITATIONS
963	Non-Macrophage-Tropic Human Immunodeficiency Virus Type 1 R5 Envelopes Predominate in Blood, Lymph Nodes, and Semen: Implications for Transmission and Pathogenesis. <i>Journal of Virology</i> , 2006, 80, 6324-6332.	1.5	95
964	Antibody Binding Is a Dominant Determinant of the Efficiency of Human Immunodeficiency Virus Type 1 Neutralization. <i>Journal of Virology</i> , 2006, 80, 11404-11408.	1.5	44
965	Bursts of nonsynonymous substitutions in HIV-1 evolution reveal instances of positive selection at conservative protein sites. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19396-19401.	3.3	28
966	The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15160-15165.	3.3	153
967	Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 159-164.	3.3	91
968	Fold Recognition of the Human Immunodeficiency Virus Type 1 V3 Loop and Flexibility of Its Crown Structure During the Course of Adaptation to a Host. <i>Genetics</i> , 2006, 172, 1385-1396.	1.2	10
969	Sequential Turnover of Human Immunodeficiency Virus Type 1 env throughout the Course of Infection. <i>Journal of Virology</i> , 2006, 80, 10591-10599.	1.5	14
970	Subunit Stoichiometry of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers during Virus Entry into Host Cells. <i>Journal of Virology</i> , 2006, 80, 4388-4395.	1.5	68
971	A Study of the Coevolutionary Patterns Operating within the env Gene of the HIV-1 Group M Subtypes. <i>Molecular Biology and Evolution</i> , 2007, 24, 2787-2801.	3.5	41
973	N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. <i>Journal of Virology</i> , 2007, 81, 10769-10776.	1.5	42
974	The Reovirus $\sigma 1$ Aspartic Acid Sandwich. <i>Journal of Biological Chemistry</i> , 2007, 282, 11582-11589.	1.6	24
975	Gp120 V3-dependent Impairment of R5 HIV-1 Infectivity Due to Virion-incorporated CCR5. <i>Journal of Biological Chemistry</i> , 2007, 282, 36923-36932.	1.6	8
976	Cryoelectron Tomographic Analysis of an HIV-neutralizing Protein and Its Complex with Native Viral gp120*. <i>Journal of Biological Chemistry</i> , 2007, 282, 27754-27759.	1.6	35
977	Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies. <i>Journal of Virology</i> , 2007, 81, 6402-6411.	1.5	46
978	Functional Links between the Fusion Peptide-proximal Polar Segment and Membrane-proximal Region of Human Immunodeficiency Virus gp41 in Distinct Phases of Membrane Fusion*. <i>Journal of Biological Chemistry</i> , 2007, 282, 23104-23116.	1.6	73
979	Genetic Diversity of HIV Type 1 Subtype C <i>env</i> Gene Sequences from India. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 934-940.	0.5	19
980	Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates. <i>Current Medicinal Chemistry</i> , 2007, 14, 2257-2277.	1.2	73
981	Receptor-Induced Thiolate Couples Env Activation to Retrovirus Fusion and Infection. <i>PLoS Pathogens</i> , 2007, 3, e198.	2.1	33

#	ARTICLE	IF	CITATIONS
982	Creating Functional Artificial Proteins. <i>Current Protein and Peptide Science</i> , 2007, 8, 3-18.	0.7	23
983	Trp/Met/Phe Hot Spots in Protein-Protein Interactions: Potential Targets in Drug Design. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 999-1005.	1.0	94
984	Evolutionary Interactions between N-Linked Glycosylation Sites in the HIV-1 Envelope. <i>PLoS Computational Biology</i> , 2007, 3, e11.	1.5	63
985	V3 Loop Truncations in HIV-1 Envelope Impart Resistance to Coreceptor Inhibitors and Enhanced Sensitivity to Neutralizing Antibodies. <i>PLoS Pathogens</i> , 2007, 3, e117.	2.1	68
986	Allosteric Theory: Taking Therapeutic Advantage of the Malleable Nature of GPCRs. <i>Current Neuropharmacology</i> , 2007, 5, 149-156.	1.4	38
987	HIV Entry Inhibitors Targeting gp41: From Polypeptides to Small-Molecule Compounds. <i>Current Pharmaceutical Design</i> , 2007, 13, 143-162.	0.9	138
988	Immune Responses to HIV Gp120 that Facilitate Viral Escape. <i>Current HIV Research</i> , 2007, 5, 47-54.	0.2	15
989	Defining Carbohydrate Antigens as HIV Vaccine Candidates. <i>Current Pharmaceutical Design</i> , 2007, 13, 185-201.	0.9	17
990	Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection. <i>Journal of Virology</i> , 2007, 81, 1350-1359.	1.5	130
991	Protein-Protein Interaction Hotspots Carved into Sequences. <i>PLoS Computational Biology</i> , 2007, 3, e119.	1.5	229
992	Rational Modifications of HIV-1 Envelope Glycoproteins for Immunogen Design. <i>Current Pharmaceutical Design</i> , 2007, 13, 213-227.	0.9	79
993	An Update in the Development of HIV Entry Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1273-1289.	1.0	67
994	Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. <i>Nucleic Acids Research</i> , 2007, 35, 69-78.	6.5	102
995	Production and Characterization of High-Affinity Human Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in a Mouse Model Expressing Human Immunoglobulins. <i>Vaccine Journal</i> , 2007, 14, 157-167.	3.2	5
996	Roles of HIV-1 Env Variable Regions in Viral Neutralization and Vaccine Development. <i>Current HIV Research</i> , 2007, 5, 542-553.	0.2	33
997	A new era in HIV vaccine development. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 205-215.	2.0	2
998	HIV-1 Neutralization: Mechanisms and Relevance to Vaccine Design. <i>Current HIV Research</i> , 2007, 5, 608-624.	0.2	52
999	Strategies for targeting HIV-1 envelope glycoprotein gp120 in the development of new antivirals. <i>Future HIV Therapy</i> , 2007, 1, 223-229.	0.5	2

#	ARTICLE	IF	CITATIONS
1000	Structural Basis for Coreceptor Selectivity by The HIV Type 1 V3 Loop. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 415-426.	0.5	146
1001	Genetic Changes Associated with Distinct Patterns of HIV Type 1 Persistence in Chronically Infected Cell Lines. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 251-260.	0.5	3
1002	Cell Entry by Enveloped Viruses: Redox Considerations for HIV and SARS-Coronavirus. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 1009-1034.	2.5	84
1003	Generation of Infectious Molecular Clones of Simian Immunodeficiency Virus from Fecal Consensus Sequences of Wild Chimpanzees. <i>Journal of Virology</i> , 2007, 81, 7463-7475.	1.5	62
1004	Broad-Spectrum Anti-Human Immunodeficiency Virus (HIV) Potential of a Peptide HIV Type 1 Entry Inhibitor. <i>Journal of Virology</i> , 2007, 81, 3645-3648.	1.5	42
1005	Mutations in Envelope gp120 Can Impact Proteolytic Processing of the gp160 Precursor and Thereby Affect Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Pseudoviruses. <i>Journal of Virology</i> , 2007, 81, 13037-13049.	1.5	21
1006	Independent Evolution of Human Immunodeficiency Virus Type 1 env V1/V2 and V4/V5 Hypervariable Regions during Chronic Infection. <i>Journal of Virology</i> , 2007, 81, 5413-5417.	1.5	23
1007	Replication-Competent Variants of Human Immunodeficiency Virus Type 2 Lacking the V3 Loop Exhibit Resistance to Chemokine Receptor Antagonists. <i>Journal of Virology</i> , 2007, 81, 9956-9966.	1.5	32
1008	Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus. <i>Journal of Virology</i> , 2007, 81, 362-373.	1.5	99
1009	Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. <i>Journal of Virology</i> , 2007, 81, 6548-6562.	1.5	181
1010	Mutational Analysis of Aminopeptidase N, a Receptor for Several Group 1 Coronaviruses, Identifies Key Determinants of Viral Host Range. <i>Journal of Virology</i> , 2007, 81, 1261-1273.	1.5	87
1011	Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding. <i>Journal of Virology</i> , 2007, 81, 9584-9590.	1.5	54
1012	Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 4303-4308.	3.3	28
1013	Identification and Characterization of UK-201844, a Novel Inhibitor That Interferes with Human Immunodeficiency Virus Type 1 gp160 Processing. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3554-3561.	1.4	14
1014	Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. <i>Journal of Virology</i> , 2007, 81, 5579-5593.	1.5	101
1015	Carbohydrate-Binding Agents: A Potential Future Cornerstone for the Chemotherapy of Enveloped Viruses?. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 1-11.	0.3	94
1016	A Rapid Progressor-Specific Variant Clone of Simian Immunodeficiency Virus Replicates Efficiently In Vivo Only in the Absence of Immune Responses. <i>Journal of Virology</i> , 2007, 81, 8891-8904.	1.5	14
1017	Stability of a Receptor-Binding Active Human Immunodeficiency Virus Type 1 Recombinant gp140 Trimer Conferred by Intermonomer Disulfide Bonding of the V3 Loop: Differential Effects of Protein Disulfide Isomerase on CD4 and Coreceptor Binding. <i>Journal of Virology</i> , 2007, 81, 4604-4614.	1.5	14

#	ARTICLE	IF	CITATIONS
1018	Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate. <i>Journal of Virology</i> , 2007, 81, 3757-3768.	1.5	29
1019	The Neutralization Properties of a HIV-Specific Antibody Are Markedly Altered by Glycosylation Events Outside the Antigen-Binding Domain. <i>Journal of Immunology</i> , 2007, 178, 7132-7138.	0.4	37
1020	Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 566-575.	1.4	320
1021	HIV-1 Integrase: From Biology to Chemotherapeutics. <i>Current HIV Research</i> , 2007, 5, 365-388.	0.2	31
1022	The Presence of Antibodies Recognizing a Peptide Derived from the Second Conserved Region of HIV-1 gp120 Correlates with Non-Progressive HIV Infection. <i>Current HIV Research</i> , 2007, 5, 443-448.	0.2	13
1023	Reovirus Binding Determinants in Junctional Adhesion Molecule-A. <i>Journal of Biological Chemistry</i> , 2007, 282, 17930-17940.	1.6	51
1024	Unique Mutational Patterns in the Envelope ± 2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2007, 81, 5658-5668.	1.5	92
1025	Coreceptor Switch in R5-Tropic Simian/Human Immunodeficiency Virus-Infected Macaques. <i>Journal of Virology</i> , 2007, 81, 8621-8633.	1.5	57
1026	Infectivity and Neutralization of Simian Immunodeficiency Virus with FLAG Epitope Insertion in gp120 Variable Loops. <i>Journal of Virology</i> , 2007, 81, 10838-10848.	1.5	17
1027	The bull's-eye for HIV vaccine development defined. <i>Future HIV Therapy</i> , 2007, 1, 153-155.	0.5	0
1028	CD4-Induced Epitopes in the HIV Envelope Glycoprotein, Gp120. <i>Current HIV Research</i> , 2007, 5, 561-571.	0.2	39
1029	Clade Specific Neutralising Vaccines for HIV: An Appropriate Target?. <i>Current HIV Research</i> , 2007, 5, 554-560.	0.2	10
1030	Antibody-Mediated Neutralization and Simian Immunodeficiency Virus Models of HIV/AIDS. <i>Current HIV Research</i> , 2007, 5, 594-607.	0.2	19
1031	Designing Immunogens to Elicit Broadly Neutralizing Antibodies to the HIV-1 Envelope Glycoprotein. <i>Current HIV Research</i> , 2007, 5, 514-541.	0.2	29
1032	Characterization of the antibody response elicited by HIV-1 Env glycomutants in rabbits. <i>Vaccine</i> , 2007, 25, 535-546.	1.7	3
1033	Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIIB Gag-Pol-Nef proteins of clade B. <i>Vaccine</i> , 2007, 25, 2863-2885.	1.7	84
1034	Analysis of the exposure of induced HIV glycoprotein epitopes in a potential HIV pseudovirion vaccine. <i>Vaccine</i> , 2007, 25, 2161-2167.	1.7	2
1035	Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. <i>Vaccine</i> , 2007, 25, 3841-3850.	1.7	25

#	ARTICLE	IF	CITATIONS
1036	Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. <i>Vaccine</i> , 2007, 25, 4949-4959.	1.7	7
1037	Antibodies to HIV-1: aiming at the right target. <i>Trends in Microbiology</i> , 2007, 15, 291-294.	3.5	10
1038	Prediction of HIV-1 entry inhibitors neomycin-arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2007, 1768, 2107-2119.	1.4	15
1039	Discovery of small-molecule HIV-1 fusion and integrase inhibitors oleuropein and hydroxytyrosol: Part I. Integrase inhibition. <i>Biochemical and Biophysical Research Communications</i> , 2007, 354, 872-878.	1.0	123
1040	Defining and solving the essential protein-protein interactions in HIV infection. <i>Journal of Structural Biology</i> , 2007, 158, 148-155.	1.3	3
1041	An Envelope-determined Endocytic Route of Viral Entry Allows HIV-1 to Escape from Secreted Phospholipase A2 Entry Blockade. <i>Journal of Molecular Biology</i> , 2007, 367, 702-714.	2.0	14
1042	An Allosteric Rheostat in HIV-1 gp120 Reduces CCR5 Stoichiometry Required for Membrane Fusion and Overcomes Diverse Entry Limitations. <i>Journal of Molecular Biology</i> , 2007, 374, 64-79.	2.0	22
1043	Antibodies to the superantigenic site of HIV-1 gp120: Hydrolytic and binding activities of the light chain subunit. <i>Molecular Immunology</i> , 2007, 44, 2707-2718.	1.0	30
1044	Heparin enhances the furin cleavage of HIV-1 gp160 peptides. <i>FEBS Letters</i> , 2007, 581, 5807-5813.	1.3	29
1045	Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens. <i>Virology</i> , 2007, 366, 433-445.	1.1	24
1046	Chemotherapeutic Interventions Targeting HIV Interactions with Host-Associated Carbohydrates. <i>Chemical Reviews</i> , 2007, 107, 1533-1552.	23.0	60
1047	Functional Anthology of Intrinsic Disorder. 3. Ligands, Post-Translational Modifications, and Diseases Associated with Intrinsically Disordered Proteins. <i>Journal of Proteome Research</i> , 2007, 6, 1917-1932.	1.8	369
1048	Role of Superallergens in Allergic Disorders. , 2007, 93, 195-213.		46
1049	Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17477-17482.	3.3	77
1050	Cancer Genomics and Proteomics. , 2007, 383, v-vii.		4
1052	QUASI analysis of the HIV-1 envelope sequences in the Los Alamos National Laboratory HIV sequence database: pattern and distribution of positive selection sites and their frequencies over years This paper is one of a selection of papers in this Special Issue, entitled International Symposium on Recent Advances in Molecular, Clinical, and Social Medicine, and has undergone the Journal's usual peer-review process. <i>Biochemistry and Cell Biology</i> , 2007, 85, 258-264.	0.9	21
1053	Conformation of Trimeric Envelope Glycoproteins: The CD4-dependent Membrane Fusion Mechanism of HIV-1. <i>Journal of Biomolecular Structure and Dynamics</i> , 2007, 25, 1-9.	2.0	5
1054	Peptides Selected from a Phage Display Library with an HIV-Neutralizing Antibody Elicit Antibodies to HIV gp120 in Rabbits, But Not to the Same Epitope. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1416-1427.	0.5	11

#	ARTICLE	IF	CITATIONS
1055	Epitope Mapping. <i>BioDrugs</i> , 2007, 21, 145-156.	2.2	217
1056	Rational Optimization of the Binding Affinity of CD4 Targeting Peptidomimetics with Potential Anti HIV Activity. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3482-3488.	2.9	27
1057	Synthesis and Conformational Analysis of Novel Trimeric Maleimide Cross-Linking Reagents. <i>Journal of Organic Chemistry</i> , 2007, 72, 6776-6785.	1.7	16
1058	An HIV Vaccine "Evolving Concepts. <i>New England Journal of Medicine</i> , 2007, 356, 2073-2081.	13.9	245
1059	Structure and Function of the HIV Envelope Glycoprotein as Entry Mediator, Vaccine Immunogen, and Target for Inhibitors. <i>Advances in Pharmacology</i> , 2007, 55, 33-97.	1.2	27
1060	Addressing the Protein Crystallization Bottleneck By Cocrystallization. <i>Crystal Growth and Design</i> , 2007, 7, 2219-2225.	1.4	18
1061	Immunogenicity of the outer domain of a HIV-1 clade C gp120. <i>Retrovirology</i> , 2007, 4, 33.	0.9	35
1062	CD4-independent use of the CCR5 receptor by sequential primary SIVsm isolates. <i>Retrovirology</i> , 2007, 4, 50.	0.9	4
1063	The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segment. <i>Retrovirology</i> , 2007, 4, 55.	0.9	14
1064	Structure and Plasticity of the Human Immunodeficiency Virus gp41 Fusion Domain in Lipid Micelles and Bilayers. <i>Biophysical Journal</i> , 2007, 93, 876-885.	0.2	91
1065	Targeting protein-protein interactions for HIV therapeutics. <i>Future HIV Therapy</i> , 2007, 1, 369-385.	0.5	9
1067	Protein Crystallography in Drug Discovery. , 2007, , 875-900.		4
1068	Novel Cell type-specific aptamer-siRNA delivery system for HIV-1 therapy. <i>Nature Precedings</i> , 2007, , .	0.1	1
1069	Enzymatic and Extraenzymatic Role of Adenosine Deaminase 1 in T-Cell-Dendritic Cell Contacts and in Alterations of the Immune Function. <i>Critical Reviews in Immunology</i> , 2007, 27, 495-509.	1.0	53
1070	Synthetic Mimetics of the CD4 Binding Site of HIV-1 gp120 for the Design of Immunogens. <i>Angewandte Chemie - International Edition</i> , 2007, 46, 1253-1255.	7.2	32
1072	Synthesis and anti-HIV activity of trivalent CD4-mimetic miniproteins. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 4220-4228.	1.4	27
1073	Effects of chronic alcohol drinking on receptor-binding, internalization, and degradation of human immunodeficiency virus 1 envelope protein gp120 in hepatocytes. <i>Alcohol</i> , 2007, 41, 591-606.	0.8	16
1074	Molecular motions in HIV-1 gp120 mutants reveal their preferences for different conformations. <i>Journal of Molecular Graphics and Modelling</i> , 2007, 26, 306-318.	1.3	15

#	ARTICLE	IF	CITATIONS
1075	Isolation and characterization of lectins from kidney beans (<i>Phaseolus vulgaris</i>). <i>Process Biochemistry</i> , 2007, 42, 1436-1442.	1.8	38
1076	(NZ)CH...O Contacts assist crystallization of a ParB-like nuclease. <i>BMC Structural Biology</i> , 2007, 7, 46.	2.3	17
1077	A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. <i>Proteins: Structure, Function and Bioinformatics</i> , 2007, 67, 617-629.	1.5	18
1078	Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. <i>Proteins: Structure, Function and Bioinformatics</i> , 2007, 68, 294-304.	1.5	82
1079	Conformation-activity relationship of peptide T and new pseudocyclic hexapeptide analogs. <i>Journal of Peptide Science</i> , 2007, 13, 413-421.	0.8	5
1080	The rational design of biological complexity: A deceptive metaphor. <i>Proteomics</i> , 2007, 7, 965-975.	1.3	46
1081	Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. <i>Nature Reviews Microbiology</i> , 2007, 5, 583-597.	13.6	264
1082	Adenovirus type 11 binding alters the conformation of its receptor CD46. <i>Nature Structural and Molecular Biology</i> , 2007, 14, 164-166.	3.6	86
1083	Structural definition of a conserved neutralization epitope on HIV-1 gp120. <i>Nature</i> , 2007, 445, 732-737.	13.7	715
1084	Exploiting the defensive sugars of HIV-1 for drug and vaccine design. <i>Nature</i> , 2007, 446, 1038-1045.	13.7	240
1085	Mutational analysis of human CEACAM1: the potential of receptor polymorphism in increasing host susceptibility to bacterial infection. <i>Cellular Microbiology</i> , 2007, 9, 329-346.	1.1	24
1086	Humoral immunity to HIV-1: neutralization and beyond. <i>Journal of Internal Medicine</i> , 2007, 262, 5-25.	2.7	94
1087	Targeting HIV-1 Through Molecular Modeling and Docking Studies of CXCR4: Leads for Therapeutic Development. <i>Chemical Biology and Drug Design</i> , 2007, 69, 191-203.	1.5	22
1088	Human immunodeficiency virus type 1 efficiently binds to human fetal astrocytes and induces neuroinflammatory responses independent of infection. <i>BMC Neuroscience</i> , 2007, 8, 31.	0.8	43
1089	The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. <i>Virology</i> , 2007, 358, 23-38.	1.1	23
1090	Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. <i>Virology</i> , 2007, 358, 334-346.	1.1	54
1091	T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates. <i>Virology</i> , 2007, 359, 92-104.	1.1	8
1092	Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. <i>Virology</i> , 2007, 360, 218-234.	1.1	67

#	ARTICLE	IF	CITATIONS
1093	Mutations in the V3 stem versus the V3 crown and C4 region have different effects on the binding and fusion steps of human immunodeficiency virus type 1 gp120 interaction with the CCR5 coreceptor. <i>Virology</i> , 2007, 360, 182-190.	1.1	44
1094	Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. <i>Virology</i> , 2007, 360, 294-304.	1.1	40
1095	Functional epitopes on porcine endogenous retrovirus envelope protein interacting with neutralizing antibody combining sites. <i>Virology</i> , 2007, 361, 364-371.	1.1	8
1096	Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies. <i>Virology</i> , 2007, 361, 283-293.	1.1	51
1097	Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection. <i>Virology</i> , 2007, 363, 69-78.	1.1	8
1098	Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. <i>Virology</i> , 2007, 367, 222-234.	1.1	79
1099	High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. <i>Virology</i> , 2007, 368, 145-154.	1.1	65
1100	AIDS virus envelope spike structure. <i>Current Opinion in Structural Biology</i> , 2007, 17, 244-252.	2.6	87
1101	Structural basis of viral invasion: lessons from paramyxovirus F. <i>Current Opinion in Structural Biology</i> , 2007, 17, 427-436.	2.6	256
1102	Chemokine Antagonists as Therapeutics: Focus on HIV-1. <i>Annual Review of Medicine</i> , 2007, 58, 445-459.	5.0	62
1103	Structure-Activity Relationships in the Binding of Chemically Derivatized CD4 to gp120 from Human Immunodeficiency Virus. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4898-4908.	2.9	55
1104	The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160. <i>Protein Science</i> , 2007, 16, 1236-1241.	3.1	20
1105	Dynamic domains and geometrical properties of HIV-1 gp120 during conformational changes induced by CD4 binding. <i>Journal of Molecular Modeling</i> , 2007, 13, 411-424.	0.8	8
1106	HIV-1 vaccine development: Progress and prospects. <i>Current Infectious Disease Reports</i> , 2007, 9, 71-75.	1.3	19
1107	Molecular motions and conformational transition between different conformational states of HIV-1 gp120 envelope glycoprotein. <i>Science Bulletin</i> , 2007, 52, 3074-3088.	1.7	5
1108	Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in NeuroAIDS. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 883-909.	2.9	127
1109	Rapid Evolution by Positive Darwinian Selection in T-Cell Antigen CD4 in Primates. <i>Journal of Molecular Evolution</i> , 2008, 66, 446-456.	0.8	33
1110	Comparison of the immunogenicities of HIV-1 mutants based on structural modification of env. <i>Virologica Sinica</i> , 2008, 23, 233-246.	1.2	1

#	ARTICLE	IF	CITATIONS
1111	Molecular motions of human HIV-1 gp120 envelope glycoproteins. <i>Journal of Molecular Modeling</i> , 2008, 14, 857-870.	0.8	26
1112	Anti-HIV adaptive immunity: determinants for viral persistence. <i>Reviews in Medical Virology</i> , 2008, 18, 293-303.	3.9	16
1113	Nanoscale organization of CD4 molecules of human T helper cell mapped by NSOM and quantum dots. <i>Scanning</i> , 2008, 30, 448-451.	0.7	9
1114	N-linked glycans of the human insulin receptor and their distribution over the crystal structure. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 71, 426-439.	1.5	68
1115	Antigen structure influences helper T-cell epitope dominance in the human immune response to HIV envelope glycoprotein gp120. <i>European Journal of Immunology</i> , 2008, 38, 1231-1237.	1.6	27
1116	Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state. <i>Biopolymers</i> , 2008, 90, 320-329.	1.2	7
1117	Construction and infection of a new simian/human immunodeficiency chimeric virus (SHIV) containing the integrase gene of the human immunodeficiency virus type 1 genome and analysis of its adaptation to monkey cells. <i>Microbes and Infection</i> , 2008, 10, 531-539.	1.0	9
1118	Molecular modeling studies of N-substituted pyrrole derivatives—Potential HIV-1 gp41 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3039-3048.	1.4	68
1119	Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1498-1501.	1.0	22
1120	Structural Determinants for Affinity Enhancement of a Dual Antagonist Peptide Entry Inhibitor of Human Immunodeficiency Virus Type-1. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2638-2647.	2.9	45
1121	Nasal Immunization with a Recombinant HIV gp120 and Nanoemulsion Adjuvant Produces Th1 Polarized Responses and Neutralizing Antibodies to Primary HIV Type 1 Isolates. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 271-281.	0.5	97
1122	Toward chaperone-assisted crystallography: Protein engineering enhancement of crystal packing and X-ray phasing capabilities of a camelid single-domain antibody (V _H) scaffold. <i>Protein Science</i> , 2008, 17, 1175-1187.	3.1	61
1123	Genotypic Characterization and Comparison of Full-Length Envelope Glycoproteins from South African HIV Type 1 Subtype C Primary Isolates That Utilize CCR5 and/or CXCR4. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 743-751.	0.5	21
1124	Insight into the mechanisms of aminoglycoside derivatives interaction with HIV-1 entry steps and viral gene transcription. <i>FEBS Journal</i> , 2008, 275, 5236-5257.	2.2	19
1125	Turning of the receptor-binding domains opens up the murine leukaemia virus Env for membrane fusion. <i>EMBO Journal</i> , 2008, 27, 2799-2808.	3.5	15
1126	Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. <i>Nature</i> , 2008, 454, 177-182.	13.7	638
1127	Molecular architecture of native HIV-1 gp120 trimers. <i>Nature</i> , 2008, 455, 109-113.	13.7	720
1128	Challenges in the development of an HIV-1 vaccine. <i>Nature</i> , 2008, 455, 613-619.	13.7	307

#	ARTICLE	IF	CITATIONS
1129	Neutralism and selectionism: a network-based reconciliation. <i>Nature Reviews Genetics</i> , 2008, 9, 965-974.	7.7	244
1130	The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. <i>Nature Reviews Microbiology</i> , 2008, 6, 143-155.	13.6	298
1131	High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors. <i>Microbiology and Immunology</i> , 2008, 52, 209-215.	0.7	10
1132	Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. <i>Virology</i> , 2008, 370, 246-254.	1.1	37
1133	Conservation of inner domain modules in the surface envelope glycoproteins of an ancient rabbit lentivirus and extant lentiviruses and betaretroviruses. <i>Virology</i> , 2008, 372, 201-207.	1.1	8
1134	Targeted deletion in the β 20 α 21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding. <i>Virology</i> , 2008, 377, 330-338.	1.1	14
1135	Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. <i>Virology</i> , 2008, 377, 364-378.	1.1	45
1136	Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. <i>Virology</i> , 2008, 379, 125-134.	1.1	45
1137	Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. <i>Virology</i> , 2008, 380, 285-295.	1.1	36
1138	An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. <i>Virology</i> , 2008, 381, 46-54.	1.1	52
1139	Molecular and structural characterization of HIV-1 subtype B Brazilian isolates with GWGR tetramer at the tip of the V3-loop. <i>Virology</i> , 2008, 381, 222-229.	1.1	15
1140	Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. <i>Virology</i> , 2008, 382, 10-19.	1.1	31
1141	Reducing the false positive rate in the non-parametric analysis of molecular coevolution. <i>BMC Evolutionary Biology</i> , 2008, 8, 106.	3.2	10
1142	Protein intrinsic disorder toolbox for comparative analysis of viral proteins. <i>BMC Genomics</i> , 2008, 9, S4.	1.2	61
1143	25 years of HIV-1 research – progress and perspectives. <i>BMC Medicine</i> , 2008, 6, 31.	2.3	43
1144	Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120. <i>Structure</i> , 2008, 16, 1689-1701.	1.6	160
1145	Plugging gp120s Cavity. <i>Structure</i> , 2008, 16, 1603-1604.	1.6	5
1146	Structure-based antigen design: a strategy for next generation vaccines. <i>Trends in Biotechnology</i> , 2008, 26, 659-667.	4.9	143

#	ARTICLE	IF	CITATIONS
1147	Role of gp120 Trimerization on HIV Binding Elucidated with Brownian Adhesive Dynamics. <i>Biophysical Journal</i> , 2008, 95, 40-53.	0.2	12
1148	The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. <i>Retrovirology</i> , 2008, 5, 10.	0.9	42
1149	Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. <i>Retrovirology</i> , 2008, 5, 111.	0.9	146
1150	Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. <i>Retrovirology</i> , 2008, 5, 5.	0.9	71
1151	A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction. <i>Retrovirology</i> , 2008, 5, 77.	0.9	19
1152	The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. <i>Retrovirology</i> , 2008, 5, 89.	0.9	42
1153	Characterization of the steric defense of the HIV-1 gp41 trimer region. <i>Protein Science</i> , 2008, 17, 2091-2100.	3.1	31
1154	Novel Dual Inhibitory Function Aptamer-siRNA Delivery System for HIV-1 Therapy. <i>Molecular Therapy</i> , 2008, 16, 1481-1489.	3.7	302
1155	Critical issues in mucosal immunity for HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 3-9.	1.5	68
1156	HIV-2 neutralization by intact V3-specific Fab fragments. <i>Virology Journal</i> , 2008, 5, 96.	1.4	3
1157	Molecular Biology of HIV: Implications for New Therapies. , 2008, , 23-38.		2
1158	Structure of Antibody F425-B4e8 in Complex with a V3 Peptide Reveals a New Binding Mode for HIV-1 Neutralization. <i>Journal of Molecular Biology</i> , 2008, 375, 969-978.	2.0	71
1159	Peptide Mimic of the HIV Envelope gp120-gp41 Interface. <i>Journal of Molecular Biology</i> , 2008, 376, 786-797.	2.0	19
1160	Combinatorial Optimization of a CD4-Mimetic Miniprotein and Cocrystal Structures with HIV-1 gp120 Envelope Glycoprotein. <i>Journal of Molecular Biology</i> , 2008, 382, 510-524.	2.0	54
1161	A novel computer algorithm improves antibody epitope prediction using affinity-selected mimotopes: A case study using monoclonal antibodies against the West Nile virus E protein. <i>Molecular Immunology</i> , 2008, 46, 125-134.	1.0	22
1162	Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells. <i>Protein Expression and Purification</i> , 2008, 59, 223-231.	0.6	13
1163	Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses. <i>Vaccine</i> , 2008, 26, 1541-1551.	1.7	27
1164	Genetic subspecies diversity of the chimpanzee CD4 virus-receptor gene. <i>Genomics</i> , 2008, 92, 322-328.	1.3	18

#	ARTICLE	IF	CITATIONS
1165	The Ixodes scapularis salivary protein, salp15, prevents the association of HIV-1 gp120 and CD4. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 41-46.	1.0	10
1166	HIV-1 at 25. <i>Cell</i> , 2008, 133, 561-565.	13.5	43
1167	Chemotaxis, chemokine receptors and human disease. <i>Cytokine</i> , 2008, 44, 1-8.	1.4	224
1168	Targeting HIV Attachment and Entry for Therapy. <i>Advances in Pharmacology</i> , 2008, 56, 93-120.	1.2	8
1169	Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2008, 43, 189-219.	2.3	744
1171	Functional Assays as Prismatic Views of Drug Activity: Relevance to New Drug Discovery. <i>Journal of Receptor and Signal Transduction Research</i> , 2008, 28, 109-125.	1.3	5
1172	Glycosylation Site-Specific Analysis of HIV Envelope Proteins (JR-FL and CON-S) Reveals Major Differences in Glycosylation Site Occupancy, Glycoform Profiles, and Antigenic Epitopes' Accessibility. <i>Journal of Proteome Research</i> , 2008, 7, 1660-1674.	1.8	133
1173	Role of the HIV gp120 Conserved Domain 5 in Processing and Viral Entry. <i>Biochemistry</i> , 2008, 47, 7788-7795.	1.2	27
1174	Peptide Inhibition of HIV-1. <i>BioDrugs</i> , 2008, 22, 161-175.	2.2	24
1175	Role of the HIV gp120 Conserved Domain 1 in Processing and Viral Entry. <i>Journal of Biological Chemistry</i> , 2008, 283, 32644-32649.	1.6	30
1176	Target Peptide Sequence within Infectious Human Immunodeficiency Virus Type 1 Does Not Ensure Envelope-Specific T-Helper Cell Reactivation: Influences of Cysteine Protease and Gamma Interferon-Induced Thiol Reductase Activities. <i>Vaccine Journal</i> , 2008, 15, 713-719.	3.2	28
1177	Comparison of G-to-A Mutation Frequencies Induced by APOBEC3 Proteins in H9 Cells and Peripheral Blood Mononuclear Cells in the Context of Impaired Processivities of Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Variants. <i>Journal of Virology</i> , 2008, 82, 6536-6545.	1.5	15
1178	The First Hypervariable Region of the gp120 Env Glycoprotein Defines the Neutralizing Susceptibility of Heterologous Human Immunodeficiency Virus Type 1 Isolates to Neutralizing Antibodies Elicited by the SF162gp140 Immunogen. <i>Journal of Virology</i> , 2008, 82, 949-956.	1.5	26
1179	Only Five of 10 Strictly Conserved Disulfide Bonds Are Essential for Folding and Eight for Function of the HIV-1 Envelope Glycoprotein. <i>Molecular Biology of the Cell</i> , 2008, 19, 4298-4309.	0.9	44
1180	Perspectives for a Protective HIV-1 Vaccine. <i>Advances in Pharmacology</i> , 2008, 56, 423-452.	1.2	5
1181	Effects of Partial Deletions within the Human Immunodeficiency Virus Type 1 V3 Loop on Coreceptor Tropism and Sensitivity to Entry Inhibitors. <i>Journal of Virology</i> , 2008, 82, 664-673.	1.5	38
1182	Genetic and Neutralization Properties of HIV-1 env Clones From Subtype B/BC/AE Infections in China. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 535-543.	0.9	32
1183	Update on the development of HIV entry inhibitors. <i>Future HIV Therapy</i> , 2008, 2, 479-507.	0.5	3

#	ARTICLE	IF	CITATIONS
1184	Analysis of Putative N-Linked Glycosylation Sites and Variable Region of Envelope HIV-1 CRF07_BC Recombinant in Intravenous Drug Users in Xinjiang Autonomous Region, China. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 521-527.	0.5	7
1185	Identification of an N-Linked Glycosylation in the C4 Region of HIV-1 Envelope gp120 That Is Critical for Recognition of Neighboring CD4 T Cell Epitopes. <i>Journal of Immunology</i> , 2008, 180, 4011-4021.	0.4	37
1186	Conformational Rearrangement within the Soluble Domains of the CD4 Receptor Is Ligand-specific. <i>Journal of Biological Chemistry</i> , 2008, 283, 2761-2772.	1.6	30
1187	A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. <i>Journal of Virology</i> , 2008, 82, 6359-6368.	1.5	112
1188	R5X4 Viruses Are Evolutionary, Functional, and Antigenic Intermediates in the Pathway of a Simian-Human Immunodeficiency Virus Coreceptor Switch. <i>Journal of Virology</i> , 2008, 82, 7089-7099.	1.5	30
1189	The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion. <i>FASEB Journal</i> , 2008, 22, 1179-1192.	0.2	20
1190	Conformational landscape of the HIV-V3 hairpin loop from all-atom free-energy simulations. <i>Journal of Chemical Physics</i> , 2008, 128, 105103.	1.2	2
1191	Cryoelectron Tomography of HIV-1 Envelope Spikes: Further Evidence for Tripod-Like Legs. <i>PLoS Pathogens</i> , 2008, 4, e1000203.	2.1	77
1192	B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4. <i>PLoS Pathogens</i> , 2008, 4, e1000171.	2.1	57
1193	Structure of Reovirus $\sigma 1$ in Complex with Its Receptor Junctional Adhesion Molecule-A. <i>PLoS Pathogens</i> , 2008, 4, e1000235.	2.1	99
1194	CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 818-826.	1.3	59
1195	Potent Antibody-Mediated Neutralization and Evolution of Antigenic Escape Variants of Simian Immunodeficiency Virus Strain SIVmac239 In Vivo. <i>Journal of Virology</i> , 2008, 82, 9739-9752.	1.5	23
1196	Engineering of a Human Vaginal <i>Lactobacillus</i> Strain for Surface Expression of Two-Domain CD4 Molecules. <i>Applied and Environmental Microbiology</i> , 2008, 74, 4626-4635.	1.4	39
1197	Betulinic Acid Derivatives That Target gp120 and Inhibit Multiple Genetic Subtypes of Human Immunodeficiency Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 128-136.	1.4	39
1198	Natural Resistance of Human Immunodeficiency Virus Type 1 to the CD4bs Antibody b12 Conferred by a Glycan and an Arginine Residue Close to the CD4 Binding Loop. <i>Journal of Virology</i> , 2008, 82, 5807-5814.	1.5	63
1199	The HIV-1 Envelope Glycoprotein gp120 Features Four Heparan Sulfate Binding Domains, Including the Co-receptor Binding Site. <i>Journal of Biological Chemistry</i> , 2008, 283, 15193-15200.	1.6	77
1200	Binding of equine infectious anemia virus to the equine lentivirus receptor-1 is mediated by complex discontinuous sequences in the viral envelope gp90 protein. <i>Journal of General Virology</i> , 2008, 89, 2011-2019.	1.3	14
1201	Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17121-17126.	3.3	100

#	ARTICLE	IF	CITATIONS
1202	Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2008, 82, 7932-7941.	1.5	155
1203	Importance of the V1/V2 Loop Region of Simian-Human Immunodeficiency Virus Envelope Glycoprotein gp120 in Determining the Strain Specificity of the Neutralizing Antibody Response. <i>Journal of Virology</i> , 2008, 82, 11054-11065.	1.5	21
1204	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. <i>Journal of Virology</i> , 2008, 82, 1860-1869.	1.5	142
1205	Evolution Rescues Folding of Human Immunodeficiency Virus-1 Envelope Glycoprotein GP120 Lacking a Conserved Disulfide Bond. <i>Molecular Biology of the Cell</i> , 2008, 19, 4707-4716.	0.9	12
1206	Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. <i>Journal of Virology</i> , 2008, 82, 638-651.	1.5	154
1207	Adaptation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins to New World Monkey Receptors. <i>Journal of Virology</i> , 2008, 82, 346-357.	1.5	16
1208	Neutralization of HIV-1 by redirection of natural antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12515-12520.	3.3	33
1209	Simian Immunodeficiency Virus Is Susceptible to Inhibition by Carbohydrate-Binding Agents in a Manner Similar to That of HIV: Implications for Further Preclinical Drug Development. <i>Molecular Pharmacology</i> , 2008, 74, 330-337.	1.0	11
1210	Monitoring Early Fusion Dynamics of Human Immunodeficiency Virus Type 1 at Single-Molecule Resolution. <i>Journal of Virology</i> , 2008, 82, 7022-7033.	1.5	49
1211	Nonprimate Models of HIV-1 Infection and Pathogenesis. <i>Advances in Pharmacology</i> , 2008, 56, 399-422.	1.2	2
1212	Systematic Analysis of Host Immunological Pressure on the Envelope Gene of Human Immunodeficiency Virus Type 1 by an Immunobioinformatics Approach. <i>Current HIV Research</i> , 2008, 6, 370-379.	0.2	6
1213	High-Affinity Binding of Southern African HIV Type 1 Subtype C Envelope Protein, gp120, to the CCR5 Coreceptor. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1527-1536.	0.5	4
1214	HLA Homology within the C5 Domain Promotes Peptide Binding by HIV Type 1 gp120. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 845-855.	0.5	11
1215	Implications from the SIV model in understanding HIV neutralization. <i>Future HIV Therapy</i> , 2008, 2, 47-58.	0.5	2
1216	Correlates of antibody-mediated protection against HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 368-374.	1.5	12
1217	The Design of a Global AIDS Vaccine. , 2008, , 81-90.		1
1218	New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 473-485.	0.9	14
1219	Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly. <i>Molecules</i> , 2008, 13, 2426-2441.	1.7	27

#	ARTICLE	IF	CITATIONS
1220	HIV vaccines. , 2009, , 53-84.		0
1221	Physical Aspects of Viral Membrane Fusion. Scientific World Journal, The, 2009, 9, 764-780.	0.8	4
1223	Derivation and Characterization of a Simian Immunodeficiency Virus SIVmac239 Variant with Tropism for CXCR4. Journal of Virology, 2009, 83, 9911-9922.	1.5	21
1224	Human Immunodeficiency Virus Type 1 V1-to-V5 Envelope Variants from the Chronic Phase of Infection Use CCR5 and Fuse More Efficiently than Those from Early after Infection. Journal of Virology, 2009, 83, 9694-9708.	1.5	41
1225	Proximal Glycans Outside of the Epitopes Regulate the Presentation of HIV-1 Envelope gp120 Helper Epitopes. Journal of Immunology, 2009, 182, 6369-6378.	0.4	42
1226	Toward Effective HIV Vaccination. Journal of Biological Chemistry, 2009, 284, 30627-30642.	1.6	15
1227	Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38. Expert Opinion on Therapeutic Targets, 2009, 13, 141-152.	1.5	5
1228	Expression of a Modified Form of CD4 Results in the Release of an Anti-HIV Factor Derived from the Env Sequence. Journal of Immunology, 2009, 183, 1188-1196.	0.4	0
1229	Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7385-7390.	3.3	146
1230	Evolutionary Trajectories of Primate Genes Involved in HIV Pathogenesis. Molecular Biology and Evolution, 2009, 26, 2865-2875.	3.5	50
1231	Transitions to and from the CD4-Bound Conformation Are Modulated by a Single-Residue Change in the Human Immunodeficiency Virus Type 1 gp120 Inner Domain. Journal of Virology, 2009, 83, 8364-8378.	1.5	57
1232	Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation. Journal of Virology, 2009, 83, 4476-4488.	1.5	50
1233	Selective Expansion of HIV-1 Envelope Glycoprotein-Specific B Cell Subsets Recognizing Distinct Structural Elements Following Immunization. Journal of Immunology, 2009, 183, 3373-3382.	0.4	42
1234	Human Immunodeficiency Virus Type 1 Escape from Cyclotriazadisulfonamide-Induced CD4-Targeted Entry Inhibition Is Associated with Increased Neutralizing Antibody Susceptibility. Journal of Virology, 2009, 83, 9577-9583.	1.5	10
1235	Determinants Flanking the CD4 Binding Loop Modulate Macrophage Tropism of Human Immunodeficiency Virus Type 1 R5 Envelopes. Journal of Virology, 2009, 83, 2575-2583.	1.5	68
1236	Deglycosylation or Partial Removal of HIV-1 CN54 gp140 V1/V2 Domain Enhances Env-Specific T Cells. AIDS Research and Human Retroviruses, 2009, 25, 607-617.	0.5	10
1237	Appreciating HIV Type 1 Diversity: Subtype Differences in Env. AIDS Research and Human Retroviruses, 2009, 25, 237-248.	0.5	69
1238	Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opinion on Biological Therapy, 2009, 9, 355-368.	1.4	52

#	ARTICLE	IF	CITATIONS
1239	The Therapeutic Potential of Cell-Internalizing Aptamers. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1144-1157.	1.0	44
1240	Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives. <i>Current Medicinal Chemistry</i> , 2009, 16, 1673-1687.	1.2	133
1241	A New World Primate Deficient in Tetherin-Mediated Restriction of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2009, 83, 8771-8780.	1.5	21
1242	Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. <i>Journal of Virology</i> , 2009, 83, 1045-1059.	1.5	238
1243	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. <i>PLoS Pathogens</i> , 2009, 5, e1000598.	2.1	213
1244	Immunoglobulin Superfamily Virus Receptors and the Evolution of Adaptive Immunity. <i>PLoS Pathogens</i> , 2009, 5, e1000481.	2.1	49
1245	Preclinical and Clinical Development of a Multi-Envelope, DNA-Virus-Protein (D-V-P) HIV-1 Vaccine. <i>International Reviews of Immunology</i> , 2009, 28, 49-68.	1.5	18
1246	Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways. <i>PLoS Pathogens</i> , 2009, 5, e1000594.	2.1	172
1247	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site. <i>PLoS Pathogens</i> , 2009, 5, e1000445.	2.1	113
1248	Is Assembly of the SNARE Complex Enough to Fuel Membrane Fusion?. <i>Journal of Biological Chemistry</i> , 2009, 284, 13143-13152.	1.6	65
1249	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. <i>Journal of Virology</i> , 2009, 83, 5077-5086.	1.5	43
1250	Optimization of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins with V1/V2 Deleted, Using Virus Evolution. <i>Journal of Virology</i> , 2009, 83, 368-383.	1.5	43
1251	Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. <i>Journal of Virology</i> , 2009, 83, 7337-7348.	1.5	538
1252	Adaptive Mutations in a Human Immunodeficiency Virus Type 1 Envelope Protein with a Truncated V3 Loop Restore Function by Improving Interactions with CD4. <i>Journal of Virology</i> , 2009, 83, 11005-11015.	1.5	30
1253	Characterization of a Human Immunodeficiency Virus Type 1 V3 Deletion Mutation That Confers Resistance to CCR5 Inhibitors and the Ability To Use APlaviroc-Bound Receptor. <i>Journal of Virology</i> , 2009, 83, 3798-3809.	1.5	28
1254	Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3952-3957.	3.3	70
1255	The Phthalocyanine Prototype Derivative Alcian Blue Is the First Synthetic Agent with Selective Anti-Human Immunodeficiency Virus Activity Due to Its gp120 Glycan-Binding Potential. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4852-4859.	1.4	11
1256	Specificity switching in virus-receptor complexes. <i>Current Opinion in Structural Biology</i> , 2009, 19, 181-188.	2.6	15

#	ARTICLE	IF	CITATIONS
1257	SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. <i>Virology</i> , 2009, 393, 265-271.	1.1	56
1258	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. <i>Virology</i> , 2009, 394, 91-98.	1.1	28
1259	Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. <i>Virology</i> , 2009, 395, 33-44.	1.1	20
1261	Design of Protein-Protein Interaction Inhibitors Based on Protein Epitope Mimetics. <i>ChemBioChem</i> , 2009, 10, 971-973.	1.3	30
1262	Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. <i>Journal of Molecular Recognition</i> , 2009, 22, 169-174.	1.1	41
1263	HIV entry inhibitors and their potential in HIV therapy. <i>Medicinal Research Reviews</i> , 2009, 29, 369-393.	5.0	108
1264	Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. <i>Journal of Molecular Modeling</i> , 2009, 15, 281-294.	0.8	10
1265	Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 74, 881-894.	1.5	26
1266	Crystal structure of a 3B3 variant-A broadly neutralizing HIV-1 scFv antibody. <i>Protein Science</i> , 2009, 18, 2429-2441.	3.1	16
1267	Structural improvement of unliganded simian immunodeficiency virus gp120 core by normal-mode-based X-ray crystallographic refinement. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2009, 65, 339-347.	2.5	15
1268	Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2009, 65, 1162-1180.	2.5	26
1269	Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2009, 65, 705-708.	0.7	2
1270	Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review. <i>AIDS Research and Therapy</i> , 2009, 6, 25.	0.7	22
1271	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. <i>Nature</i> , 2009, 458, 636-640.	13.7	806
1272	Architecture and secondary structure of an entire HIV-1 RNA genome. <i>Nature</i> , 2009, 460, 711-716.	13.7	719
1273	Protein structures: Structures of desire. <i>Nature</i> , 2009, 459, 24-27.	13.7	27
1274	A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry. <i>Nature Chemical Biology</i> , 2009, 5, 743-748.	3.9	112
1275	HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. <i>Apmis</i> , 2009, 117, 400-412.	0.9	42

#	ARTICLE	IF	CITATIONS
1276	Stabilization of two smallest possible diastereomeric $\hat{1}^2$ -hairpins in a water soluble tetrapeptide containing non-coded $\hat{1}^{\pm}$ -amino isobutyric acid (Aib) and m-amino benzoic acid. <i>Journal of Molecular Structure</i> , 2009, 928, 138-143.	1.8	3
1277	Inhibitors of HIV-1 attachment. Part 2: An initial survey of indole substitution patterns. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1977-1981.	1.0	58
1278	Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3524-3532.	2.6	34
1279	Conformational analysis of trimeric maleimide substituted 1,5,9-triazacyclododecane HIV fusion scaffolds. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1251-1258.	1.4	2
1281	Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation. <i>Biochemistry</i> , 2009, 48, 2915-2923.	1.2	59
1282	Binding Thermodynamics of the N-Terminal Peptide of the CCR5 Coreceptor to HIV-1 Envelope Glycoprotein gp120. <i>Biochemistry</i> , 2009, 48, 779-785.	1.2	22
1283	Understanding of the Bridging Sheet Formation of HIV-1 Glycoprotein gp120. <i>Journal of Physical Chemistry B</i> , 2009, 113, 14536-14543.	1.2	16
1284	Antibody Recognition of a Highly Conserved Influenza Virus Epitope. <i>Science</i> , 2009, 324, 246-251.	6.0	1,220
1285	Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. <i>Nucleic Acids Research</i> , 2009, 37, 3094-3109.	6.5	264
1286	A large library based on a novel (CH ₂) scaffold: Identification of HIV-1 inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2009, 387, 387-392.	1.0	64
1287	RISUG [®] : A potential candidate for the entry inhibitor group of antiretroviral drugs. <i>Medical Hypotheses</i> , 2009, 73, 150-152.	0.8	7
1288	Vaccinology in the genome era. <i>Journal of Clinical Investigation</i> , 2009, 119, 2515-2525.	3.9	132
1289	Preclinical development of the green tea catechin, epigallocatechin gallate, as an HIV-1 therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 459-465.	1.5	101
1290	HIV-derived peptide mimics. <i>Drug Discovery Today: Technologies</i> , 2009, 6, e19-e25.	4.0	5
1291	Determination of Epitopes by Mass Spectrometry. <i>Springer Protocols</i> , 2009, , 1859-1872.	0.1	0
1292	Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection. <i>Journal of Translational Medicine</i> , 2009, 7, 101.	1.8	5
1293	Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer. <i>Retrovirology</i> , 2009, 6, 75.	0.9	19
1294	Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19970-19974.	3.3	283

#	ARTICLE	IF	CITATIONS
1295	Inhibitors of Viral Entry. Handbook of Experimental Pharmacology, 2009, , 177-202.	0.9	22
1296	Viral Applications of Green Fluorescent Protein. Methods in Molecular Biology, 2009, , .	0.4	0
1297	Increased Chemokine Signaling in a Model of HIV1-Associated Peripheral Neuropathy. Molecular Pain, 2009, 5, 1744-8069-5-48.	1.0	89
1298	Allosteric Drug Antagonism. , 2009, , 129-147.		1
1299	Antiviral Strategies. Handbook of Experimental Pharmacology, 2009, , .	0.9	3
1300	Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 63, 1087-1096.	1.3	26
1301	A general approach for the non-stop solid phase synthesis of TAC-scaffolded loops towards protein mimics containing discontinuous epitopes. Chemical Communications, 2009, , 821-823.	2.2	22
1302	Chemokine receptors and other G protein-coupled receptors. Current Opinion in HIV and AIDS, 2009, 4, 88-95.	1.5	46
1303	Challenges for structure-based HIV vaccine design. Current Opinion in HIV and AIDS, 2009, 4, 431-440.	1.5	104
1304	Specificity of the autologous neutralizing antibody response. Current Opinion in HIV and AIDS, 2009, 4, 358-363.	1.5	59
1305	Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Current Opinion in HIV and AIDS, 2009, 4, 112-117.	1.5	33
1306	The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Current Opinion in HIV and AIDS, 2009, 4, 408-417.	1.5	50
1307	The biology of CCR5 and CXCR4. Current Opinion in HIV and AIDS, 2009, 4, 96-103.	1.5	158
1309	The human Pk histo-blood group antigen provides protection against HIV-1 infection. Blood, 2009, 113, 4980-4991.	0.6	69
1311	Broadly Neutralizing Antibodies and their Significance for HIV-1 Vaccines. Current HIV Research, 2010, 8, 602-612.	0.2	12
1312	Structure-based Vaccine Design in HIV: Blind Men and the Elephant?. Current Pharmaceutical Design, 2010, 16, 3744-3753.	0.9	43
1313	Antibody Epitope Exposure and Neutralization of HIV-1. Current Pharmaceutical Design, 2010, 16, 3729-3743.	0.9	17
1314	Discovery of a Small Molecule Inhibitor of the Interaction Between HIV-1 Proteins and Cellular Cofactors: A Novel Candidate Anti-HIV-1 Drug. Current Chemical Biology, 2010, 4, 188-199.	0.2	0

#	ARTICLE	IF	CITATIONS
1315	Peptide-Based Inhibitors of the HIV Envelope Protein and Other Class I Viral Fusion Proteins. <i>Current Pharmaceutical Design</i> , 2010, 16, 1143-1158.	0.9	52
1316	Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. <i>Aids</i> , 2010, 24, 875-884.	1.0	36
1318	Involvement of Envelope-Glycoprotein Glycans in HIV-1 Biology and Infection. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 191-208.	1.0	14
1319	Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 1143-1152.	1.9	28
1320	Carbohydrate biomarkers for future disease detection and treatment. <i>Science China Chemistry</i> , 2010, 53, 3-20.	4.2	30
1321	Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. <i>Journal of Virological Methods</i> , 2010, 168, 155-161.	1.0	35
1322	Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody. <i>Structure</i> , 2010, 18, 1632-1641.	1.6	62
1323	Hierarchical kernel mixture models for the prediction of AIDS disease progression using HIV structural gp120 profiles. <i>BMC Genomics</i> , 2010, 11, S22.	1.2	7
1324	sCD4-17b bifunctional protein: Extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. <i>Retrovirology</i> , 2010, 7, 11.	0.9	35
1325	Modulation of HIV-1 macrophage-tropism among R5 envelopes occurs before detection of neutralizing antibodies. <i>Retrovirology</i> , 2010, 7, 48.	0.9	10
1326	Entry inhibitors in the treatment of HIV-1 infection. <i>Antiviral Research</i> , 2010, 85, 91-100.	1.9	186
1327	Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. <i>Antiviral Research</i> , 2010, 88, 107-115.	1.9	38
1328	Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. <i>Drug Discovery Today</i> , 2010, 15, 186-197.	3.2	61
1329	Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. <i>Virology</i> , 2010, 396, 339-348.	1.1	33
1330	Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. <i>Virology</i> , 2010, 401, 236-247.	1.1	72
1331	Residues in the membrane-spanning domain core modulate conformation and fusogenicity of the HIV-1 envelope glycoprotein. <i>Virology</i> , 2010, 404, 158-167.	1.1	20
1332	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. <i>Virology</i> , 2010, 402, 187-196.	1.1	95
1333	Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies. <i>Virology</i> , 2010, 402, 256-261.	1.1	19

#	ARTICLE	IF	CITATIONS
1334	Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. <i>Virology</i> , 2010, 404, 59-70.	1.1	30
1335	An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. <i>Virology</i> , 2010, 404, 269-278.	1.1	55
1336	Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. <i>Virology</i> , 2010, 408, 80-88.	1.1	37
1337	A clinical case-control study on the association between mannose-binding lectin and susceptibility to HIV-1 infection among northern Han Chinese population. <i>International Journal of Immunogenetics</i> , 2010, 37, 445-454.	0.8	11
1338	Inhibition of HIV-1 Entry: Multiple Keys to Close the Door. <i>ChemMedChem</i> , 2010, 5, 1825-1835.	1.6	18
1339	Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. <i>Journal of the American Society for Mass Spectrometry</i> , 2010, 21, 1687-1698.	1.2	7
1340	Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds. <i>Chemistry and Biology</i> , 2010, 17, 357-370.	6.2	125
1341	Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: The HIV-1 CD4:gp120 paradigm. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5754-5761.	1.4	13
1342	Application of protein engineering to enhance crystallizability and improve crystal properties. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2010, 66, 604-615.	2.5	98
1343	Mode of antiviral action of silver nanoparticles against HIV-1. <i>Journal of Nanobiotechnology</i> , 2010, 8, 1.	4.2	762
1344	Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies. <i>Journal of Translational Medicine</i> , 2010, 9, S1.	1.8	7
1345	Aptamer-targeted cell-specific RNA interference. <i>Silence: A Journal of RNA Regulation</i> , 2010, 1, 4.	8.0	116
1346	Glycoproteomics and clinical applications. <i>Proteomics - Clinical Applications</i> , 2010, 4, 124-132.	0.8	91
1347	Computational alanine scanning with linear scaling semiempirical quantum mechanical methods. <i>Proteins: Structure, Function and Bioinformatics</i> , 2010, 78, 2329-2337.	1.5	17
1348	Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network. <i>Proteins: Structure, Function and Bioinformatics</i> , 2010, 78, 2935-2949.	1.5	8
1349	Structure of the measles virus hemagglutinin bound to the CD46 receptor. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 124-129.	3.6	117
1350	Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 608-613.	3.6	92
1351	Conserved structural elements in the V3 crown of HIV-1 gp120. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 955-961.	3.6	147

#	ARTICLE	IF	CITATIONS
1352	Structureâ€“function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. <i>Nature Reviews Immunology</i> , 2010, 10, 527-535.	10.6	140
1353	A Strategy for Eliciting Antibodies against Cryptic, Conserved, Conformationally Dependent Epitopes of HIV Envelope Glycoprotein. <i>PLoS ONE</i> , 2010, 5, e8555.	1.1	13
1354	Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction. <i>PLoS ONE</i> , 2010, 5, e10482.	1.1	33
1355	R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models. <i>PLoS ONE</i> , 2010, 5, e11689.	1.1	52
1356	Few and Far Between: How HIV May Be Evading Antibody Avidity. <i>PLoS Pathogens</i> , 2010, 6, e1000908.	2.1	226
1357	Subtle evolutionary changes in the distribution of N-glycosylation sequons in the HIV-1 envelope glycoprotein 120. <i>International Journal of Biological Sciences</i> , 2010, 6, 407-418.	2.6	6
1358	Current progress in the development of a prophylactic vaccine for HIV-1. <i>Drug Design, Development and Therapy</i> , 2010, 5, 9.	2.0	29
1359	Epitope Mapping of Ibalizumab, a Humanized Anti-CD4 Monoclonal Antibody with Anti-HIV-1 Activity in Infected Patients. <i>Journal of Virology</i> , 2010, 84, 6935-6942.	1.5	64
1360	RNA Structures Facilitate Recombination-Mediated Gene Swapping in HIV-1. <i>Journal of Virology</i> , 2010, 84, 12675-12682.	1.5	51
1361	Stabilization of HIV-1 gp120-CD4 Receptor Complex through Targeted Interchain Disulfide Exchange. <i>Journal of Biological Chemistry</i> , 2010, 285, 25743-25752.	1.6	24
1362	3D Visualization of HIV Virions by Cryoelectron Tomography. <i>Methods in Enzymology</i> , 2010, 483, 267-290.	0.4	30
1363	Pradimicin S, a Highly Soluble Nonpeptidic Small-Size Carbohydrate-Binding Antibiotic, Is an Anti-HIV Drug Lead for both Microbicidal and Systemic Use. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1425-1435.	1.4	46
1364	Influence of Disulfide-Stabilized Structure on the Specificity of Helper T-Cell and Antibody Responses to HIV Envelope Glycoprotein gp120. <i>Journal of Virology</i> , 2010, 84, 3303-3311.	1.5	19
1365	Mutation at a Single Position in the V2 Domain of the HIV-1 Envelope Protein Confers Neutralization Sensitivity to a Highly Neutralization-Resistant Virus. <i>Journal of Virology</i> , 2010, 84, 11200-11209.	1.5	38
1366	Two N-Linked Glycosylation Sites in the V2 and C2 Regions of Human Immunodeficiency Virus Type 1 CRF01_AE Envelope Glycoprotein gp120 Regulate Viral Neutralization Susceptibility to the Human Monoclonal Antibody Specific for the CD4 Binding Domain. <i>Journal of Virology</i> , 2010, 84, 4311-4320.	1.5	35
1367	Microvirin, a Novel Î±(1,2)-Mannose-specific Lectin Isolated from <i>Microcystis aeruginosa</i> , Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile. <i>Journal of Biological Chemistry</i> , 2010, 285, 24845-24854.	1.6	108
1368	Role of Complex Carbohydrates in Human Immunodeficiency Virus Type 1 Infection and Resistance to Antibody Neutralization. <i>Journal of Virology</i> , 2010, 84, 5637-5655.	1.5	127
1369	Peptide Ligands Selected with CD4-Induced Epitopes on Native Dualtropic HIV-1 Envelope Proteins Mimic Extracellular Coreceptor Domains and Bind to HIV-1 gp120 Independently of Coreceptor Usage. <i>Journal of Virology</i> , 2010, 84, 10131-10138.	1.5	13

#	ARTICLE	IF	CITATIONS
1370	OrfA Downregulates Feline Immunodeficiency Virus Primary Receptor CD134 on the Host Cell Surface and Is Important in Viral Infection. <i>Journal of Virology</i> , 2010, 84, 7225-7232.	1.5	14
1371	Neutralization Efficiency Is Greatly Enhanced by Bivalent Binding of an Antibody to Epitopes in the V4 Region and the Membrane-Proximal External Region within One Trimer of Human Immunodeficiency Virus Type 1 Glycoproteins. <i>Journal of Virology</i> , 2010, 84, 7114-7123.	1.5	18
1372	Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18844-18849.	3.3	55
1374	Deglycosylation of HIV-1 AE Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies Against the Heterologous HIV-1 Clade. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 569-575.	0.5	8
1375	Glycosylation Patterns of HIV-1 gp120 Depend on the Type of Expressing Cells and Affect Antibody Recognition. <i>Journal of Biological Chemistry</i> , 2010, 285, 20860-20869.	1.6	131
1376	Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution. <i>Journal of Biological Chemistry</i> , 2010, 285, 36456-36470.	1.6	23
1377	HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2010, 84, 6505-6514.	1.5	59
1378	Actinohivin, a Broadly Neutralizing Prokaryotic Lectin, Inhibits HIV-1 Infection by Specifically Targeting High-Mannose-Type Glycans on the gp120 Envelope. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3287-3301.	1.4	54
1379	Design of a Non-glycosylated Outer Domain-derived HIV-1 gp120 Immunogen That Binds to CD4 and Induces Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2010, 285, 27100-27110.	1.6	33
1380	Selection of a Rare Neutralization-Resistant Variant following Passive Transfer of Convalescent Immune Plasma in Equine Infectious Anemia Virus-Challenged SCID Horses. <i>Journal of Virology</i> , 2010, 84, 6536-6548.	1.5	17
1381	Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 1166-1171.	3.3	304
1382	Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. <i>Journal of Experimental Medicine</i> , 2010, 207, 1995-2002.	4.2	62
1383	Mapping of Domains on HIV Envelope Protein Mediating Association with Calnexin and Protein-disulfide Isomerase. <i>Journal of Biological Chemistry</i> , 2010, 285, 13788-13796.	1.6	13
1384	Disulfide Bond That Constrains the HIV-1 gp120 V3 Domain Is Cleaved by Thioredoxin. <i>Journal of Biological Chemistry</i> , 2010, 285, 40072-40080.	1.6	31
1385	Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. <i>Journal of General Virology</i> , 2010, 91, 1354-1364.	1.3	8
1386	A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer. <i>Journal of Virology</i> , 2010, 84, 3147-3161.	1.5	64
1387	Constraints on HIV-1 Diversity from Protein Structure. <i>Journal of Virology</i> , 2010, 84, 12995-13003.	1.5	25
1388	Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds. <i>Journal of Virology</i> , 2010, 84, 7558-7568.	1.5	74

#	ARTICLE	IF	CITATIONS
1389	Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. <i>Viruses</i> , 2010, 2, 547-565.	1.5	15
1390	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2493-2501.	1.3	35
1391	Organization of Cellular Receptors into a Nanoscale Junction during HIV-1 Adhesion. <i>PLoS Computational Biology</i> , 2010, 6, e1000855.	1.5	18
1392	Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure. <i>PLoS Pathogens</i> , 2010, 6, e1001249.	2.1	161
1393	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. <i>PLoS Computational Biology</i> , 2010, 6, e1000955.	1.5	78
1394	HIV-1 Envelope Subregion Length Variation during Disease Progression. <i>PLoS Pathogens</i> , 2010, 6, e1001228.	2.1	79
1395	Estimating the Stoichiometry of HIV Neutralization. <i>PLoS Computational Biology</i> , 2010, 6, e1000713.	1.5	31
1396	HIV-1 Entry, Inhibitors, and Resistance. <i>Viruses</i> , 2010, 2, 1069-1105.	1.5	56
1397	Local Conformational Stability of HIV-1 gp120 in Unliganded and CD4-Bound States as Defined by Amide Hydrogen/Deuterium Exchange. <i>Journal of Virology</i> , 2010, 84, 10311-10321.	1.5	32
1398	Protease Cleavage Sites in HIV-1 gp120 Recognized by Antigen Processing Enzymes Are Conserved and Located at Receptor Binding Sites. <i>Journal of Virology</i> , 2010, 84, 1513-1526.	1.5	29
1399	Topics in Nucleic Acids Structure: Noncanonical Helices and RNA Structure. <i>Interdisciplinary Applied Mathematics</i> , 2010, , 205-236.	0.2	2
1400	Antibodyâ€™Antigen Recognition and Conformational Changes. , 2010, , 29-36.		0
1401	GPI-anchored single chain Fv - an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. <i>Retrovirology</i> , 2010, 7, 79.	0.9	30
1402	Structural Analysis of a Highly Glycosylated and Unliganded gp120-Based Antigen Using Mass Spectrometry. <i>Biochemistry</i> , 2010, 49, 9032-9045.	1.2	19
1403	Naturally Occurring Variability in the Envelope Glycoprotein of HIV-1 and Development of Cell Entry Inhibitors. <i>Biochemistry</i> , 2010, 49, 2359-2367.	1.2	16
1404	Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists. <i>Science</i> , 2010, 330, 1066-1071.	6.0	1,610
1405	Toward an Antibody-Based HIV-1 Vaccine. <i>Annual Review of Medicine</i> , 2010, 61, 135-152.	5.0	110
1406	Topological Layers in the HIV-1 gp120 Inner Domain Regulate gp41 Interaction and CD4-Triggered Conformational Transitions. <i>Molecular Cell</i> , 2010, 37, 656-667.	4.5	194

#	ARTICLE	IF	CITATIONS
1407	HIV Fusion Peptide Penetrates, Disorders, and Softens T-Cell Membrane Mimics. <i>Journal of Molecular Biology</i> , 2010, 402, 139-153.	2.0	72
1408	Expression-System-Dependent Modulation of HIV-1 Envelope Glycoprotein Antigenicity and Immunogenicity. <i>Journal of Molecular Biology</i> , 2010, 403, 131-147.	2.0	67
1409	Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function. <i>Biochemical and Biophysical Research Communications</i> , 2010, 394, 904-908.	1.0	11
1410	A Modeled Structure of an Aptamer-gp120 Complex Provides Insight into the Mechanism of HIV-1 Neutralization. <i>Biochemistry</i> , 2010, 49, 5880-5890.	1.2	16
1411	Targeting Protein-Protein Interactions: A Promising Avenue of Anti-HIV Drug Discovery. <i>Current Medicinal Chemistry</i> , 2010, 17, 3393-3409.	1.2	16
1413	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. <i>Science</i> , 2010, 329, 811-817.	6.0	1,050
1414	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	6.0	1,600
1415	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. <i>Journal of Virology</i> , 2010, 84, 1439-1452.	1.5	589
1416	HIV-1 Vaccine Development After STEP. <i>Annual Review of Medicine</i> , 2010, 61, 153-167.	5.0	89
1417	A General Approach for Receptor and Antibody-Targeted Detection of Native Proteins Utilizing Split-Luciferase Reassembly. <i>ACS Chemical Biology</i> , 2010, 5, 943-952.	1.6	29
1419	Alanine Scanning Mutagenesis of HIV-1 gp41 Heptad Repeat 1: Insight into the gp120-gp41 Interaction. <i>Biochemistry</i> , 2010, 49, 5057-5065.	1.2	31
1420	Peptidomimetic inhibitors targeting the CCR5-binding site on the human immunodeficiency virus type-1 gp120 glycoprotein complexed to CD4. <i>Chemical Communications</i> , 2010, 46, 7754.	2.2	11
1421	Back to the future: covalent epitope-based HIV vaccine development. <i>Expert Review of Vaccines</i> , 2010, 9, 1027-1043.	2.0	18
1422	B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. <i>Nature Communications</i> , 2010, 1, 102.	5.8	62
1423	Cell Signaling Reactions. , 2011, , .		4
1424	Monoclonal Antibody m18 Paratope Leading to Dual Receptor Antagonism of HIV-1 gp120. <i>Biochemistry</i> , 2011, 50, 2769-2779.	1.2	1
1425	LocaPep: Localization of Epitopes on Protein Surfaces Using Peptides from Phage Display Libraries. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 1465-1473.	2.5	16
1426	Analysis of the Disulfide Bond Arrangement of the HIV-1 Envelope Protein CON-S gp140 Shows Variability in the V1 and V2 Regions. <i>Journal of Proteome Research</i> , 2011, 10, 578-591.	1.8	41

#	ARTICLE	IF	CITATIONS
1427	Enhanced Dynamics of HIV gp120 Glycoprotein by Small Molecule Binding. <i>Biochemistry</i> , 2011, 50, 4173-4183.	1.2	14
1428	Viral attachment strategies: the many faces of adenoviruses. <i>Current Opinion in Virology</i> , 2011, 1, 84-91.	2.6	27
1429	Cell entry of enveloped viruses. <i>Current Opinion in Virology</i> , 2011, 1, 92-100.	2.6	94
1430	Structure-Based Identification and Neutralization Mechanism of Tyrosine Sulfate Mimetics That Inhibit HIV-1 Entry. <i>ACS Chemical Biology</i> , 2011, 6, 1069-1077.	1.6	31
1431	The Molecular Biology of Feline Immunodeficiency Virus (FIV). <i>Viruses</i> , 2011, 3, 2192-2213.	1.5	27
1432	Targeting the protein-protein interactions of the HIV lifecycle. <i>Chemical Society Reviews</i> , 2011, 40, 1337-1346.	18.7	23
1433	Conformational and Structural Features of HIV-1 gp120 Underlying the Dual Receptor Antagonism by Cross-Reactive Neutralizing Antibody m18. <i>Biochemistry</i> , 2011, 50, 2756-2768.	1.2	5
1434	Antiviral RNAi. <i>Methods in Molecular Biology</i> , 2011, , .	0.4	7
1435	HIV Fusion Peptide Penetrates, Disorders and Softens T-Cell Membrane Mimics. <i>Biophysical Journal</i> , 2011, 100, 186a.	0.2	1
1436	Density functional theory study of dipicolinic acid isomers and crystalline polytypes. <i>Computational and Theoretical Chemistry</i> , 2011, 977, 148-156.	1.1	6
1437	Synthetic Fab fragments that bind the HIV-1 gp41 heptad repeat regions. <i>Biochemical and Biophysical Research Communications</i> , 2011, 413, 611-615.	1.0	14
1438	Cells under siege: Viral glycoprotein interactions at the cell surface. <i>Journal of Structural Biology</i> , 2011, 175, 120-126.	1.3	29
1439	Computational Protein Design Using Flexible Backbone Remodeling and Resurfacing: Case Studies in Structure-Based Antigen Design. <i>Journal of Molecular Biology</i> , 2011, 405, 284-297.	2.0	60
1440	HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and Incorporation. <i>Journal of Molecular Biology</i> , 2011, 410, 582-608.	2.0	368
1441	Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env. <i>Vaccine</i> , 2011, 29, 2637-2647.	1.7	19
1442	Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. <i>Vaccine</i> , 2011, 29, 9064-9074.	1.7	37
1443	Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 Inhibition. <i>Methods</i> , 2011, 54, 284-294.	1.9	77
1444	HIV envelope: challenges and opportunities for development of entry inhibitors. <i>Trends in Microbiology</i> , 2011, 19, 191-197.	3.5	75

#	ARTICLE	IF	CITATIONS
1445	Anti-HIV Activity of Extracts and Compounds from Marine Algae. <i>Advances in Food and Nutrition Research</i> , 2011, 64, 255-265.	1.5	37
1446	Abundant Non-canonical dUTP Found in Primary Human Macrophages Drives Its Frequent Incorporation by HIV-1 Reverse Transcriptase. <i>Journal of Biological Chemistry</i> , 2011, 286, 25047-25055.	1.6	34
1447	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. <i>Science</i> , 2011, 333, 1633-1637.	6.0	1,046
1448	Structure of Herpes Simplex Virus Glycoprotein D Bound to the Human Receptor Nectin-1. <i>PLoS Pathogens</i> , 2011, 7, e1002277.	2.1	154
1449	Role for the Terminal Clasp of HIV-1 gp41 Glycoprotein in the Initiation of Membrane Fusion*. <i>Journal of Biological Chemistry</i> , 2011, 286, 41331-41343.	1.6	10
1451	HIV-1 Glycoprotein Immunogenicity. , 0, , .		0
1453	Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides. <i>Advances in Bioinformatics</i> , 2011, 2011, 1-12.	5.7	6
1454	Dipeptidyl peptidase in autoimmune pathophysiology. <i>Advances in Clinical Chemistry</i> , 2011, 53, 51-84.	1.8	61
1455	Evolutionary and Structural Features of the C2, V3 and C3 Envelope Regions Underlying the Differences in HIV-1 and HIV-2 Biology and Infection. <i>PLoS ONE</i> , 2011, 6, e14548.	1.1	27
1456	Induction of HIV Neutralizing Antibodies against the MPER of the HIV Envelope Protein by HA/gp41 Chimeric Protein-Based DNA and VLP Vaccines. <i>PLoS ONE</i> , 2011, 6, e14813.	1.1	39
1457	A Directed Molecular Evolution Approach to Improved Immunogenicity of the HIV-1 Envelope Glycoprotein. <i>PLoS ONE</i> , 2011, 6, e20927.	1.1	14
1458	Adoption of an "Open" Envelope Conformation Facilitating CD4 Binding and Structural Remodeling Precedes Coreceptor Switch in R5 SHIV-Infected Macaques. <i>PLoS ONE</i> , 2011, 6, e21350.	1.1	18
1459	Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses. <i>PLoS ONE</i> , 2011, 6, e24078.	1.1	99
1460	Siglecs Facilitate HIV-1 Infection of Macrophages through Adhesion with Viral Sialic Acids. <i>PLoS ONE</i> , 2011, 6, e24559.	1.1	94
1462	Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope. <i>Aids</i> , 2011, 25, 2209-2216.	1.0	3
1464	Some Binding-Related Drug Properties are Dependent on Thermodynamic Signature. <i>Chemical Biology and Drug Design</i> , 2011, 77, 161-165.	1.5	35
1465	Structural Basis of the Anti-HIV Activity of the Cyanobacterial <i>Oscillatoria Agardhii</i> Agglutinin. <i>Structure</i> , 2011, 19, 1170-1181.	1.6	44
1466	Cryo-electron tomography: gaining insight into cellular processes by structural approaches. <i>Current Opinion in Structural Biology</i> , 2011, 21, 670-677.	2.6	44

#	ARTICLE	IF	CITATIONS
1467	In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. <i>Journal of Virological Methods</i> , 2011, 171, 329-338.	1.0	16
1468	CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. <i>Virology</i> , 2011, 410, 418-428.	1.1	26
1469	A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop. <i>Virology</i> , 2011, 418, 123-132.	1.1	17
1470	HIV vaccine: hopes and hurdles. <i>Drug Discovery Today</i> , 2011, 16, 948-956.	3.2	9
1471	Lymphocytic choriomeningitis virus (LCMV) infection of macaques: A model for Lassa fever. <i>Antiviral Research</i> , 2011, 92, 125-138.	1.9	36
1472	Small molecular CD4 mimics as HIV entry inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6735-6742.	1.4	44
1473	A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield. <i>Science</i> , 2011, 334, 1097-1103.	6.0	644
1474	Prospective CCR5 Small Molecule Antagonist Compound Design Using a Combined Mutagenesis/Modeling Approach. <i>Journal of the American Chemical Society</i> , 2011, 133, 16477-16485.	6.6	17
1475	Cell surface glycan-lectin interactions in tumor metastasis. <i>Acta Histochemica</i> , 2011, 113, 591-600.	0.9	72
1476	Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. <i>Journal of Biomolecular NMR</i> , 2011, 50, 197-207.	1.6	18
1477	Imaging and determining friction forces of specific interactions between human IgG and rat anti-human IgG. <i>Journal of Biological Physics</i> , 2011, 37, 417-427.	0.7	4
1478	Virus entry paradigms. <i>Amino Acids</i> , 2011, 41, 1147-1157.	1.2	53
1479	Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. <i>European Biophysics Journal</i> , 2011, 40, 349-357.	1.2	29
1480	Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 91-101.	1.4	72
1481	Early Events of HIV-1 Infection: Can Signaling be the Next Therapeutic Target?. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 269-283.	2.1	9
1482	HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. <i>Journal of Translational Medicine</i> , 2011, 9, S2.	1.8	110
1483	Clinical significance of HIV-1 coreceptor usage. <i>Journal of Translational Medicine</i> , 2011, 9, S5.	1.8	71
1484	Differences in the mannose oligomer specificities of the closely related lectins from <i>Galanthus nivalis</i> and <i>Zea mays</i> strongly determine their eventual anti-HIV activity. <i>Retrovirology</i> , 2011, 8, 10.	0.9	24

#	ARTICLE	IF	CITATIONS
1485	Selected amino acid mutations in HIV-1 B subtype gp41 are Associated with Specific gp120V3 signatures in the regulation of Co-Receptor usage. <i>Retrovirology</i> , 2011, 8, 33.	0.9	38
1486	Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues. <i>Retrovirology</i> , 2011, 8, 42.	0.9	10
1487	A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain ± 1 helix in an engineered HIV-1 gp120. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 537-546.	1.5	5
1488	Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 1810-1819.	1.5	12
1489	Limitations to the structure-based design of HIV-1 vaccine immunogens. <i>Journal of Molecular Recognition</i> , 2011, 24, 741-753.	1.1	41
1490	An evaluation of poisson-boltzmann electrostatic free energy calculations through comparison with experimental mutagenesis data. <i>Biopolymers</i> , 2011, 95, n/a-n/a.	1.2	37
1491	Peptides and Proteins as a Continuing Exciting Source of Inspiration for Peptidomimetics. <i>ChemBioChem</i> , 2011, 12, 1626-1653.	1.3	144
1492	Bioactive synthetic heparan sulfate and heparin derivatives: From long fragments mimetics to chimeras. <i>Comptes Rendus Chimie</i> , 2011, 14, 59-73.	0.2	24
1493	Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 979-992.	2.6	52
1494	Restricted occupancy models for neutralization of HIV virions and populations. <i>Journal of Theoretical Biology</i> , 2011, 283, 192-202.	0.8	20
1495	CCR5/CXCR4 discriminating sites in the HIV-1 gp120 core. , 2011, , .		0
1496	Membrane Fusion Mediated by Human Immunodeficiency Virus Envelope Glycoprotein. <i>Current Topics in Membranes</i> , 2011, 68, 81-106.	0.5	57
1497	Three-Dimensional Structures of Soluble CD4-Bound States of Trimeric Simian Immunodeficiency Virus Envelope Glycoproteins Determined by Using Cryo-Electron Tomography. <i>Journal of Virology</i> , 2011, 85, 12114-12123.	1.5	46
1498	Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2011, 85, 2524-2535.	1.5	46
1499	Stabilization of HIV-1 Envelope in the CD4-bound Conformation through Specific Cross-linking of a CD4 Mimetic. <i>Journal of Biological Chemistry</i> , 2011, 286, 21706-21716.	1.6	25
1501	Therapeutic compounds: patent evaluation of WO2011011652A1. <i>Expert Opinion on Therapeutic Patents</i> , 2011, 21, 1491-1495.	2.4	2
1502	Recent advances in antiretroviral treatment and prevention in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2011, 6, S21-S30.	1.5	19
1503	Human monoclonal antibodies to HIV-1 gp140 from mice bearing YAC-based human immunoglobulin transloci. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 791-799.	1.0	18

#	ARTICLE	IF	CITATIONS
1504	Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. <i>Journal of General Virology</i> , 2011, 92, 2367-2373.	1.3	32
1505	Progress in the rational design of an AIDS vaccine. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011, 366, 2759-2765.	1.8	50
1506	In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 729-737.	1.4	47
1507	MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. <i>Journal of Experimental Medicine</i> , 2011, 208, 439-454.	4.2	95
1508	Potent Strategy To Inhibit HIV-1 by Binding both gp120 and gp41. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 264-275.	1.4	30
1509	A Tyrosine-Sulfated CCR5-Mimetic Peptide Promotes Conformational Transitions in the HIV-1 Envelope Glycoprotein. <i>Journal of Virology</i> , 2011, 85, 7563-7571.	1.5	18
1510	Phenylboronic-Acid-Based Carbohydrate Binders as Antiviral Therapeutics: Bisphenylboronic Acids. <i>Antiviral Chemistry and Chemotherapy</i> , 2011, 21, 129-142.	0.3	15
1511	Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site. <i>Journal of Virology</i> , 2011, 85, 9039-9050.	1.5	49
1512	Two Closely Related Env Antigens from the Same Patient Elicited Different Spectra of Neutralizing Antibodies against Heterologous HIV-1 Isolates. <i>Journal of Virology</i> , 2011, 85, 4927-4936.	1.5	11
1513	Engineered Single Human CD4 Domains as Potent HIV-1 Inhibitors and Components of Vaccine Immunogens. <i>Journal of Virology</i> , 2011, 85, 9395-9405.	1.5	35
1514	Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a007278-a007278.	2.9	135
1515	A Conserved Determinant in the V1 Loop of HIV-1 Modulates the V3 Loop To Prime Low CD4 Use and Macrophage Infection. <i>Journal of Virology</i> , 2011, 85, 2397-2405.	1.5	49
1516	Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab. <i>Journal of Virology</i> , 2011, 85, 3872-3880.	1.5	56
1517	Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6091-6096.	3.3	30
1518	Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. <i>Journal of Experimental Medicine</i> , 2011, 208, 1419-1433.	4.2	92
1519	Identification and Characterization of an Immunogenic Hybrid Epitope Formed by both HIV gp120 and Human CD4 Proteins. <i>Journal of Virology</i> , 2011, 85, 13097-13104.	1.5	16
1520	Probing the HIV gp120 Envelope Glycoprotein Conformation by NMR. <i>Journal of Biological Chemistry</i> , 2011, 286, 23975-23981.	1.6	12
1521	The Highly Conserved Glycan at Asparagine 260 of HIV-1 gp120 Is Indispensable for Viral Entry. <i>Journal of Biological Chemistry</i> , 2011, 286, 42900-42910.	1.6	28

#	ARTICLE	IF	CITATIONS
1522	A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses. <i>Journal of Virology</i> , 2011, 85, 5331-5337.	1.5	71
1523	Novel Fold and Carbohydrate Specificity of the Potent Anti-HIV Cyanobacterial Lectin from <i>Oscillatoria agardhii</i> . <i>Journal of Biological Chemistry</i> , 2011, 286, 1588-1597.	1.6	59
1524	Towards an AIDS vaccine: The transmembrane envelope protein as target for broadly neutralizing antibodies. <i>Hum Vaccin</i> , 2011, 7, 4-9.	2.4	15
1525	Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies. <i>Journal of Virology</i> , 2011, 85, 6986-6995.	1.5	86
1526	Adaptation of Subtype A Human Immunodeficiency Virus Type 1 Envelope to Pig-Tailed Macaque Cells. <i>Journal of Virology</i> , 2011, 85, 4409-4420.	1.5	32
1527	Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy. <i>Current Pharmaceutical Design</i> , 2011, 17, 3713-3728.	0.9	22
1528	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	13.7	794
1529	Structural Comparison of HIV-1 Envelope Spikes with and without the V1/V2 Loop. <i>Journal of Virology</i> , 2011, 85, 2741-2750.	1.5	47
1530	New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection. <i>Journal of Biological Chemistry</i> , 2011, 286, 4978-4990.	1.6	73
1531	Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. <i>FASEB Journal</i> , 2011, 25, 2156-2166.	0.2	16
1532	Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11440-11445.	3.3	149
1533	Interaction of the HIV-1 gp120 Viral Protein V3 Loop with Bacterial Lipopolysaccharide. <i>Journal of Biological Chemistry</i> , 2011, 286, 26228-26237.	1.6	7
1534	Affinity maturation of human CD4 by yeast surface display and crystal structure of a CD4-HLA-DR1 complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15960-15965.	3.3	47
1535	Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 419-435.	2.5	13
1536	Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design. <i>Science</i> , 2011, 334, 1289-1293.	6.0	345
1538	Current progress in the development of RNAi-based therapeutics for HIV-1. <i>Gene Therapy</i> , 2011, 18, 1134-1138.	2.3	41
1539	Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41. <i>Journal of Virology</i> , 2011, 85, 12929-12938.	1.5	21
1540	Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 9286-9299.	1.5	24

#	ARTICLE	IF	CITATIONS
1541	Crystal Structure of Reovirus Attachment Protein $\sigma 1$ in Complex with Sialylated Oligosaccharides. PLoS Pathogens, 2011, 7, e1002166.	2.1	130
1542	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	1.5	54
1543	Deep Sequencing to Infer HIV-1 Co-Receptor Usage: Application to Three Clinical Trials of Maraviroc in Treatment-Experienced Patients. Journal of Infectious Diseases, 2011, 203, 237-245.	1.9	137
1544	Intercompartmental Recombination of HIV-1 Contributes to <i>env</i> Intra-host Diversity and Modulates Viral Tropism and Sensitivity to Entry Inhibitors. Journal of Virology, 2011, 85, 6024-6037.	1.5	50
1545	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. PLoS Pathogens, 2012, 8, e1002721.	2.1	159
1546	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. International Journal of Molecular Sciences, 2012, 13, 5674-5699.	1.8	22
1547	Novel Approaches to Inhibit HIV Entry. Viruses, 2012, 4, 309-324.	1.5	46
1548	Structure-Based Design for High-Hanging Vaccine Fruits. Advances in Immunology, 2012, 114, 33-50.	1.1	7
1549	Structural Mechanism of Trimeric HIV-1 Envelope Glycoprotein Activation. PLoS Pathogens, 2012, 8, e1002797.	2.1	182
1550	Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors. Viruses, 2012, 4, 3859-3911.	1.5	31
1551	Antibodies to a Superantigenic Glycoprotein 120 Epitope as the Basis for Developing an HIV Vaccine. Journal of Immunology, 2012, 189, 5367-5381.	0.4	16
1552	A Species-Specific Amino Acid Difference in the Macaque CD4 Receptor Restricts Replication by Global Circulating HIV-1 Variants Representing Viruses from Recent Infection. Journal of Virology, 2012, 86, 12472-12483.	1.5	52
1553	HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12111-12116.	3.3	163
1554	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. Journal of Virology, 2012, 86, 4394-4403.	1.5	109
1555	Glycosylation of Simian Immunodeficiency Virus Influences Immune-Tissue Targeting during Primary Infection, Leading to Immunodeficiency or Viral Control. Journal of Virology, 2012, 86, 9323-9336.	1.5	6
1556	Cloning and Analysis of Sooty Mangabey Alternative Coreceptors That Support Simian Immunodeficiency Virus SIVsmm Entry Independently of CCR5. Journal of Virology, 2012, 86, 898-908.	1.5	29
1557	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2083-90.	3.3	212
1558	Broad and Potent Neutralizing Antibody Responses Elicited in Natural HIV-2 Infection. Journal of Virology, 2012, 86, 947-960.	1.5	55

#	ARTICLE	IF	CITATIONS
1559	HIV Type 1 Mother-to-Child Transmission Facilitated by Distinctive Glycosylation Sites in the gp120 Envelope Glycoprotein. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 715-724.	0.5	10
1560	Comprehensive Investigation of Common Antibody-Dependent Cell-Mediated Cytotoxicity Antibody Epitopes of HIV-1 CRF01_AE gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1250-1258.	0.5	11
1561	HIV Inhibition by CD4 and CCR5-Derived Glycopeptides. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1052-1058.	0.5	0
1562	HIV Entry and Envelope Glycoprotein-mediated Fusion. <i>Journal of Biological Chemistry</i> , 2012, 287, 40841-40849.	1.6	181
1563	Trimeric, Coiled-coil Extension on Peptide Fusion Inhibitor of HIV-1 Influences Selection of Resistance Pathways. <i>Journal of Biological Chemistry</i> , 2012, 287, 8297-8309.	1.6	21
1564	A Single Residue within the V5 Region of HIV-1 Envelope Facilitates Viral Escape from the Broadly Neutralizing Monoclonal Antibody VRC01. <i>Journal of Biological Chemistry</i> , 2012, 287, 43170-43179.	1.6	28
1565	Complex-type <i>N</i> -glycan recognition by potent broadly neutralizing HIV antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3268-77.	3.3	505
1566	High-Mannose Glycan-Dependent Epitopes Are Frequently Targeted in Broad Neutralizing Antibody Responses during Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2012, 86, 2153-2164.	1.5	57
1567	Lineage-Specific Differences between Human and Simian Immunodeficiency Virus Regulation of gp120 Trimer Association and CD4 Binding. <i>Journal of Virology</i> , 2012, 86, 8974-8986.	1.5	30
1568	Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2012, 86, 12105-12114.	1.5	26
1569	Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site. <i>Journal of Biological Chemistry</i> , 2012, 287, 5673-5686.	1.6	50
1570	Monoclonal Antibody-Based Candidate Therapeutics Against HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 425-434.	0.5	17
1571	UCLA1, a Synthetic Derivative of a gp120 RNA Aptamer, Inhibits Entry of Human Immunodeficiency Virus Type 1 Subtype C. <i>Journal of Virology</i> , 2012, 86, 4989-4999.	1.5	38
1572	Optimum Length and Flexibility of Reovirus Attachment Protein $\sigma 1$ Are Required for Efficient Viral Infection. <i>Journal of Virology</i> , 2012, 86, 10270-10280.	1.5	17
1573	CD4 binding determinant mimicry for HIV vaccine design. <i>Frontiers in Immunology</i> , 2012, 3, 383.	2.2	7
1574	Basic research in HIV vaccinology is hampered by reductionist thinking. <i>Frontiers in Immunology</i> , 2012, 3, 194.	2.2	59
1575	Solution Structure, Conformational Dynamics, and CD4-Induced Activation in Full-Length, Glycosylated, Monomeric HIV gp120. <i>Journal of Virology</i> , 2012, 86, 8750-8764.	1.5	60
1576	HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4257-4267.	1.4	30

#	ARTICLE	IF	CITATIONS
1577	Envelope Variable Region 4 Is the First Target of Neutralizing Antibodies in Early Simian Immunodeficiency Virus mac251 Infection of Rhesus Monkeys. <i>Journal of Virology</i> , 2012, 86, 7052-7059.	1.5	7
1578	Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants. <i>Journal of Virology</i> , 2012, 86, 12417-12421.	1.5	24
1579	Resampling-based Methods in Single and Multiple Testing for Equality of Covariance/Correlation Matrices. <i>International Journal of Biostatistics</i> , 2012, 8, Article 13.	0.4	2
1580	Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus. <i>Journal of Virology</i> , 2012, 86, 12676-12685.	1.5	40
1581	Synthesis of Cyclic Peptides Containing a Thioester Handle for Native Chemical Ligation. <i>Journal of Organic Chemistry</i> , 2012, 77, 10058-10064.	1.7	17
1582	Epitope Mapping of Broadly Neutralizing HIV-2 Human Monoclonal Antibodies. <i>Journal of Virology</i> , 2012, 86, 12115-12128.	1.5	27
1583	Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. <i>Immunity</i> , 2012, 37, 412-425.	6.6	417
1585	Structure and Design of Broadly-Neutralizing Antibodies Against HIV. <i>Molecules and Cells</i> , 2012, 34, 231-238.	1.0	6
1586	Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120. <i>Virology</i> , 2012, 433, 308-319.	1.1	19
1587	Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human α -Defensin. <i>Journal of Biological Chemistry</i> , 2012, 287, 28821-28838.	1.6	74
1588	A combinatorial approach toward smart libraries of discontinuous epitopes of HIV gp120 on a TAC synthetic scaffold. <i>Chemical Communications</i> , 2012, 48, 10007.	2.2	22
1589	HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. <i>Journal of Virology</i> , 2012, 86, 11231-11241.	1.5	61
1590	CCR5 inhibitors: emergence, success, and challenges. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 135-145.	1.0	40
1591	Spontaneous Rearrangement of the β 20/ β 21 Strands in Simulations of Unliganded HIV-1 Glycoprotein, gp120. <i>Biochemistry</i> , 2012, 51, 7783-7793.	1.2	14
1592	Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site. <i>Journal of Virology</i> , 2012, 86, 5844-5856.	1.5	75
1593	Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2012, 83, 128-134.	0.6	16
1594	An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. <i>Vaccine</i> , 2012, 30, 922-930.	1.7	27
1595	Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12. <i>Virology</i> , 2012, 432, 394-404.	1.1	1

#	ARTICLE	IF	CITATIONS
1596	Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 893-899.	3.6	151
1597	A Novel Assay for Antibody-Dependent Cell-Mediated Cytotoxicity against HIV-1- or SIV-Infected Cells Reveals Incomplete Overlap with Antibodies Measured by Neutralization and Binding Assays. <i>Journal of Virology</i> , 2012, 86, 12039-12052.	1.5	94
1598	Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2012, 425, 931-937.	1.0	6
1599	Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 556-562.	1.2	36
1600	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. <i>Nature</i> , 2012, 492, 118-122.	13.7	463
1601	MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. <i>Retrovirology</i> , 2012, 9, 36.	0.9	17
1602	Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors. <i>Virology Journal</i> , 2012, 9, 196.	1.4	6
1603	Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. <i>Immunological Reviews</i> , 2012, 250, 180-198.	2.8	84
1604	The structural basis of T cell lineage immune recognition: TCR docking topologies, mechanotransduction, and co-receptor function. <i>Immunological Reviews</i> , 2012, 250, 102-119.	2.8	92
1605	Carbohydrate-Based Vaccines against HIV/AIDS. <i>ACS Symposium Series</i> , 2012, , 157-186.	0.5	1
1606	Binding of HIV-1 gp120 Glycoprotein to Silica Nanoparticles Modified with CD4 Glycoprotein and CD4 Peptide Fragments. <i>ACS Applied Materials & Interfaces</i> , 2012, 4, 235-243.	4.0	34
1607	Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors. <i>Biochemical Pharmacology</i> , 2012, 84, 1366-1380.	2.0	77
1608	Therapeutic Potential of Aptamer-siRNA Conjugates for Treatment of HIV-1. <i>BioDrugs</i> , 2012, 26, 393-400.	2.2	32
1609	New anti-HIV aptamers based on tetra-end-linked DNA G-quadruplexes: effect of the base sequence on anti-HIV activity. <i>Chemical Communications</i> , 2012, 48, 9516.	2.2	31
1610	Candidate Antibody-Based Therapeutics Against HIV-1. <i>BioDrugs</i> , 2012, 26, 143-162.	2.2	13
1611	Protein-Protein Interaction Targets to Inhibit HIV-1 Infection. <i>Topics in Medicinal Chemistry</i> , 2012, , 105-165.	0.4	0
1612	Carbohydrate biomarker recognition using synthetic lectin mimics. <i>Pure and Applied Chemistry</i> , 2012, 84, 2479-2498.	0.9	17
1613	Molecular biology of HIV. , 2012, , 25-43.		0

#	ARTICLE	IF	CITATIONS
1614	Targeting host cofactors to inhibit viral infection. <i>Frontiers in Biology</i> , 2012, 7, 445-458.	0.7	0
1615	Designed Cyclic Permutants of HIV-1 gp120: Implications for Envelope Trimer Structure and Immunogen Design. <i>Biochemistry</i> , 2012, 51, 1836-1847.	1.2	20
1616	Structures of Novel HIV-Inactivating Lectins. <i>NATO Science for Peace and Security Series B: Physics and Biophysics</i> , 2012, , 59-67.	0.2	0
1617	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5663-5668.	3.3	222
1618	HIV: Cell Binding and Entry. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006866-a006866.	2.9	438
1619	High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site. <i>Science Translational Medicine</i> , 2012, 4, 142ra96.	5.8	108
1620	Gene Vaccines. , 2012, , .		2
1621	Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes. <i>PLoS ONE</i> , 2012, 7, e36750.	1.1	113
1622	Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of $\hat{1}\pm 4\hat{1}^27$ Binding. <i>PLoS ONE</i> , 2012, 7, e39045.	1.1	38
1623	Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization. <i>PLoS ONE</i> , 2012, 7, e46713.	1.1	7
1624	Algal Lectins as Potential HIV Microbicide Candidates. <i>Marine Drugs</i> , 2012, 10, 1476-1497.	2.2	74
1625	Macromolecular crystallography and medicine. , 2012, , 13-38.		0
1626	Point Mutations Associated with HIV-1 Drug Resistance, Evasion of the Immune Response and AIDS Pathogenesis. , 2012, , .		0
1627	Are mast cells the Trojan horse in HIV-1 infection?. <i>Central-European Journal of Immunology</i> , 2012, 4, 382-386.	0.4	0
1628	Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120. <i>Beilstein Journal of Organic Chemistry</i> , 2012, 8, 1858-1866.	1.3	6
1629	The changing face of HIV vaccine research. <i>Journal of the International AIDS Society</i> , 2012, 15, 17407.	1.2	47
1630	Automatch: Target-binding protein design and enzyme design by automatic pinpointing potential active sites in available protein scaffolds. <i>Proteins: Structure, Function and Bioinformatics</i> , 2012, 80, 1078-1094.	1.5	18
1631	Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. <i>Reviews in Medical Virology</i> , 2012, 22, 339-349.	3.9	58

#	ARTICLE	IF	CITATIONS
1632	Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4382-4396.	2.9	90
1633	Molecular Mechanisms of HIV Entry. <i>Advances in Experimental Medicine and Biology</i> , 2012, 726, 223-242.	0.8	177
1634	Design, Synthesis, and Antiviral Activity of Entry Inhibitors That Target the CD4-Binding Site of HIV-1. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4764-4775.	2.9	83
1635	Toward a Carbohydrate-Based HIV-1 Vaccine. <i>ACS Symposium Series</i> , 2012, , 187-215.	0.5	3
1636	The structural biology of HIV-1: mechanistic and therapeutic insights. <i>Nature Reviews Microbiology</i> , 2012, 10, 279-290.	13.6	272
1637	A Functionally Selective Synthetic Mimic of the HIV-1 Coreceptor CXCR4. <i>Chemistry - A European Journal</i> , 2012, 18, 8292-8295.	1.7	23
1638	Importance of V3 Loop Flexibility and Net Charge in the Context of Co-Receptor Recognition. A Molecular Dynamics Study on HIV gp120. <i>Journal of Biomolecular Structure and Dynamics</i> , 2012, 29, 879-891.	2.0	19
1639	Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1211-1259.	2.4	94
1640	Molecular modeling study of HIV-1 gp120 attachment inhibitors. <i>Medicinal Chemistry Research</i> , 2012, 21, 1892-1904.	1.1	6
1641	A Synthetic Heparan Sulfate-Mimetic Peptide Conjugated to a Mini CD4 Displays Very High Anti- HIV-1 Activity Independently of Coreceptor Usage. <i>Chemistry and Biology</i> , 2012, 19, 131-139.	6.2	21
1642	Blocking HIV-1 entry by a gp120 surface binding inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3358-3361.	1.0	16
1643	Crystal Structure of the Pestivirus Envelope Glycoprotein Erns and Mechanistic Analysis of Its Ribonuclease Activity. <i>Structure</i> , 2012, 20, 862-873.	1.6	41
1644	Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. <i>Virology</i> , 2012, 422, 22-36.	1.1	22
1645	Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. <i>Virology</i> , 2012, 422, 174-184.	1.1	29
1646	Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction. <i>Virology</i> , 2012, 423, 97-106.	1.1	51
1647	The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4+ cells. <i>Virology</i> , 2012, 423, 175-186.	1.1	50
1648	Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. <i>Virology</i> , 2012, 426, 34-41.	1.1	28
1649	Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. <i>Virology</i> , 2012, 427, 198-207.	1.1	85

#	ARTICLE	IF	CITATIONS
1650	V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. <i>Virology</i> , 2012, 427, 158-165.	1.1	35
1651	Comparison of the convergent receptor utilization of a retargeted feline leukemia virus envelope with a naturally-occurring porcine endogenous retrovirus A. <i>Virology</i> , 2012, 427, 118-126.	1.1	9
1652	The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies. <i>Retrovirology</i> , 2012, 9, 9.	0.9	10
1653	Glycosylation Assists Binding of HIV Protein gp120 to Human CD4 Receptor. <i>ChemBioChem</i> , 2012, 13, 524-527.	1.3	10
1654	Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. <i>Archives of Virology</i> , 2012, 157, 1-20.	0.9	48
1655	Development of prophylactic vaccines against HIV-1. <i>Retrovirology</i> , 2013, 10, 72.	0.9	64
1656	The frantic play of the concealed HIV envelope cytoplasmic tail. <i>Retrovirology</i> , 2013, 10, 54.	0.9	47
1657	Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein. <i>Retrovirology</i> , 2013, 10, 33.	0.9	14
1658	Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques. <i>Retrovirology</i> , 2013, 10, 9.	0.9	10
1659	Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance. <i>AIDS Research and Therapy</i> , 2013, 10, 15.	0.7	7
1660	Structure and Physics of Viruses. <i>Sub-Cellular Biochemistry</i> , 2013, , .	1.0	41
1661	Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer. <i>Journal of Chemical Physics</i> , 2013, 139, 024905.	1.2	21
1662	Probing interactions of the HIV protein GP120 with lipids and CD4 receptors. <i>Soft Matter</i> , 2013, 9, 2803.	1.2	5
1663	Viral Entry into Host Cells. <i>Advances in Experimental Medicine and Biology</i> , 2013, , .	0.8	16
1664	Computational identification of epitopes in the glycoproteins of novel bunyavirus (SFTS virus) recognized by a human monoclonal antibody (MAb 4-5). <i>Journal of Computer-Aided Molecular Design</i> , 2013, 27, 539-550.	1.3	9
1665	Thirty years on: HIV receptor gymnastics and the prevention of infection. <i>BMC Biology</i> , 2013, 11, 57.	1.7	23
1666	Cellular Entry of Retroviruses. <i>Advances in Experimental Medicine and Biology</i> , 2013, 790, 128-149.	0.8	21
1667	Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1. <i>Virologica Sinica</i> , 2013, 28, 71-80.	1.2	14

#	ARTICLE	IF	CITATIONS
1668	Identification of human immunodeficiency virus type 1 (HIV-1) gp120-binding sites on scavenger receptor cysteine rich 1 (SRCR1) domain of gp340. <i>Journal of Biomedical Science</i> , 2013, 20, 44.	2.6	10
1669	Virus-host interaction in feline immunodeficiency virus (FIV) infection. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2013, 36, 549-557.	0.7	12
1670	Computational Studies Identifying Entry Inhibitor Scaffolds Targeting the Phe43 Cavity of HIV-1 gp120. <i>ChemMedChem</i> , 2013, 8, 475-483.	1.6	9
1671	Advances in antiviral vaccine development. <i>Immunological Reviews</i> , 2013, 255, 230-242.	2.8	83
1672	The crystal structure of HIV CRF07_B4/C gp41 reveals a hyper-mutant site in the middle of HR2 heptad repeat. <i>Virology</i> , 2013, 446, 86-94.	1.1	5
1673	Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 7096.	1.5	1
1674	Design of Substituted Imidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 8049-8065.	2.9	8
1676	Past, present and future: 30 years of HIV research. <i>Nature Reviews Microbiology</i> , 2013, 11, 877-883.	13.6	230
1677	Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. <i>Science</i> , 2013, 342, 1477-1483.	6.0	793
1678	Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. <i>Science</i> , 2013, 342, 1484-1490.	6.0	662
1679	Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5Å... Cocystal Structure of gp120 and M48U1. <i>Structure</i> , 2013, 21, 1018-1029.	1.6	29
1680	Blocking HIV-1 gp120 at the Phe43 Cavity: If the Extension Fits. <i>Structure</i> , 2013, 21, 871-872.	1.6	4
1681	Detection of Berry's Phase in a Bulk Rashba Semiconductor. <i>Science</i> , 2013, 342, 1490-1493.	6.0	244
1682	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. <i>Journal of Virology</i> , 2013, 87, 2294-2306.	1.5	34
1683	HIV-1 neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013, 254, 225-244.	2.8	442
1684	HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. <i>Retrovirology</i> , 2013, 10, 102.	0.9	39
1685	Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. <i>Retrovirology</i> , 2013, 10, 147.	0.9	4
1686	Molecular Recognition of CXCR4 by a Dual Tropic HIV-1 gp120 V3 Loop. <i>Biophysical Journal</i> , 2013, 105, 1502-1514.	0.2	52

#	ARTICLE	IF	CITATIONS
1687	Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6049-6054.	3.3	60
1688	Max Bergmann lecture Protein epitope mimetics in the age of structural vaccinology. <i>Journal of Peptide Science</i> , 2013, 19, 127-140.	0.8	40
1689	Rapid, Quantitative Mapping of Anti-HIV Type 1 Envelope Serum Antibody Specificities. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 971-978.	0.5	1
1690	Self assembly and pore formation of HIV GP160 revealed at molecular resolution. <i>Soft Matter</i> , 2013, 9, 283-290.	1.2	2
1691	Pharmacological descriptors related to the binding of Gp120 to CD4 corresponding to 60 representative HIV-1 strains. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2013, 28, 1015-1025.	2.5	3
1692	Broadly neutralizing antibodies against HIV-1: Templates for a vaccine. <i>Virology</i> , 2013, 435, 46-56.	1.1	104
1693	HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120. <i>Journal of Virology</i> , 2013, 87, 923-934.	1.5	48
1694	Magnetic quantum ratchet effect in graphene. <i>Nature Nanotechnology</i> , 2013, 8, 104-107.	15.6	116
1695	Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. <i>Journal of Gastroenterology</i> , 2013, 48, 159-168.	2.3	34
1696	Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1422-1427.	3.3	20
1697	Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120. <i>Journal of Biomolecular Structure and Dynamics</i> , 2013, 31, 403-413.	2.0	14
1698	Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2013, 31, 1251-1276.	2.0	13
1699	Straightforward Selection of Broadly Neutralizing Single-Domain Antibodies Targeting the Conserved CD4 and Coreceptor Binding Sites of HIV-1 gp120. <i>Journal of Virology</i> , 2013, 87, 1137-1149.	1.5	40
1700	Rapid Conformational Epitope Mapping of Anti-gp120 Antibodies with a Designed Mutant Panel Displayed on Yeast. <i>Journal of Molecular Biology</i> , 2013, 425, 444-456.	2.0	56
1701	The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations. <i>Journal of Molecular Modeling</i> , 2013, 19, 905-917.	0.8	6
1702	Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses. <i>Nature Nanotechnology</i> , 2013, 8, 130-136.	15.6	125
1703	HIV-1 ENV gp120 structural determinants for peptide triazole dual receptor site antagonism. <i>Proteins: Structure, Function and Bioinformatics</i> , 2013, 81, 271-290.	1.5	17
1704	Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies. <i>Vaccine</i> , 2013, 31, 5789-5797.	1.7	71

#	ARTICLE	IF	CITATIONS
1705	Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. <i>Virology</i> , 2013, 446, 66-76.	1.1	25
1706	Ultrasensitive analysis of binding affinity of HIV receptor and neutralizing antibodies using solution-phase electrochemiluminescence assay. <i>Journal of Electroanalytical Chemistry</i> , 2013, 688, 53-60.	1.9	4
1707	Macromolecular assemblies. <i>Current Opinion in Structural Biology</i> , 2013, 23, 224-228.	2.6	0
1708	HHARI Is One HECT of a RING. <i>Structure</i> , 2013, 21, 872-874.	1.6	0
1709	HIV-1 envelope glycoprotein structure. <i>Current Opinion in Structural Biology</i> , 2013, 23, 268-276.	2.6	73
1710	A brief history of the global effort to develop a preventive HIV vaccine. <i>Vaccine</i> , 2013, 31, 3502-3518.	1.7	115
1711	Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions. <i>Vaccine</i> , 2013, 31, 2119-2125.	1.7	8
1712	Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2727-2732.	1.0	2
1713	Contribution of VH replacement products to the generation of anti-HIV antibodies. <i>Clinical Immunology</i> , 2013, 146, 46-55.	1.4	23
1714	Evolution of diffraction methods for solving crystal structures. <i>Acta Crystallographica Section A: Foundations and Advances</i> , 2013, 69, 51-59.	0.3	23
1715	A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. <i>Retrovirology</i> , 2013, 10, 14.	0.9	102
1716	Optimization of CD4/gp120 Inhibitors by Thermodynamic-Guided Alanine-Scanning Mutagenesis. <i>Chemical Biology and Drug Design</i> , 2013, 81, 72-78.	1.5	23
1717	Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 338-343.	1.3	56
1718	CD4 mimics as HIV entry inhibitors: Lead optimization studies of the aromatic substituents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2518-2526.	1.4	35
1719	A Model of Peptide Triazole Entry Inhibitor Binding to HIV-1 gp120 and the Mechanism of Bridging Sheet Disruption. <i>Biochemistry</i> , 2013, 52, 2245-2261.	1.2	29
1720	Scaffold optimization in discontinuous epitope containing protein mimics of gp120 using smart libraries. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 2676.	1.5	16
1721	<i>Burkholderia oklahomensis</i> agglutinin is a canonical two-domain OAA-family lectin: structures, carbohydrate binding and anti-HIV activity. <i>FEBS Journal</i> , 2013, 280, 2056-2067.	2.2	33
1723	Molecular docking guided structure based design of symmetrical N,N ² -disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 4591-4599.	1.4	20

#	ARTICLE	IF	CITATIONS
1724	Entry inhibitors and their use in the treatment of HIV-1 infection. <i>Antiviral Research</i> , 2013, 98, 158-170.	1.9	109
1725	Structural basis for diverse N-glycan recognition by HIV-1 neutralizing V1V2 directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 804-813.	3.6	257
1726	X-Ray Crystallography of Viruses. <i>Sub-Cellular Biochemistry</i> , 2013, 68, 117-144.	1.0	8
1727	Virus-Receptor Interactions and Receptor-Mediated Virus Entry into Host Cells. <i>Sub-Cellular Biochemistry</i> , 2013, 68, 441-466.	1.0	26
1728	Interfacial Cavity Filling To Optimize CD4 Mimetic Miniprotein Interactions with HIV-1 Surface Glycoprotein. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5033-5047.	2.9	21
1729	Role of Human CD4 D1D2 Domain in HIV-1 Infection. <i>Immunological Investigations</i> , 2013, 42, 106-121.	1.0	3
1730	Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 1352-1357.	3.6	152
1731	Viral envelope glycoprotein processing by proprotein convertases. <i>Antiviral Research</i> , 2013, 99, 49-60.	1.9	22
1732	Human immunodeficiency virus vaccines. , 2013, , 1097-1121.		1
1733	Glycan Analysis by Isobaric Aldehyde Reactive Tags and Mass Spectrometry. <i>Analytical Chemistry</i> , 2013, 85, 8188-8195.	3.2	73
1734	STEREOCHEMISTRY OF POLYPEPTIDE CONFORMATION IN COARSE GRAINED ANALYSIS. , 2013, , 136-147.		1
1735	Research Applications of Proteolytic Enzymes in Molecular Biology. <i>Biomolecules</i> , 2013, 3, 923-942.	1.8	171
1736	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. <i>PLoS Pathogens</i> , 2013, 9, e1003738.	2.1	190
1737	Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity. <i>PLoS Pathogens</i> , 2013, 9, e1003218.	2.1	12
1738	A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein. <i>PLoS Computational Biology</i> , 2013, 9, e1003046.	1.5	53
1739	Sub-Inhibitory Concentrations of Human α -defensin Potentiate Neutralizing Antibodies against HIV-1 gp41 Pre-Hairpin Intermediates in the Presence of Serum. <i>PLoS Pathogens</i> , 2013, 9, e1003431.	2.1	20
1740	The CD8-Derived Chemokine XCL1/Lymphotactin Is a Conformation-Dependent, Broad-Spectrum Inhibitor of HIV-1. <i>PLoS Pathogens</i> , 2013, 9, e1003852.	2.1	30
1741	Human Immunodeficiency Virus and Heparan Sulfate: From Attachment to Entry Inhibition. <i>Frontiers in Immunology</i> , 2013, 4, 385.	2.2	104

#	ARTICLE	IF	CITATIONS
1742	Improvement of HIV-1 coreceptor tropism prediction by employing selected nucleotide positions of the env gene in a Bayesian network classifier. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1471-1485.	1.3	12
1743	Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 382-392.	1.5	27
1744	Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1). <i>Therapeutic Advances in Vaccines</i> , 2013, 1, 67-80.	2.7	7
1745	The Highly Conserved Layer-3 Component of the HIV-1 gp120 Inner Domain Is Critical for CD4-Required Conformational Transitions. <i>Journal of Virology</i> , 2013, 87, 2549-2562.	1.5	49
1746	Heavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding Sites. <i>Journal of Virology</i> , 2013, 87, 10173-10181.	1.5	22
1747	A Functional Interaction between gp41 and gp120 Is Observed for Monomeric but Not Oligomeric, Uncleaved HIV-1 Env gp140. <i>Journal of Virology</i> , 2013, 87, 11462-11475.	1.5	36
1748	Aptamer-Based Therapeutics: New Approaches to Combat Human Viral Diseases. <i>Pharmaceuticals</i> , 2013, 6, 1507-1542.	1.7	58
1749	Heterogeneity in Neutralization Sensitivities of Viruses Comprising the Simian Immunodeficiency Virus SIVsmE660 Isolate and Vaccine Challenge Stock. <i>Journal of Virology</i> , 2013, 87, 5477-5492.	1.5	32
1750	Efficiency of Bridging-Sheet Recruitment Explains HIV-1 R5 Envelope Glycoprotein Sensitivity to Soluble CD4 and Macrophage Tropism. <i>Journal of Virology</i> , 2013, 87, 187-198.	1.5	21
1751	Design of an Escherichia coli Expressed HIV-1 gp120 Fragment Immunogen That Binds to b12 and Induces Broad and Potent Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2013, 288, 9815-9825.	1.6	28
1752	Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 513-518.	3.3	44
1753	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E69-78.	3.3	138
1754	Split green fluorescent protein as a modular binding partner for protein crystallization. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2013, 69, 2513-2523.	2.5	29
1755	Conformation-Dependent Recognition of HIV gp120 by Designed Ankyrin Repeat Proteins Provides Access to Novel HIV Entry Inhibitors. <i>Journal of Virology</i> , 2013, 87, 5868-5881.	1.5	34
1756	High-Throughput Peptide Epitope Mapping Using Carbon Nanotube Field-Effect Transistors. <i>International Journal of Peptides</i> , 2013, 2013, 1-6.	0.7	3
1757	Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5. <i>Journal of Leukocyte Biology</i> , 2013, 93, 113-126.	1.5	36
1758	Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120. <i>Journal of Virology</i> , 2013, 87, 10855-10873.	1.5	29
1759	Independent Expansion of Epitope-Specific Plasma Cell Responses upon HIV-1 Envelope Glycoprotein Immunization. <i>Journal of Immunology</i> , 2013, 191, 44-51.	0.4	15

#	ARTICLE	IF	CITATIONS
1761	Synthetic Glycopolypeptides as Potential Inhibitory Agents for Dendritic Cells and HIV-1 Trafficking. <i>Macromolecular Rapid Communications</i> , 2013, 34, 1542-1546.	2.0	18
1762	Glycosylation in HIV-1 envelope glycoprotein and its biological implications. <i>Future Virology</i> , 2013, 8, 783-800.	0.9	3
1763	Use of G-Protein-Coupled and -Uncoupled CCR5 Receptors by CCR5 Inhibitor-Resistant and -Sensitive Human Immunodeficiency Virus Type 1 Variants. <i>Journal of Virology</i> , 2013, 87, 6569-6581.	1.5	38
1764	Inhibition of the HIV-1 Spike by Single-PG9/16-Antibody Binding Suggests a Coordinated-Activation Model for Its Three Protomeric Units. <i>Journal of Virology</i> , 2013, 87, 7000-7007.	1.5	13
1765	CD4 ⁺ T Cells Support Production of Simian Immunodeficiency Virus Env Antibodies That Enforce CD4-Dependent Entry and Shape Tropism <i>In Vivo</i> . <i>Journal of Virology</i> , 2013, 87, 9719-9732.	1.5	12
1766	Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12438-12443.	3.3	101
1767	Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 1235-1249.	4.2	85
1768	Genetic diversity of the highly variable V1 region interferes with Human Immunodeficiency Virus type 1 envelope functionality. <i>Retrovirology</i> , 2013, 10, 114.	0.9	15
1769	Adhesion and fusion efficiencies of human immunodeficiency virus type 1 (HIV-1) surface proteins. <i>Scientific Reports</i> , 2013, 3, 3014.	1.6	12
1770	Putative role of Tat-Env interaction in HIV infection. <i>Aids</i> , 2013, 27, 2345-2354.	1.0	3
1771	- Health Benefits of Sulfated Polysaccharides from Marine Algae. , 2013, , 356-367.		0
1772	The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies. <i>Aids</i> , 2013, 27, 2529-2539.	1.0	10
1773	Epitope Specificity of Human Immunodeficiency Virus-1 Antibody Dependent Cellular Cytotoxicity [ADCC] Responses. <i>Current HIV Research</i> , 2013, 11, 378-387.	0.2	82
1774	Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate. <i>PLoS ONE</i> , 2013, 8, e52732.	1.1	17
1775	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	1.1	165
1776	Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. <i>PLoS ONE</i> , 2013, 8, e65950.	1.1	29
1777	HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans. <i>PLoS ONE</i> , 2013, 8, e75277.	1.1	7
1778	Peptide-Derivatized SB105-A10 Dendrimer Inhibits the Infectivity of R5 and X4 HIV-1 Strains in Primary PBMCs and Cervicovaginal Histocultures. <i>PLoS ONE</i> , 2013, 8, e76482.	1.1	32

#	ARTICLE	IF	CITATIONS
1779	The Influence of N-Linked Glycans on the Molecular Dynamics of the HIV-1 gp120 V3 Loop. PLoS ONE, 2013, 8, e80301.	1.1	35
1780	Computational Prediction of Broadly Neutralizing HIV-1 Antibody Epitopes from Neutralization Activity Data. PLoS ONE, 2013, 8, e80562.	1.1	20
1781	Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity. PLoS ONE, 2013, 8, e66638.	1.1	8
1782	Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens. Vaccines, 2013, 1, 497-512.	2.1	15
1783	HIV-1 Tropism Testing and Clinical Management of CCR5 Antagonists: Quebec Review and Recommendations. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, 202-208.	0.7	5
1784	HIV-2 Interaction with Target Cell Receptors, or Why HIV-2 is Less Pathogenic than HIV-1. , 2013, , .		1
1785	Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site. PLoS ONE, 2014, 9, e85940.	1.1	49
1786	V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100. PLoS ONE, 2014, 9, e89515.	1.1	2
1787	Estimated Secondary Structure Propensities within V1/V2 Region of HIV gp120 Are an Important Global Antibody Neutralization Sensitivity Determinant. PLoS ONE, 2014, 9, e94002.	1.1	13
1788	Molecular Characterization of HIV-1 Subtype C gp-120 Regions Potentially Involved in Virus Adaptive Mechanisms. PLoS ONE, 2014, 9, e95183.	1.1	3
1789	Insight Derived from Molecular Dynamics Simulations into Molecular Motions, Thermodynamics and Kinetics of HIV-1 gp120. PLoS ONE, 2014, 9, e104714.	1.1	12
1790	An HIV-1 Envelope Immunogen with W427S Mutation in CD4 Binding Site Induced More T Follicular Helper Memory Cells and Reduced Non-Specific Antibody Responses. PLoS ONE, 2014, 9, e115047.	1.1	4
1791	HIV-1 and Its Resistance to Peptidic Carbohydrate-Binding Agents (CBAs): An Overview. Molecules, 2014, 19, 21085-21112.	1.7	6
1792	The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. Expert Review of Vaccines, 2014, 13, 1489-1500.	2.0	28
1793	Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E738-47.	3.3	66
1794	Allosteric Modulation. , 2014, , 155-180.		2
1795	Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2â€“V3 interaction and modulates neutralization sensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3152-3157.	3.3	31
1796	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. Journal of Virology, 2014, 88, 9538-9552.	1.5	30

#	ARTICLE	IF	CITATIONS
1797	Microdevices for examining immunological responses of single cells to HIV. <i>Bioscience Reports</i> , 2014, 34, .	1.1	4
1798	HIV-1 Entry Inhibitor Resistance. , 2014, , 1-21.		0
1799	HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization. <i>PLoS Pathogens</i> , 2014, 10, e1004337.	2.1	23
1800	HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission. <i>PLoS Medicine</i> , 2014, 11, e1001616.	3.9	29
1801	Applications of Chemical Ligation in Peptide Synthesis via Acyl Transfer. <i>Topics in Current Chemistry</i> , 2014, 362, 229-265.	4.0	6
1802	Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5439-5445.	1.0	25
1803	Discovery of protective <sc>B</sc>-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. <i>Immunology</i> , 2014, 142, 1-23.	2.0	49
1804	Probing of CD4 binding pocket of HIV-1 gp120 glycoprotein using unnatural phenylalanine analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5699-5703.	1.0	6
1805	<sc>NMR</sc> evidence for oligosaccharide release from the dendritic-cell specific intercellular adhesion molecule-3-grabbing non-integrin-related (<sc>CLEC</sc>4M) carbohydrate recognition domain at low pH. <i>FEBS Journal</i> , 2014, 281, 3739-3750.	2.2	8
1806	Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection. <i>Clinical Medicine Insights Women's Health</i> , 2014, 7, CMWH.S10353.	0.6	30
1807	Enhanced Fusion and Virion Incorporation for HIV-1 Subtype C Envelope Glycoproteins with Compact V1/V2 Domains. <i>Journal of Virology</i> , 2014, 88, 2083-2094.	1.5	17
1808	Targeting Cellular Cofactors in HIV Therapy. <i>Topics in Medicinal Chemistry</i> , 2014, , 183-222.	0.4	8
1809	Identification of an env-defective HIV-1 mutant capable of spontaneous reversion to a wild-type phenotype in certain T-cell lines. <i>Virology Journal</i> , 2014, 11, 177.	1.4	4
1810	HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. <i>Retrovirology</i> , 2014, 11, 99.	0.9	9
1811	Rational Design and Characterization of the Novel, Broad and Potent Bispecific HIV-1 Neutralizing Antibody iMabm36. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 473-483.	0.9	40
1812	Deficient synthesis of class-switched, HIV-neutralizing antibodies to the CD4 binding site and correction by electrophilic gp120 immunogen. <i>Aids</i> , 2014, 28, 2201-2211.	1.0	4
1813	Tropism and Properties of the HIV-1 Envelope Glycoprotein in Transmission. , 2014, , 1-12.		0
1814	Molecular Recognition of CCR5 by an HIV-1 gp120 V3 Loop. <i>PLoS ONE</i> , 2014, 9, e95767.	1.1	56

#	ARTICLE	IF	CITATIONS
1815	Disulfide Reduction in CD4 Domain 1 or 2 Is Essential for Interaction with HIV Glycoprotein 120 (gp120), which Impairs Thioredoxin-driven CD4 Dimerization. <i>Journal of Biological Chemistry</i> , 2014, 289, 10455-10465.	1.6	31
1816	Immunogen design to focus the B-cell repertoire. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 217-223.	1.5	13
1817	Cell-Type-Specific Aptamer and Aptamer-Small Interfering RNA Conjugates for Targeted Human Immunodeficiency Virus Type 1 Therapy. <i>Journal of Investigative Medicine</i> , 2014, 62, 914-919.	0.7	19
1818	Structure of 2G12 Fab in Complex with Soluble and Fully Glycosylated HIV-1 Env by Negative-Stain Single-Particle Electron Microscopy. <i>Journal of Virology</i> , 2014, 88, 10177-10188.	1.5	67
1819	Constraints from protein structure and intra-molecular coevolution influence the fitness of HIV-1 recombinants. <i>Virology</i> , 2014, 454-455, 34-39.	1.1	12
1820	Positive selection of primate genes that promote HIV-1 replication. <i>Virology</i> , 2014, 454-455, 291-298.	1.1	43
1821	Persistence of VRC01-resistant HIV-1 during antiretroviral therapy. <i>Science China Life Sciences</i> , 2014, 57, 88-96.	2.3	3
1822	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Journal of Virology</i> , 2014, 88, 2633-2644.	1.5	237
1823	Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 71, 259-266.	2.6	13
1824	Physicochemical bases for protein folding, dynamics, and protein-ligand binding. <i>Science China Life Sciences</i> , 2014, 57, 287-302.	2.3	29
1825	2-Aminothiazolones as Anti-HIV Agents That Act as gp120-CD4 Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3043-3052.	1.4	13
1826	Structures of viral membrane proteins by high-resolution cryoEM. <i>Current Opinion in Virology</i> , 2014, 5, 111-119.	2.6	8
1827	Humoral Immune Responses to HIV in the Mucosal Secretions and Sera of HIV-Infected Women. <i>American Journal of Reproductive Immunology</i> , 2014, 71, 600-607.	1.2	11
1828	Efficient Synthesis of Protein Mimics by Sequential Native Chemical Ligation. <i>Organic Letters</i> , 2014, 16, 2138-2141.	2.4	9
1829	Antigenic Properties of the HIV Envelope on Virions in Solution. <i>Journal of Virology</i> , 2014, 88, 1795-1808.	1.5	38
1830	Design and expression of a short peptide as an HIV detection probe. <i>Biochemical and Biophysical Research Communications</i> , 2014, 443, 308-312.	1.0	24
1831	Structure-Based Design, Synthesis and Validation of CD4-Mimetic Small Molecule Inhibitors of HIV-1 Entry: Conversion of a Viral Entry Agonist to an Antagonist. <i>Accounts of Chemical Research</i> , 2014, 47, 1228-1237.	7.6	88
1832	Chloroplast expression of an HIV envelop-derived multi-epitope protein: towards a multivalent plant-based vaccine. <i>Plant Cell, Tissue and Organ Culture</i> , 2014, 116, 111-123.	1.2	13

#	ARTICLE	IF	CITATIONS
1833	Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. <i>Journal of Virology</i> , 2014, 88, 1125-1139.	1.5	51
1834	Neutralization of HIV subtypes A and D by breast milk IgG from women with HIV infection in Uganda. <i>Journal of Infection</i> , 2014, 68, 264-272.	1.7	1
1835	Gp120 in the pathogenesis of human immunodeficiency virus-associated pain. <i>Annals of Neurology</i> , 2014, 75, 837-850.	2.8	76
1836	Phylogenomics resolves the timing and pattern of insect evolution. <i>Science</i> , 2014, 346, 763-767.	6.0	2,096
1837	Binding Mode Characterization of NBD Series CD4-Mimetic HIV-1 Entry Inhibitors by X-Ray Structure and Resistance Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5478-5491.	1.4	41
1838	Glyconanomaterials: Emerging applications in biomedical research. <i>Nano Research</i> , 2014, 7, 1381-1403.	5.8	51
1839	NMR observation of HIV gp120 conformational flexibility resulting from V3 truncation. <i>FEBS Journal</i> , 2014, 281, 3019-3031.	2.2	7
1840	Macromolecular (pro)drugs in antiviral research. <i>Polymer Chemistry</i> , 2014, 5, 6407-6425.	1.9	30
1841	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	1.5	248
1842	Protein surface recognition by calixarenes. <i>RSC Advances</i> , 2014, 4, 41529-41542.	1.7	37
1843	Scaffolded multiple cyclic peptide libraries for protein mimics by native chemical ligation. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 4471-4478.	1.5	16
1844	HIV Control Is Mediated in Part by CD8 ⁺ T-Cell Targeting of Specific Epitopes. <i>Journal of Virology</i> , 2014, 88, 12937-12948.	1.5	69
1845	A stamp on the envelope. <i>Nature</i> , 2014, 514, 437-438.	13.7	29
1846	Site-Selective Solid-Phase Synthesis of a CCR5 Sulfopeptide Library To Interrogate HIV Binding and Entry. <i>ACS Chemical Biology</i> , 2014, 9, 2074-2081.	1.6	22
1847	Protein-protein interactions and human cellular cofactors as new targets for HIV therapy. <i>Current Opinion in Pharmacology</i> , 2014, 18, 1-8.	1.7	27
1848	The lectin pathway of complement: Advantage or disadvantage in HIV pathogenesis?. <i>Clinical Immunology</i> , 2014, 154, 13-25.	1.4	15
1849	Glycosylation and Disulfide Bond Analysis of Transiently and Stably Expressed Clade C HIV-1 gp140 Trimers in 293T Cells Identifies Disulfide Heterogeneity Present in Both Proteins and Differences in <i>O</i> -Linked Glycosylation. <i>Journal of Proteome Research</i> , 2014, 13, 4012-4027.	1.8	42
1850	Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. <i>Virology</i> , 2014, 462-463, 363-376.	1.1	19

#	ARTICLE	IF	CITATIONS
1852	Covalent Conjugation of a Peptide Triazole to HIV-1 gp120 Enables Intramolecular Binding Site Occupancy. <i>Biochemistry</i> , 2014, 53, 3403-3414.	1.2	11
1853	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	1.5	16
1854	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. <i>Journal of Virology</i> , 2014, 88, 6542-6555.	1.5	55
1855	Targeting strategies for delivery of anti-HIV drugs. <i>Journal of Controlled Release</i> , 2014, 192, 271-283.	4.8	47
1856	Optical trapping of individual human immunodeficiency viruses in culture fluid reveals heterogeneity with single-molecule resolution. <i>Nature Nanotechnology</i> , 2014, 9, 624-630.	15.6	120
1857	Visualization of Retroviral Envelope Spikes in Complex with the V3 Loop Antibody 447-52D on Intact Viruses by Cryo-Electron Tomography. <i>Journal of Virology</i> , 2014, 88, 12265-12275.	1.5	7
1858	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 573-581.	1.3	56
1859	Glycosphingolipid-functionalized nanoparticles recapitulate CD169-dependent HIV-1 uptake and trafficking in dendritic cells. <i>Nature Communications</i> , 2014, 5, 4136.	5.8	59
1860	HIV-1 Envelope Glycan Moieties Modulate HIV-1 Transmission. <i>Journal of Virology</i> , 2014, 88, 14258-14267.	1.5	20
1861	Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 1993-2004.	2.0	7
1862	Herpes B virus gD interaction with its human receptor - an in silico analysis approach. <i>Theoretical Biology and Medical Modelling</i> , 2014, 11, 27.	2.1	4
1863	Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection. <i>AIDS Research and Therapy</i> , 2014, 11, 23.	0.7	29
1864	Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. <i>Science</i> , 2014, 346, 759-763.	6.0	439
1865	The macrophage: a therapeutic target in HIV-1 infection. <i>Molecular and Cellular Therapies</i> , 2014, 2, 10.	0.2	62
1866	Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. <i>Retrovirology</i> , 2014, 11, 32.	0.9	9
1867	Computer-aided design and discovery of protein-protein interaction inhibitors as agents for anti-HIV therapy. <i>SAR and QSAR in Environmental Research</i> , 2014, 25, 457-471.	1.0	17
1868	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	13.7	702
1869	Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 14002-14016.	1.5	43

#	ARTICLE	IF	CITATIONS
1870	Broad anti-HIV activity of the <i>Oscillatoria agardhii</i> agglutinin homologue lectin family. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2746-2758.	1.3	39
1871	Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy. <i>Cell</i> , 2014, 156, 633-648.	13.5	318
1872	Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike. <i>Cell Reports</i> , 2014, 7, 785-795.	2.9	199
1873	Structural dynamics of V3 loop in a trimeric ambience, a molecular dynamics study on gp120-CD4 trimeric mimic. <i>Journal of Structural Biology</i> , 2014, 186, 132-140.	1.3	4
1874	Stabilizing the Native Trimer of HIV-1 Env by Destabilizing the Heterodimeric Interface of the gp41 Postfusion Six-Helix Bundle. <i>Journal of Virology</i> , 2014, 88, 9590-9604.	1.5	42
1875	Replacement of the V3 Domain in the Surface Subunit of the Feline Immunodeficiency Virus Envelope Glycoprotein with the Equivalent Region of a T Cell-Tropic Human Immunodeficiency Virus Type 1 Results in a Chimeric Surface Protein That Efficiently Binds to CXCR4. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 250-259.	0.5	4
1876	Immunogen design for HIV-1 and influenza. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1891-1906.	1.1	23
1877	Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 52-64.	2.0	1
1878	Protein dynamics and motions in relation to their functions: several case studies and the underlying mechanisms. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014, 32, 372-393.	2.0	95
1879	Hsp90: a chaperone for HIV-1. <i>Parasitology</i> , 2014, 141, 1192-1202.	0.7	14
1880	Antibody engineering for increased potency, breadth and half-life. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 151-159.	1.5	46
1881	The C4 region as a target for HIV entry inhibitors – NMR mapping of the interacting segments of T20 and gp120. <i>FEBS Journal</i> , 2015, 282, 4643-4657.	2.2	6
1882	Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides. <i>Future Medicinal Chemistry</i> , 2015, 7, 1055-1077.	1.1	2
1883	Methods for the Construction of Phage-Displayed Libraries. , 2015, , 92-113.		0
1884	Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops. <i>Scientific Reports</i> , 2015, 4, 7025.	1.6	9
1885	Chemokine co-receptor usage in HIV-1-infected treatment-naive voluntary counselling and testing clients in Southern Taiwan. <i>BMJ Open</i> , 2015, 5, e007334-e007334.	0.8	8
1886	Structural and bio-molecular interactions in human tenascin C and HIV: An in silico approach to avert AIDS, for infants under the exposure of HIV: Computational approach for aversion of AIDS in infants by breast milk. , 2015, , .		0
1887	A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity. <i>Retrovirology</i> , 2015, 12, 50.	0.9	27

#	ARTICLE	IF	CITATIONS
1888	Functional bottlenecks for generation of HIV-1 intersubtype Env recombinants. <i>Retrovirology</i> , 2015, 12, 44.	0.9	4
1889	N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 270-277.	0.9	17
1890	Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology. <i>Biotechnology Journal</i> , 2015, 10, 1329-1344.	1.8	47
1891	Double Variational Binding (SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19553-19601.	1.8	7
1892	Morphology and ultrastructure of retrovirus particles. <i>AIMS Biophysics</i> , 2015, 2, 343-369.	0.3	52
1893	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. <i>Viruses</i> , 2015, 7, 5115-5132.	1.5	42
1894	Protein Crystallography in Vaccine Research and Development. <i>International Journal of Molecular Sciences</i> , 2015, 16, 13106-13140.	1.8	54
1895	Diversity and Inter-Connections in the CXCR4 Chemokine Receptor/Ligand Family: Molecular Perspectives. <i>Frontiers in Immunology</i> , 2015, 6, 429.	2.2	154
1896	Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS. <i>Frontiers in Microbiology</i> , 2015, 6, 931.	1.5	34
1897	A novel small-molecule inhibitor of HIV-1 entry. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5469.	2.0	7
1898	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0120648.	1.1	5
1899	Effects of the I559P gp41 Change on the Conformation and Function of the Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimer. <i>PLoS ONE</i> , 2015, 10, e0122111.	1.1	52
1900	Computational Design of Hypothetical New Peptides Based on a Cyclotide Scaffold as HIV gp120 Inhibitor. <i>PLoS ONE</i> , 2015, 10, e0139562.	1.1	8
1901	Functional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes. <i>PLoS ONE</i> , 2015, 10, e0144043.	1.1	10
1902	HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	21
1903	HIV Vaccine Research: The Challenge and the Way Forward. <i>Journal of Immunology Research</i> , 2015, 2015, 1-5.	0.9	33
1904	Receptor Binding Domain Based HIV Vaccines. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	5
1905	Antiretroviral Therapy for Human Immunodeficiency Virus Infection. , 2015, , 1622-1641.e6.		7

#	ARTICLE	IF	CITATIONS
1906	Therapy of Viral Infections. Topics in Medicinal Chemistry, 2015, , .	0.4	6
1907	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. Journal of Virology, 2015, 89, 5318-5329.	1.5	125
1908	Fluorescent CD4 probe for potential HIV-1 gp120 protein detection. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1182-1185.	1.0	3
1909	HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Expert Opinion on Therapeutic Targets, 2015, 19, 765-783.	1.5	34
1910	Griffithsin tandemers: flexible and potent lectin inhibitors of the human immunodeficiency virus. Retrovirology, 2015, 12, 6.	0.9	34
1911	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	13.5	305
1912	Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. Journal of Virology, 2015, 89, 6685-6694.	1.5	95
1913	Structural Determinants for the Selective Anti-HIV-1 Activity of the All- β^2 Alternative Conformer of XCL1. Journal of Virology, 2015, 89, 9061-9067.	1.5	11
1914	HIV-Specific Antibody Responses in HIV-Infected Patients: From a Monoclonal to a Polyclonal View. International Archives of Allergy and Immunology, 2015, 167, 223-241.	0.9	8
1915	GPCR crystal structures: Medicinal chemistry in the pocket. Bioorganic and Medicinal Chemistry, 2015, 23, 3880-3906.	1.4	105
1916	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature Communications, 2015, 6, 6144.	5.8	130
1917	Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies. Cell, 2015, 160, 785-797.	13.5	173
1918	Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains. Virology, 2015, 475, 187-203.	1.1	22
1919	Germlining of the HIV-1 broadly neutralizing antibody domain m36. Antiviral Research, 2015, 116, 62-66.	1.9	2
1920	Enhancement and Induction of HIV-1 Infection through an Assembled Peptide Derived from the CD4 Binding Site of gp120. ChemBioChem, 2015, 16, 446-454.	1.3	14
1921	Structural insight into equine lentivirus receptor 1. Protein Science, 2015, 24, 633-642.	3.1	5
1922	Insights into the trimeric HIV-1 envelope glycoprotein structure. Trends in Biochemical Sciences, 2015, 40, 101-107.	3.7	95
1923	HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. Journal of Virological Methods, 2015, 215-216, 37-44.	1.0	21

#	ARTICLE	IF	CITATIONS
1925	Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation. <i>Journal of Biological Chemistry</i> , 2015, 290, 529-543.	1.6	46
1926	A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. <i>Immunology and Cell Biology</i> , 2015, 93, 396-405.	1.0	34
1927	Polymorphism characteristics of HIV-1 gp120 and 5 hypervariable regions. <i>Turkish Journal of Medical Sciences</i> , 2015, 45, 47-54.	0.4	1
1928	Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. <i>Journal of Virology</i> , 2015, 89, 8840-8854.	1.5	51
1929	Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01. <i>Journal of Molecular Graphics and Modelling</i> , 2015, 61, 262-271.	1.3	8
1930	Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. <i>Emerging Microbes and Infections</i> , 2015, 4, 1-8.	3.0	14
1931	Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. <i>Journal of Virology</i> , 2015, 89, 9090-9102.	1.5	10
1932	The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel. <i>Journal of Virology</i> , 2015, 89, 8003-8010.	1.5	68
1933	Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies. <i>Nature Communications</i> , 2015, 6, 7479.	5.8	113
1934	Antigenic Properties of the Human Immunodeficiency Virus Envelope Glycoprotein Gp120 on Virions Bound to Target Cells. <i>PLoS Pathogens</i> , 2015, 11, e1004772.	2.1	43
1935	Human Immunodeficiency Virus Type 1 Cellular Entry and Exit in the T Lymphocytic and Monocytic Compartments. <i>Advances in Virus Research</i> , 2015, 93, 257-311.	0.9	11
1936	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 522-531.	3.6	333
1937	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	5.8	47
1938	Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State. <i>Structure</i> , 2015, 23, 1138-1149.	1.6	25
1939	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. <i>Cell</i> , 2015, 161, 1505-1515.	13.5	239
1940	The Shear Stress of Host Cell Invasion: Exploring the Role of Biomolecular Complexes. <i>PLoS Pathogens</i> , 2015, 11, e1004539.	2.1	7
1941	Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 3843-3858.	2.9	41
1942	Resistance against inhibitors of HIV-1 entry into target cells. <i>Future Virology</i> , 2015, 10, 97-112.	0.9	1

#	ARTICLE	IF	CITATIONS
1943	A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice. <i>Molecular Biotechnology</i> , 2015, 57, 662-674.	1.3	24
1944	Recent advance in the structural analysis of HIV-1 envelope protein. <i>Science China Life Sciences</i> , 2015, 58, 420-424.	2.3	1
1945	Protein Ligation and Total Synthesis I. <i>Topics in Current Chemistry</i> , 2015, , .	4.0	2
1946	CD4 mimetics sensitize HIV-1-infected cells to ADCC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2687-94.	3.3	118
1947	Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. <i>Virology</i> , 2015, 479-480, 508-517.	1.1	103
1948	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2015, 89, 545-551.	1.5	173
1949	A mannose-recognizable chemosensor using gold nanoparticles functionalized with pradimicin, a nonpeptidic mannose-binding natural product. <i>Tetrahedron</i> , 2015, 71, 2603-2609.	1.0	7
1950	Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2015, 71, 2099-2108.	2.5	69
1951	Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols. <i>ACS Chemical Biology</i> , 2015, 10, 2861-2873.	1.6	13
1952	CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. <i>Nucleic Acids Research</i> , 2015, 43, W213-W219.	6.5	118
1953	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. <i>Journal of Virology</i> , 2015, 89, 2507-2519.	1.5	42
1954	Compact Representation of Continuous Energy Surfaces for More Efficient Protein Design. <i>Journal of Chemical Theory and Computation</i> , 2015, 11, 2292-2306.	2.3	25
1955	Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6909-6927.	2.9	59
1956	Stabilization of Outer Domain of gp120 from HIV-1 Subtype C for Vaccine Immunogen Design. <i>Procedia in Vaccinology</i> , 2015, 9, 6-15.	0.4	2
1957	A Comprehensive Study of Neutralizing Antigenic Sites on the Hepatitis E Virus (HEV) Capsid by Constructing, Clustering, and Characterizing a Tool Box. <i>Journal of Biological Chemistry</i> , 2015, 290, 19910-19922.	1.6	45
1958	Carbohydrate nanocarriers in biomedical applications: functionalization and construction. <i>Chemical Society Reviews</i> , 2015, 44, 8301-8325.	18.7	196
1959	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. <i>MBio</i> , 2015, 6, .	1.8	25
1961	Identification of Owl Monkey CD4 Receptors Broadly Compatible with Early-Stage HIV-1 Isolates. <i>Journal of Virology</i> , 2015, 89, 8611-8622.	1.5	22

#	ARTICLE	IF	CITATIONS
1962	Identification of dual-tropic HIV-1 using evolved neural networks. <i>BioSystems</i> , 2015, 137, 12-19.	0.9	8
1963	Homology models of the HIV-1 attachment inhibitor BMS626529 bound to gp120 suggest a unique mechanism of action. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015, 83, 331-350.	1.5	47
1964	How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses?. <i>Immunology Letters</i> , 2015, 163, 69-75.	1.1	11
1965	Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition. <i>Critical Reviews in Microbiology</i> , 2015, 41, 473-487.	2.7	19
1966	Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. <i>Annual Review of Medicine</i> , 2015, 66, 423-437.	5.0	150
1967	In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β -galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop. <i>Journal of Biomolecular Structure and Dynamics</i> , 2015, 33, 1051-1066.	2.0	2
1968	Polymeric Anti-HIV Therapeutics. <i>Macromolecular Bioscience</i> , 2015, 15, 9-35.	2.1	24
1969	QSAR and docking studies of some 1,2,3,4-tetrahydropyrimidines: evaluation of gp41 as possible target for anti-HIV-1 activity. <i>Medicinal Chemistry Research</i> , 2015, 24, 1707-1724.	1.1	12
1970	Role of Host Proteins in HIV-1 Early Replication. , 2016, , .		2
1971	Anti-CD4: An Alternative Way to Inhibit HIV Infection. <i>Journal of HIV & Retro Virus</i> , 2016, 02, .	0.0	1
1973	IMMUNO-MODULATORY PROPERTIES OF PREBIOTICS EXTRACTED FROM <i>Vernonia amygdalina</i> . <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2016, 13, 11-17.	0.3	4
1974	A Machine Learning Approach for Hot-Spot Detection at Protein-Protein Interfaces. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1215.	1.8	46
1975	Antibody Responses to HIV-1 gp120 Hypervariable Regions in Six Long-Term Non-Progressors. <i>American Journal of Infectious Diseases</i> , 2016, 12, 38-45.	0.1	0
1976	Recent Insights into the HIV/AIDS Pandemic. <i>Microbial Cell</i> , 2016, 3, 450-474.	1.4	41
1977	Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding. <i>Japanese Journal of Infectious Diseases</i> , 2016, 69, 395-404.	0.5	5
1978	Structural basis for germline antibody recognition of HIV-1 immunogens. <i>ELife</i> , 2016, 5, .	2.8	68
1979	Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization. <i>Japanese Journal of Infectious Diseases</i> , 2016, 69, 236-243.	0.5	2
1980	Synthetic Peptides as Protein Mimics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2015, 3, 211.	2.0	113

#	ARTICLE	IF	CITATIONS
1981	Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. <i>Viruses</i> , 2016, 8, 15.	1.5	12
1982	Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2016, 7, 391.	2.2	9
1983	Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations. <i>PLoS Pathogens</i> , 2016, 12, e1005988.	2.1	24
1984	Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. <i>PLoS Pathogens</i> , 2016, 12, e1006098.	2.1	32
1985	Identification of a binding site of the human immunodeficiency virus envelope protein gp120 to neuronal-specific tubulin. <i>Journal of Neurochemistry</i> , 2016, 137, 287-298.	2.1	23
1986	HIV Genome-Wide Protein Associations: a Review of 30 Years of Research. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, 679-731.	2.9	61
1987	Are Basophils and Mast Cells Masters in HIV Infection?. <i>International Archives of Allergy and Immunology</i> , 2016, 171, 158-165.	0.9	24
1988	HIV-1 Nef promotes migration and chemokine synthesis of human basophils and mast cells through the interaction with CXCR4. <i>Clinical and Molecular Allergy</i> , 2016, 14, 15.	0.8	14
1989	Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. <i>Biochemistry</i> , 2016, 55, 2197-2213.	1.2	23
1990	Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers. <i>Journal of Virology</i> , 2016, 90, 2806-2817.	1.5	126
1991	The promise and challenge of epitope-focused vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2113-2116.	1.4	48
1992	Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies. <i>Journal of Virology</i> , 2016, 90, 6127-6139.	1.5	117
1993	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016, 352, 828-833.	6.0	310
1994	Evolution of coreceptor utilization to escape CCR5 antagonist therapy. <i>Virology</i> , 2016, 494, 198-214.	1.1	8
1995	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. <i>Annual Review of Immunology</i> , 2016, 34, 635-659.	9.5	500
1996	Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine. <i>Nanoscale Research Letters</i> , 2016, 11, 350.	3.1	20
1998	Detection of intermolecular transferred ¹⁵ N NOEs in large protein complexes using asymmetric deuteration: HIV-1 gp120 in complex with a CCR5 peptide. <i>FEBS Journal</i> , 2016, 283, 4084-4096.	2.2	8
1999	Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. <i>Journal of Virology</i> , 2016, 90, 9224-9236.	1.5	25

#	ARTICLE	IF	CITATIONS
2000	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. <i>Journal of Virology</i> , 2016, 90, 7822-7832.	1.5	14
2001	Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor. <i>Bioorganic Chemistry</i> , 2016, 68, 105-111.	2.0	4
2002	Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2016, 90, 10065-10073.	1.5	6
2003	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 906-915.	3.6	188
2004	Buffering deleterious polymorphisms in highly constrained parts of HIV-1 envelope by flexible regions. <i>Retrovirology</i> , 2016, 13, 50.	0.9	13
2005	Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 2069-2079.	2.5	9
2006	A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. <i>Immunity</i> , 2016, 45, 31-45.	6.6	129
2007	Guidelines for cloning, expression, purification and functional characterization of primary HIV-1 envelope glycoproteins. <i>Journal of Virological Methods</i> , 2016, 236, 184-195.	1.0	6
2008	Structure and Glycan Binding of a New Cyanovirin-N Homolog. <i>Journal of Biological Chemistry</i> , 2016, 291, 18967-18976.	1.6	23
2009	Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. <i>AIDS Patient Care and STDs</i> , 2016, 30, 291-306.	1.1	31
2010	Dendrimeric based microbicides against sexual transmitted infections associated to heparan sulfate. <i>RSC Advances</i> , 2016, 6, 46755-46764.	1.7	13
2011	Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. <i>Scientific Reports</i> , 2016, 6, 37225.	1.6	22
2012	Interactions with Human CD4 Protein Leads to Helix-to-Coil Transition in HIV-gp120 Aiding CCR5 Attachment and Viral Entry: An In Silico Structural Biology Approach for AIDS. <i>Lecture Notes in Electrical Engineering</i> , 2016, , 3-11.	0.3	0
2013	An HIV-1 Env Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. <i>Journal of Immunology</i> , 2016, 197, 3982-3998.	0.4	17
2014	<i>Glycoscience.</i> , 2016, , 7-21.		4
2015	Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, 989-1010.	2.9	93
2016	Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7151-E7158.	3.3	130
2017	Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. <i>MBio</i> , 2016, 7, .	1.8	131

#	ARTICLE	IF	CITATIONS
2018	HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. <i>Retrovirology</i> , 2016, 13, 60.	0.9	21
2019	Genotypic Prediction of Co-receptor Tropism of HIV-1 Subtypes A and C. <i>Scientific Reports</i> , 2016, 6, 24883.	1.6	29
2020	Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc. <i>Retrovirology</i> , 2016, 13, 74.	0.9	4
2021	Connecting HIV-1 integration and transcription: a step toward new treatments. <i>FEBS Letters</i> , 2016, 590, 1927-1939.	1.3	11
2022	Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. <i>Current Opinion in Immunology</i> , 2016, 42, 56-64.	2.4	30
2023	Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. <i>EBioMedicine</i> , 2016, 10, 45-54.	2.7	13
2024	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	3.3	170
2025	Molecular Evidence of Glycosylation Effect on the Peptide Assemblies Identified with Scanning Tunneling Microscopy. <i>Journal of Physical Chemistry C</i> , 2016, 120, 6577-6582.	1.5	12
2026	Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures. <i>Retrovirology</i> , 2016, 13, 32.	0.9	15
2027	Viral Inhibition Mechanism Mediated by Surface-Modified Silica Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 16564-16572.	4.0	81
2028	HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. <i>Expert Review of Vaccines</i> , 2016, 15, 349-365.	2.0	44
2029	Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 330-334.	1.3	86
2030	The future of antiviral immunotoxins. <i>Journal of Leukocyte Biology</i> , 2016, 99, 911-925.	1.5	24
2031	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. <i>Journal of Virology</i> , 2016, 90, 2127-2134.	1.5	69
2032	Structure of an HIV-2 gp120 in Complex with CD4. <i>Journal of Virology</i> , 2016, 90, 2112-2118.	1.5	19
2033	High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. <i>Journal of Immunology</i> , 2016, 196, 3729-3743.	0.4	26
2034	Human CD4 Metastability Is a Function of the Allosteric Disulfide Bond in Domain 2. <i>Biochemistry</i> , 2016, 55, 2227-2237.	1.2	13
2035	HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. <i>Trends in Immunology</i> , 2016, 37, 221-232.	2.9	96

#	ARTICLE	IF	CITATIONS
2036	Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. <i>Biochemical Pharmacology</i> , 2016, 106, 30-45.	2.0	50
2037	Derivation and Characterization of a CD4-Independent, Non-CD4-Tropic Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2016, 90, 4966-4980.	1.5	9
2038	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016, 90, 5031-5046.	1.5	38
2039	Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. <i>Journal of Virology</i> , 2016, 90, 4481-4493.	1.5	13
2040	A saposin-lipoprotein nanoparticle system for membrane proteins. <i>Nature Methods</i> , 2016, 13, 345-351.	9.0	209
2041	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , 2016, 90, 2740-2755.	1.5	58
2042	Effect of the maturation of neutralizing antibodies on human immunodeficiency virus (HIV) envelope evolution in HIV-infected subjects. <i>Infection, Genetics and Evolution</i> , 2016, 38, 82-89.	1.0	8
2043	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	3.6	162
2044	Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. <i>Journal of Virology</i> , 2016, 90, 829-841.	1.5	21
2045	Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2017, 9, 406-418.	2.2	6
2046	Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. <i>Proteins: Structure, Function and Bioinformatics</i> , 2017, 85, 843-851.	1.5	7
2047	Mapping out the intricate relationship of the HIV envelope protein and the membrane environment. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2017, 1859, 550-560.	1.4	16
2048	A Proteomic Survey Indicates Sortilin as a Secondary Substrate of the ER Translocation Inhibitor Cyclotriadiazadisulfonamide (CADA). <i>Molecular and Cellular Proteomics</i> , 2017, 16, 157-167.	2.5	17
2049	Evolution of B cell analysis and Env trimer redesign. <i>Immunological Reviews</i> , 2017, 275, 183-202.	2.8	31
2050	Germline-targeting immunogens. <i>Immunological Reviews</i> , 2017, 275, 203-216.	2.8	105
2051	The HIV-1 envelope glycoprotein structure: nailing down a moving target. <i>Immunological Reviews</i> , 2017, 275, 21-32.	2.8	251
2052	Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. <i>Immunological Reviews</i> , 2017, 275, 145-160.	2.8	160
2053	Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. <i>Immunological Reviews</i> , 2017, 275, 217-229.	2.8	27

#	ARTICLE	IF	CITATIONS
2054	Structural Analysis of the Glycosylated Intact HIV-1 gp120â€“b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting. <i>Biochemistry</i> , 2017, 56, 957-970.	1.2	27
2055	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	52
2056	JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1. <i>Journal of Virology</i> , 2017, 91, .	1.5	11
2057	Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 370-378.	3.6	94
2058	Structure-Guided Identification of a Family of Dual Receptor-Binding PfEMP1 that Is Associated with Cerebral Malaria. <i>Cell Host and Microbe</i> , 2017, 21, 403-414.	5.1	140
2059	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	81
2060	â€œFusion and binding inhibitionâ€“key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches. <i>Drug Delivery</i> , 2017, 24, 608-621.	2.5	17
2061	Interaction Entropy for Computational Alanine Scanning. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 1112-1122.	2.5	80
2062	Lessons learned from humoral responses of HIV patients. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 195-202.	1.5	16
2063	A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4. <i>Scientific Reports</i> , 2017, 7, 46733.	1.6	5
2064	Cyanobacterial lectins characteristics and their role as antiviral agents. <i>International Journal of Biological Macromolecules</i> , 2017, 102, 475-496.	3.6	42
2065	M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. <i>Scientific Reports</i> , 2017, 7, 41018.	1.6	9
2066	Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. <i>Journal of Virology</i> , 2017, 91, .	1.5	5
2067	Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 294-301.	1.5	18
2068	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	2.9	160
2069	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. <i>Journal of Biological Chemistry</i> , 2017, 292, 10197-10219.	1.6	29
2070	Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2017, 91, .	1.5	42
2071	Carbohydrateâ€“Polypeptide Contacts in the Antibody Receptor CD16A Identified through Solution NMR Spectroscopy. <i>Biochemistry</i> , 2017, 56, 3174-3177.	1.2	33

#	ARTICLE	IF	CITATIONS
2072	Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. <i>Virology</i> , 2017, 508, 90-107.	1.1	7
2073	Determinants of HIV-1 CD4-Independent Brain Adaptation. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 209-218.	0.9	4
2074	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	21
2075	Tryptophan 375 stabilizes the outer-domain core of gp120 for HIV vaccine immunogen design. <i>Vaccine</i> , 2017, 35, 3067-3075.	1.7	2
2076	Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
2077	Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FI T45. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 7, 387-395.	2.3	5
2078	The "Sticky Patch" Model of Crystallization and Modification of Proteins for Enhanced Crystallizability. <i>Methods in Molecular Biology</i> , 2017, 1607, 77-115.	0.4	17
2079	Chimeric antigen receptor engineered stem cells: a novel HIV therapy. <i>Immunotherapy</i> , 2017, 9, 401-410.	1.0	17
2080	Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120. <i>Journal of Molecular Modeling</i> , 2017, 23, 18.	0.8	6
2081	From structure to redox: The diverse functional roles of disulfides and implications in disease. <i>Proteomics</i> , 2017, 17, 1600391.	1.3	117
2082	Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
2083	X-ray and EM structures of a natively glycosylated HIV-1 envelope trimer. <i>Acta Crystallographica Section D: Structural Biology</i> , 2017, 73, 822-828.	1.1	13
2084	The bulky and the sweet: How neutralizing antibodies and glycan receptors compete for virus binding. <i>Protein Science</i> , 2017, 26, 2342-2354.	3.1	6
2085	Carbosilane dendrons with fatty acids at the core as a new potential microbicide against HSV-2/HIV-1 co-infection. <i>Nanoscale</i> , 2017, 9, 17263-17273.	2.8	19
2086	The Y206-Y211 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. <i>Nature Communications</i> , 2017, 8, 1049.	5.8	88
2087	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017, 13, 1115-1122.	3.9	110
2088	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. <i>Cell</i> , 2017, 170, 637-648.e10.	13.5	111
2089	Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site. <i>Journal of Virology</i> , 2017, 91, .	1.5	8

#	ARTICLE	IF	CITATIONS
2090	Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4. <i>Journal of Virology</i> , 2017, 91, .	1.5	3
2091	Characterization of a stable HIV-1 B/C recombinant, soluble, and trimeric envelope glycoprotein (Env) highly resistant to CD4-induced conformational changes. <i>Journal of Biological Chemistry</i> , 2017, 292, 15849-15858.	1.6	12
2092	CCR5-edited gene therapies for HIV cure: Closing the door to viral entry. <i>Cytherapy</i> , 2017, 19, 1325-1338.	0.3	34
2093	Potent <i>In Vivo</i> NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. <i>Journal of Virology</i> , 2017, 91, .	1.5	31
2094	Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents. <i>Drug Development Research</i> , 2017, 78, 268-282.	1.4	6
2095	Stability and Water Accessibility of the Trimeric Membrane Anchors of the HIV-1 Envelope Spikes. <i>Journal of the American Chemical Society</i> , 2017, 139, 18432-18435.	6.6	25
2096	Conformational Changes in HIV-1 Env Trimer Induced by a Single CD4 as Revealed by Cryo-EM. <i>Microscopy and Microanalysis</i> , 2017, 23, 1190-1191.	0.2	0
2097	Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. <i>Journal of Biological Chemistry</i> , 2017, 292, 16498-16510.	1.6	17
2098	Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. <i>Nature</i> , 2017, 547, 360-363.	13.7	217
2099	Conformational Heterogeneity of the HIV Envelope Glycan Shield. <i>Scientific Reports</i> , 2017, 7, 4435.	1.6	32
2100	Antimicrobial applications of chitosan. , 2017, , 245-274.		14
2101	Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. <i>Virology</i> , 2017, 501, 12-24.	1.1	9
2102	Staying Alive: Measuring Intact Viable Microbes with Electrospray Ionization Mass Spectrometry. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 14-20.	1.2	6
2103	Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination. <i>Molecular Biology</i> , 2017, 51, 819-829.	0.4	1
2104	CD4-Binding Site Directed Cross-Neutralizing scFv Monoclonals from HIV-1 Subtype C Infected Indian Children. <i>Frontiers in Immunology</i> , 2017, 8, 1568.	2.2	16
2105	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 1802.	2.2	78
2106	Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution. <i>Frontiers in Microbiology</i> , 2017, 08, 390.	1.5	11
2107	Evidence of Divergent Amino Acid Usage in Comparative Analyses of R5- and X4-Associated HIV-1 Vpr Sequences. <i>International Journal of Genomics</i> , 2017, 2017, 1-11.	0.8	5

#	ARTICLE	IF	CITATIONS
2108	Supramolecular Assemblies in Chemical Biology. , 2017, , 3-37.		0
2109	Protein structural disorder of the envelope V3 loop contributes to the switch in human immunodeficiency virus type 1 cell tropism. PLoS ONE, 2017, 12, e0185790.	1.1	7
2110	Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization. PLoS Pathogens, 2017, 13, e1006636.	2.1	47
2111	A single gp120 residue can affect HIV-1 tropism in macaques. PLoS Pathogens, 2017, 13, e1006572.	2.1	28
2112	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	5.8	76
2113	Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Retrovirology, 2017, 14, 44.	0.9	10
2114	Unlocking HIV-1 Env: implications for antibody attack. AIDS Research and Therapy, 2017, 14, 42.	0.7	8
2115	Synthetic Antibodies in Infectious Disease. Advances in Experimental Medicine and Biology, 2017, 1053, 79-98.	0.8	3
2116	Probing Potent Interfacial Residues in Microvirin before Complexation with Glycoproteins: Visualizing Anti-HIV Activity in silico. Journal of Marine Science: Research & Development, 2017, 07, .	0.4	0
2117	Redox exchange of the disulfides of human two-domain CD4 regulates the conformational dynamics of each domain, providing insight into its mechanisms of control. Biochemical and Biophysical Research Communications, 2018, 497, 811-817.	1.0	5
2118	Anti-HIV activity of new higher order G-quadruplex aptamers obtained from tetra-end-linked oligonucleotides. Organic and Biomolecular Chemistry, 2018, 16, 2349-2355.	1.5	16
2119	Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning. Journal of Immunology, 2018, 200, 3825-3839.	0.4	62
2120	Tuberculosis and HIV. , 2018, , 2091-2115.		0
2121	The molecular mechanism of two coreceptor binding site antibodies X5 and 17b neutralizing HIV-1: Insights from molecular dynamics simulation. Chemical Biology and Drug Design, 2018, 92, 1357-1365.	1.5	2
2122	Analysis of HIV-1 envelope evolution suggests antibody-mediated selection of common epitopes among Chinese former plasma donors from a narrow-source outbreak. Scientific Reports, 2018, 8, 5743.	1.6	3
2123	Recent updates for designing CCR5 antagonists as anti-retroviral agents. European Journal of Medicinal Chemistry, 2018, 147, 115-129.	2.6	8
2124	Specific Noncovalent Interactions Determine Optimal Structure of a Buried Ligand Moiety: QM/MM and Pure QM Modeling of Complexes of the Small Molecule CD4 Mimetics and HIV-1 gp120. ChemMedChem, 2018, 13, 627-633.	1.6	4
2125	Selective Tropism of Dengue Virus for Human Glycoprotein Ib. Scientific Reports, 2018, 8, 2688.	1.6	11

#	ARTICLE	IF	CITATIONS
2126	T-Cell Homeostasis. , 2018, , 1985-1991.		0
2127	Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs. Journal of Virology, 2018, 92, .	1.5	29
2128	Subtle differences in selective pressures applied on the envelope gene of HIV-1 in pregnant versus non-pregnant women. Infection, Genetics and Evolution, 2018, 62, 141-150.	1.0	0
2129	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nature Communications, 2018, 9, 1251.	5.8	85
2130	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. Immunity, 2018, 48, 500-513.e6.	6.6	66
2131	The interaction between mitochondria and oncoviruses. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 481-487.	1.8	9
2132	Impact of HIV-1 Envelope Conformation on ADCC Responses. Trends in Microbiology, 2018, 26, 253-265.	3.5	64
2133	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. Journal of Biological Chemistry, 2018, 293, 1688-1701.	1.6	40
2134	Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. Journal of Virology, 2018, 92, .	1.5	8
2135	A Comparative Study of Binding of Different Drugs on gp120: Insight from Molecular Dynamics Simulation Study. Oriental Journal of Chemistry, 2018, 34, 2954-2962.	0.1	0
2136	Computational-guided determination of the functional role of 447-52D long CDRH3. Protein Engineering, Design and Selection, 2018, 31, 479-487.	1.0	0
2138	CCR5 structural plasticity shapes HIV-1 phenotypic properties. PLoS Pathogens, 2018, 14, e1007432.	2.1	27
2139	Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection. Frontiers in Microbiology, 2018, 9, 2940.	1.5	47
2140	Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor. Molecules, 2018, 23, 3036.	1.7	7
2141	Defining specific residueâ€toâ€residue interactions between the gp120 bridging sheet and the Nâ€terminal segment ofCCR5: applications of transferredNOE NMR. FEBS Journal, 2018, 285, 4296-4310.	2.2	2
2142	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. Cell Host and Microbe, 2018, 24, 579-592.e4.	5.1	88
2143	HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay. PLoS ONE, 2018, 13, e0206365.	1.1	0
2144	Common helical V1V2 conformations of HIV-1 Envelope expose the $\hat{1}\pm 4\hat{1}^27$ binding site on intact virions. Nature Communications, 2018, 9, 4489.	5.8	24

#	ARTICLE	IF	CITATIONS
2145	HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 347-364.	2.3	10
2146	Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. <i>Journal of Biological Chemistry</i> , 2018, 293, 15002-15020.	1.6	11
2147	Structural basis for murine norovirus engagement of bile acids and the CD300lf receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9201-E9210.	3.3	82
2148	Retrovirus Receptor Interactions and Entry. , 2018, , 1-49.		1
2149	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to $\text{H}^{\pm}4\text{I}27$. <i>PLoS Pathogens</i> , 2018, 14, e1007278.	2.1	29
2150	CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation. <i>PLoS Biology</i> , 2018, 16, e2005817.	2.6	25
2151	Ligand accessibility to the HIV-1 Env co-receptor binding site can occur prior to CD4 engagement and is independent of viral tier category. <i>Virology</i> , 2018, 519, 99-105.	1.1	4
2152	Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120. <i>European Journal of Medicinal Chemistry</i> , 2018, 154, 367-391.	2.6	35
2153	HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. <i>ELife</i> , 2018, 7, .	2.8	127
2154	Targeting Protein-Protein Interactions by Small Molecules. , 2018, , .		7
2155	Small Molecule Inhibitors Targeting New Targets of Protein-Protein Interactions. , 2018, , 179-211.		1
2156	Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7854-E7862.	3.3	28
2157	Hydroponic Treatment of <i>Nicotiana benthamiana</i> with Kifunensine Modifies the N-glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression. <i>Frontiers in Plant Science</i> , 2018, 9, 62.	1.7	18
2159	Advances in Membrane Proteins. , 2018, , .		0
2160	Probing Structural Variation and Dynamics in the HIV-1 Env Fusion Glycoprotein. <i>Current HIV Research</i> , 2018, 16, 5-12.	0.2	12
2161	Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane. <i>Frontiers in Immunology</i> , 2017, 8, 1853.	2.2	21
2162	The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses. <i>Viruses</i> , 2018, 10, 197.	1.5	18
2163	HIV Broadly Neutralizing Antibodies: VRC01 and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 53-72.	0.8	10

#	ARTICLE	IF	CITATIONS
2164	Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 73-95.	0.8	17
2165	Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection. <i>Purinergic Signalling</i> , 2018, 14, 309-320.	1.1	28
2166	The SIV Envelope Glycoprotein, Viral Tropism, and Pathogenesis: Novel Insights from Nonhuman Primate Models of AIDS. <i>Current HIV Research</i> , 2018, 16, 29-40.	0.2	12
2167	Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. <i>Cell Host and Microbe</i> , 2018, 23, 832-844.e6.	5.1	43
2168	Conformation-Dependent Interactions Between HIV-1 Envelope Glycoproteins and Broadly Neutralizing Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 794-803.	0.5	19
2169	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. <i>PLoS Pathogens</i> , 2018, 14, e1006913.	2.1	111
2170	HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120. <i>Journal of Virology</i> , 2018, 92, .	1.5	18
2171	Human Immunodeficiency Virus Vaccines. , 2018, , 400-429.e25.		0
2172	In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4. <i>Viruses</i> , 2019, 11, 746.	1.5	10
2173	Maxillary tooth transpositions and pressure root resorption: a case report. <i>Annals of Medicine</i> , 2024, 51, 150-150.	1.5	0
2174	Illuminating the virus life cycle with single-molecule FRET imaging. <i>Advances in Virus Research</i> , 2019, 105, 239-273.	0.9	11
2175	Structural elucidation and molecular dynamics study targeting the viral surface glycoproteins against HIV-2 infection. <i>Annals of Medicine</i> , 2024, 51, 151-151.	1.5	0
2176	Biological evaluation of molecules of the azaBINOL class as antiviral agents: Inhibition of HIV-1 RNase H activity by 7-isopropoxy-8-(naphth-1-yl)quinoline. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3595-3604.	1.4	19
2177	Alternative conformations of a major antigenic site on RSV F. <i>PLoS Pathogens</i> , 2019, 15, e1007944.	2.1	29
2178	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019, 178, 567-584.e19.	13.5	106
2179	Phylogenetic measures of indel rate variation among the HIV-1 group M subtypes. <i>Virus Evolution</i> , 2019, 5, vez022.	2.2	9
2180	Concurrent Exposure of Neutralizing and Non-neutralizing Epitopes on a Single HIV-1 Envelope Structure. <i>Frontiers in Immunology</i> , 2019, 10, 1512.	2.2	6
2181	Molecular Mechanism of HIV-1 Entry. <i>Trends in Microbiology</i> , 2019, 27, 878-891.	3.5	173

#	ARTICLE	IF	CITATIONS
2182	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	5.8	35
2183	Evaluation of Phytopolyphenols for their gp120-CD4 Binding Inhibitory Properties by In Silico Molecular Modelling & In Vitro Cell Line Studies. <i>Current HIV Research</i> , 2019, 17, 102-113.	0.2	8
2184	Interaction between gp120 and ligand in HIV-1 env protein: Molecular dynamics simulations and binding free energy calculations. <i>AIP Conference Proceedings</i> , 2019, , .	0.3	0
2185	New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System. <i>Cells</i> , 2019, 8, 1245.	1.8	51
2186	Synthesis of tris-tertiary amine CycloTriVeratrilene (TACTV) derivatives as water soluble pre-organized three aromatic ring containing molecular scaffolds for the construction of protein mimics. <i>Tetrahedron Letters</i> , 2019, 60, 151245.	0.7	2
2187	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. <i>Viruses</i> , 2019, 11, 705.	1.5	30
2188	Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer. <i>Journal of Virology</i> , 2019, 93, .	1.5	1
2189	CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies. <i>Journal of Virology</i> , 2019, 93, .	1.5	29
2190	A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
2191	Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention. <i>Cells</i> , 2019, 8, 1155.	1.8	15
2192	Stoichiometric Analyses of Soluble CD4 to Native-like HIV-1 Envelope by Single-Molecule Fluorescence Spectroscopy. <i>Cell Reports</i> , 2019, 29, 176-186.e4.	2.9	11
2193	Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity. <i>Viruses</i> , 2019, 11, 69.	1.5	20
2194	VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. <i>Frontiers in Immunology</i> , 2019, 9, 3163.	2.2	15
2195	Modeling interaction between gp120 HIV protein and CCR5 receptor. <i>Journal of Peptide Science</i> , 2019, 25, e3142.	0.8	4
2196	Glycosylation of viral surface proteins probed by mass spectrometry. <i>Current Opinion in Virology</i> , 2019, 36, 56-66.	2.6	31
2197	A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. <i>Cell Reports</i> , 2019, 27, 2593-2607.e5.	2.9	8
2198	Selective use of primate CD4 receptors by HIV-1. <i>PLoS Biology</i> , 2019, 17, e3000304.	2.6	10
2199	Magnetic Multiarm Scaffold for the One-Step Purification of Epitope-Specific Neutralizing Antibodies. <i>Analytical Chemistry</i> , 2019, 91, 6172-6179.	3.2	2

#	ARTICLE	IF	CITATIONS
2200	Superantigenic Activation of Human Cardiac Mast Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1828.	1.8	39
2201	Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States. <i>Journal of Virology</i> , 2019, 93, .	1.5	14
2202	VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. <i>Current Opinion in Virology</i> , 2019, 34, 149-159.	2.6	92
2203	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. <i>Nature Microbiology</i> , 2019, 4, 734-747.	5.9	158
2204	A Boundary-Integral Approach for the Poisson-Boltzmann Equation with Polarizable Force Fields. <i>Journal of Computational Chemistry</i> , 2019, 40, 1680-1692.	1.5	4
2205	Structural Vaccinology for Viral Vaccine Design. <i>Frontiers in Microbiology</i> , 2019, 10, 738.	1.5	47
2206	Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. <i>Nature</i> , 2019, 568, 415-419.	13.7	156
2207	B-cell restriction – an alternative piece to the puzzle. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2044-2049.	1.4	1
2208	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019, 15, e1007632.	2.1	20
2209	Rice stripe virus hitchhikes the vector insect vitellogenin ligand-receptor pathway for ovary entry. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180312.	1.8	18
2210	CD4 receptor diversity in chimpanzees protects against SIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3229-3238.	3.3	21
2211	HIV Associated Neurodegenerative Disorders: A New Perspective on the Role of Lipid Rafts in Gp120-Mediated Neurotoxicity. <i>Current HIV Research</i> , 2019, 16, 258-269.	0.2	21
2212	Asymmetric opening of HIV-1 Env bound to CD4 and a coreceptor-mimicking antibody. <i>Nature Structural and Molecular Biology</i> , 2019, 26, 1167-1175.	3.6	43
2213	HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. , 2019, , .		6
2214	Opening dynamics of HIV-1 gp120 upon receptor binding is dictated by a key hydrophobic core. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 26003-26016.	1.3	5
2215	Sensitive electrochemical detection of gp120 based on the combination of NBD-556 and gp120. <i>Talanta</i> , 2019, 196, 486-492.	2.9	14
2216	Conformational Differences between Functional Human Immunodeficiency Virus Envelope Glycoprotein Trimers and Stabilized Soluble Trimers. <i>Journal of Virology</i> , 2019, 93, .	1.5	22
2217	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	5.1	124

#	ARTICLE	IF	CITATIONS
2218	Computational analysis in designing T cell epitopes enriched peptides of Ebola glycoprotein exhibiting strong binding interaction with HLA molecules. <i>Journal of Theoretical Biology</i> , 2019, 465, 34-44.	0.8	19
2219	Effects of CD4 Binding on Conformational Dynamics, Molecular Motions, and Thermodynamics of HIV-1 gp120. <i>International Journal of Molecular Sciences</i> , 2019, 20, 260.	1.8	10
2220	Structural basis of coreceptor recognition by HIV-1 envelope spike. <i>Nature</i> , 2019, 565, 318-323.	13.7	165
2221	Allosteric Modulation. , 2019, , 173-205.		1
2222	Prediction and validation of HIV-1 gp41 ecto-transmembrane domain post-fusion trimeric structure using molecular modeling. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 2592-2603.	2.0	3
2223	Can we use structural knowledge to design a protective vaccine against HIV? <i>Hla</i> , 2020, 95, 95-103.	0.4	5
2224	Refolding Dynamics of gp41 from Pre-fusion to Pre-hairpin States during HIV-1 Entry. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 162-174.	2.5	6
2225	Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes. <i>Journal of Virology</i> , 2020, 94, .	1.5	15
2226	Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120. <i>Journal of Computer-Aided Molecular Design</i> , 2020, 34, 39-54.	1.3	11
2227	Critical design criteria for engineering a nanoparticulate HIV-1 vaccine. <i>Journal of Controlled Release</i> , 2020, 317, 322-335.	4.8	19
2228	SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in "lasso"™ for the multi-faced virus. <i>Inflammation Research</i> , 2020, 69, 801-812.	1.6	21
2229	Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies. <i>IScience</i> , 2020, 23, 101711.	1.9	4
2230	Antibody-guided structure-based vaccines. <i>Seminars in Immunology</i> , 2020, 50, 101428.	2.7	29
2231	Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains. <i>Cell Reports</i> , 2020, 33, 108432.	2.9	32
2232	Roles, Characteristics, and Analysis of Intrinsically Disordered Proteins: A Minireview. <i>Life</i> , 2020, 10, 320.	1.1	11
2233	Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site. <i>BMC Biology</i> , 2020, 18, 91.	1.7	20
2234	Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity. <i>Cell Reports</i> , 2020, 31, 107749.	2.9	14
2235	Second career of a biosynthetic enzyme: Lumazine synthase as a virus-like nanoparticle in vaccine development. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2020, 27, e00494.	2.1	18

#	ARTICLE	IF	CITATIONS
2237	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles. <i>Journal of Virology</i> , 2020, 94, .	1.5	15
2239	Visualization of the HIV-1 Env glycan shield across scales. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28014-28025.	3.3	57
2240	Immune activation correlates with and predicts CXCR4 co-receptor tropism switch in HIV-1 infection. <i>Scientific Reports</i> , 2020, 10, 15866.	1.6	19
2241	The Bipartite Sequence Motif in the N and C Termini of gp85 of Subgroup J Avian Leukosis Virus Plays a Crucial Role in Receptor Binding and Viral Entry. <i>Journal of Virology</i> , 2020, 94, .	1.5	13
2242	Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 300-308.	1.5	15
2243	Identification of novel molecular determinants of co-receptor usage in HIV-1 subtype F V3 envelope sequences. <i>Scientific Reports</i> , 2020, 10, 12583.	1.6	1
2244	Probing the Structure of the HIV-1 Envelope Trimer Using Aspartate Scanning Mutagenesis. <i>Journal of Virology</i> , 2020, 94, .	1.5	4
2245	Three functional mutation sites affect the immune response of pigs through altering the expression pattern and IgV domain of the CD4 protein. <i>BMC Molecular and Cell Biology</i> , 2020, 21, 91.	1.0	0
2246	A Protocol for Studying HIV-1 Envelope Glycoprotein Function. <i>STAR Protocols</i> , 2020, 1, 100133.	0.5	13
2247	Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers. <i>Microorganisms</i> , 2020, 8, 1722.	1.6	7
2248	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. <i>PLoS Pathogens</i> , 2020, 16, e1008577.	2.1	3
2249	Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. <i>Science Advances</i> , 2020, 6, eaba0468.	4.7	31
2250	The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. <i>MBio</i> , 2020, 11, .	1.8	37
2251	Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands. <i>Journal of Virology</i> , 2020, 94, .	1.5	21
2252	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
2253	Comparison of the antiviral activity of the microbicide candidate griffithsin and its tandemers derivatives against different modes of HIV-1 transmission. <i>Virology</i> , 2020, 544, 12-20.	1.1	7
2254	Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1778-1786.	1.3	11
2255	Characteristics of Plasmablast Repertoire in Chronically HIV-Infected Individuals for Immunoglobulin H and L Chain Profiled by Single-Cell Analysis. <i>Frontiers in Immunology</i> , 2020, 10, 3163.	2.2	4

#	ARTICLE	IF	CITATIONS
2256	Subnanometer structures of HIV-1 envelope trimers on aldrithiol-2-inactivated virus particles. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 726-734.	3.6	55
2257	Characterization of envelope sequence of HIV virus in children infected with HIV in Vietnam. <i>SAGE Open Medicine</i> , 2020, 8, 205031212093719.	0.7	4
2258	Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody. <i>Cell</i> , 2020, 180, 471-489.e22.	13.5	106
2259	Molecular dynamics simulations reveal distinct differences in conformational dynamics and thermodynamics between the unliganded and CD4-bound states of HIV-1 gp120. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 5548-5560.	1.3	12
2260	CD4-binding obstacles in conformational transitions and allosteric communications of HIV gp120. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2020, 1862, 183217.	1.4	6
2261	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. <i>Journal of Immunology</i> , 2020, 204, 1543-1561.	0.4	4
2262	HIV-1 did not contribute to the 2019-nCoV genome. <i>Emerging Microbes and Infections</i> , 2020, 9, 378-381.	3.0	38
2263	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. <i>Nature Communications</i> , 2020, 11, 520.	5.8	42
2264	Targeting the N332-supersite of the HIV-1 envelope for vaccine design. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 499-509.	1.5	10
2265	Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?. <i>Cell Host and Microbe</i> , 2020, 27, 507-518.	5.1	42
2266	Role of Divalent Cations in HIV-1 Replication and Pathogenicity. <i>Viruses</i> , 2020, 12, 471.	1.5	15
2267	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020, 27, 963-975.e5.	5.1	23
2268	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. <i>Journal of Virology</i> , 2020, 94, .	1.5	21
2269	HIV long-term non-progressors share similar features with simian immunodeficiency virus infection of chimpanzees. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 2447-2454.	2.0	4
2270	Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions. <i>Journal of Virology</i> , 2021, 95, .	1.5	26
2271	The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition. <i>Journal of Molecular Biology</i> , 2021, 433, 166748.	2.0	12
2272	Macromolecular crystallization: basics and advanced methodologies. <i>Journal of the Iranian Chemical Society</i> , 2021, 18, 543-565.	1.2	3
2273	Broadly neutralizing antibodies for HIV-1 prevention and therapy. <i>Seminars in Immunology</i> , 2021, 51, 101475.	2.7	28

#	ARTICLE	IF	CITATIONS
2274	Does Antibody Stabilize the Ligand Binding in GP120 of HIV-1 Envelope Protein? Evidence from MD Simulation. <i>Molecules</i> , 2021, 26, 239.	1.7	1
2275	Understanding the Structure and Function of Viral Glycosylation by Molecular Simulations: State-of-the-Art and Recent Case Studies. , 2021, , 405-415.		1
2276	Human Pannexin 1 channel: Insight in structureâ€“function mechanism and its potential physiological roles. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1529-1540.	1.4	15
2277	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. <i>MAbs</i> , 2021, 13, 1946918.	2.6	11
2278	Structure of Retrovirus Particles (Retroviridae). , 2021, , 352-361.		0
2279	Mathematical modeling of impact of eCD4-Ig molecule in control and management of HIV within a host. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 6887-6906.	1.0	0
2280	Single-Molecule FRET Imaging of Virus Spikeâ€“Host Interactions. <i>Viruses</i> , 2021, 13, 332.	1.5	18
2281	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. <i>Immunity</i> , 2021, 54, 324-339.e8.	6.6	36
2282	Therapeutic potential of HIV-1 entry inhibitor peptidomimetics. <i>Experimental Biology and Medicine</i> , 2021, 246, 1060-1068.	1.1	1
2283	Scouting the receptor-binding domain of SARSâ€“Coronavirusâ€“2: a comprehensive immunoinformatics inquisition. <i>Future Virology</i> , 2021, 16, 117-132.	0.9	5
2284	Cryo-EM structures of HIV-1 trimer bound to CD4-mimetics BNM-III-170 and M48U1 adopt a CD4-bound open conformation. <i>Nature Communications</i> , 2021, 12, 1950.	5.8	22
2286	CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	9
2287	Adjuvantâ€“mediated enhancement of the immune response to HIV vaccines. <i>FEBS Journal</i> , 2022, 289, 3317-3334.	2.2	10
2288	HIV-1 Entry and Membrane Fusion Inhibitors. <i>Viruses</i> , 2021, 13, 735.	1.5	34
2289	Robust CAR-T memory formation and function via hematopoietic stem cell delivery. <i>PLoS Pathogens</i> , 2021, 17, e1009404.	2.1	19
2290	Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 7555-7573.	2.0	15
2291	E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types. <i>SAR and QSAR in Environmental Research</i> , 2021, 32, 353-377.	1.0	3
2292	Playing around the anaerobic threshold during COVID-19 pandemic: advantages and disadvantages of adding bouts of anaerobic work to aerobic activity in physical treatment of individuals with obesity. <i>Acta Diabetologica</i> , 2021, 58, 1329-1341.	1.2	4

#	ARTICLE	IF	CITATIONS
2293	Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure. <i>Frontiers in Immunology</i> , 2021, 12, 688747.	2.2	13
2294	HIV-1 Envelope Conformation, Allostery, and Dynamics. <i>Viruses</i> , 2021, 13, 852.	1.5	6
2295	Bacterial β -D-glucoside metabolism: perspectives and potential for biotechnology and biomedicine. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 4033-4052.	1.7	12
2296	Aptamer Laden Liquid Crystals Biosensing Platform for the Detection of HIV-1 Glycoprotein-120. <i>Molecules</i> , 2021, 26, 2893.	1.7	10
2297	Evaluation of Microalgae Antiviral Activity and Their Bioactive Compounds. <i>Antibiotics</i> , 2021, 10, 746.	1.5	30
2299	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	1.7	3
2300	Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. <i>MBio</i> , 2021, 12, e0042921.	1.8	6
2301	Species-Specific Valid Ternary Interactions of HIV-1 Env-gp120, CD4, and CCR5 as Revealed by an Adaptive Single-Amino Acid Substitution at the V3 Loop Tip. <i>Journal of Virology</i> , 2021, 95, e0217720.	1.5	5
2302	Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies. <i>Viruses</i> , 2021, 13, 1405.	1.5	6
2304	Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application. <i>Frontiers in Immunology</i> , 2021, 12, 697683.	2.2	2
2305	Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10027-10046.	2.9	7
2306	Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer. <i>MBio</i> , 2021, 12, e0127421.	1.8	4
2308	Variability in the Glycosylation Patterns of gp120 Proteins from Different Human Immunodeficiency Virus Type 1 Isolates Expressed in Different Host Cells. <i>Journal of Proteome Research</i> , 2021, 20, 4862-4874.	1.8	5
2310	Intramolecular quality control: HIV-1 envelope gp160 signal-peptide cleavage as a functional folding checkpoint. <i>Cell Reports</i> , 2021, 36, 109646.	2.9	7
2311	Asymmetric Structures and Conformational Plasticity of the Uncleaved Full-Length Human Immunodeficiency Virus Envelope Glycoprotein Trimer. <i>Journal of Virology</i> , 2021, 95, e0052921.	1.5	20
2312	A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target. <i>Viruses</i> , 2021, 13, 1774.	1.5	10
2313	Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells. <i>MBio</i> , 2021, 12, e0140521.	1.8	3
2314	Small-Molecule Inhibition of Viral Fusion Glycoproteins. <i>Annual Review of Virology</i> , 2021, 8, 459-489.	3.0	9

#	ARTICLE	IF	CITATIONS
2316	HIV replication and latency in monocytes and macrophages. <i>Seminars in Immunology</i> , 2021, 51, 101472.	2.7	30
2317	Structure-based drug designing strategy to inhibit protein-protein-interactions using in silico tools. , 2021, , 139-171.		0
2318	Molecular Recognition of HIV Glycans by Antibodies. , 2014, , 117-141.		6
2319	The Carbohydrate Epitope of the Neutralizing Anti-HIV-1 Antibody 2G12. <i>Advances in Experimental Medicine and Biology</i> , 2003, 535, 205-218.	0.8	65
2320	The Protein Data Bank. , 1984, , 441-441.		23
2321	Role of Macrophages in the Immunopathogenesis of HIV-1 Infection. , 2015, , 723-744.		2
2322	Stable Drosophila Cell Lines: An Alternative Approach to Exogenous Protein Expression. <i>Methods in Molecular Biology</i> , 2016, 1350, 349-358.	0.4	24
2323	Resistance to Enfuvirtide and Other HIV Entry Inhibitors. , 2009, , 493-506.		1
2324	Protein Crystallization. , 2007, 383, 337-349.		4
2325	Identification of Viral Peptide Fragments for Vaccine Development. <i>Methods in Molecular Biology</i> , 2009, 515, 261-274.	0.4	5
2326	Structural Biology and the Design of Effective Vaccines for HIV-1 and Other Viruses. , 2010, , 387-402.		4
2327	Aptamer-Targeted RNAi for HIV-1 Therapy. <i>Methods in Molecular Biology</i> , 2011, 721, 355-371.	0.4	33
2328	Development of a Neural Network-Based Approach for Prediction of Potential HIV-1 Entry Inhibitors Using Deep Learning and Molecular Modeling Methods. <i>Lecture Notes in Computer Science</i> , 2020, , 304-311.	1.0	4
2329	Antibodies for HIV Treatment and Prevention: Window of Opportunity?. <i>Current Topics in Microbiology and Immunology</i> , 2008, 317, 39-66.	0.7	21
2330	Viral (HIV) Entry: How Does It Work?. , 2008, , 3-10.		1
2331	HIV-1 Entry and Its Inhibition. <i>Current Topics in Microbiology and Immunology</i> , 2003, 281, 1-27.	0.7	91
2332	Alpharetrovirus Envelope-Receptor Interactions. <i>Current Topics in Microbiology and Immunology</i> , 2003, 281, 107-136.	0.7	45
2333	Receptor Structure, Binding, and Cell Entry of Arenaviruses. <i>Current Topics in Microbiology and Immunology</i> , 2002, 262, 111-137.	0.7	52

#	ARTICLE	IF	CITATIONS
2334	Adenovirus Interaction with Its Cellular Receptor CAR. Current Topics in Microbiology and Immunology, 2003, 272, 331-364.	0.7	36
2335	Shape and Electrostatic Complementarity at Viral Antigen-Antibody Complexes. Current Topics in Microbiology and Immunology, 2001, 260, 45-53.	0.7	10
2336	Structural Studies on Viral Escape from Antibody Neutralization. Current Topics in Microbiology and Immunology, 2001, 260, 55-64.	0.7	11
2337	Prime Boost Regimens for Enhancing Immunity: Magnitude, Quality of Mucosal and Systemic Gene Vaccines. , 2012, , 183-204.		1
2338	Introduction to entry inhibitors in the management of HIV infection. , 2007, , 1-15.		1
2339	Inhibitors that target gp120-CD4 interactions. , 2007, , 49-62.		3
2340	Inhibitors that target gp120 interactions with coreceptor. , 2007, , 63-78.		1
2341	Structural and Functional Properties of Viral Membrane Proteins. , 2018, , 147-181.		5
2342	Introduction to Viruses and Viral Diseases. , 2010, , 1905-1921.		3
2343	Human Immunodeficiency Viruses. , 2010, , 2323-2335.		7
2344	The Role of Chemokine Receptors in HIV Infection of Host Cells. , 2003, , 191-196.		3
2345	Allosteric Drug Antagonism. , 2006, , 127-146.		2
2346	Human Mast Cells and Basophils in Immune Responses to Infectious Agents. , 2000, , 397-418.		8
2347	Mucosal Infection and Immune Responses to Simian Immunodeficiency Virus. , 2005, , 1179-1197.		1
2348	HIV VACCINES: MILESTONES AND NEW INSIGHTS. , 2000, , 421-457.		2
2349	Human immunodeficiency virus vaccines. , 2008, , 1213-1251.		2
2350	Biology of Viruses and Viral Diseases. , 2015, , 1681-1693.e4.		8
2351	Human Immunodeficiency Viruses. , 2015, , 2054-2065.e3.		3

#	ARTICLE	IF	CITATIONS
2352	Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase. <i>Biophysical Journal</i> , 2020, 119, 2275-2289.	0.2	13
2353	The Conformational States of the HIV-1 Envelope Glycoproteins. <i>Trends in Microbiology</i> , 2020, 28, 655-667.	3.5	66
2354	Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by β 7 integrin. <i>Virology</i> , 2017, 508, 199-212.	1.1	18
2355	Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design. <i>Chemical Biology</i> , 2017, , 300-357.	0.1	4
2356	Stable Isotope Labeling of Glycoproteins for NMR Study. <i>New Developments in NMR</i> , 2017, , 194-207.	0.1	5
2357	Uterocalin, a lipocalin provisioning the preattachment equine conceptus: fatty acid and retinol binding properties, and structural characterization. <i>Biochemical Journal</i> , 2001, 356, 369.	1.7	36
2358	The correlation of immunologic derangement and juvenile recurrent parotitis: an investigation of the laboratory immunological observation. <i>Acta Oto-Laryngologica</i> , 2018, 138, 1112-1116.	0.3	5
2359	The gp120 envelope of HIV-1 binds and presents peptides in a similar manner to human leukocyte antigen. <i>Aids</i> , 1999, 13, 1799.	1.0	2
2360	Development of an HIV-1 Reference Panel of Subtype B Envelope Clones Isolated From the Plasma of Recently Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 1-11.	0.9	41
2361	Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1. <i>Journal of General Virology</i> , 2000, 81, 949-955.	1.3	127
2362	Insertion/deletion frequencies match those of point mutations in the hypervariable regions of the simian immunodeficiency virus surface envelope gene. <i>Journal of General Virology</i> , 2001, 82, 1613-1619.	1.3	18
2363	Human immunodeficiency virus type 2. <i>Journal of General Virology</i> , 2002, 83, 1253-1265.	1.3	188
2364	Cell surface receptors, virus entry and tropism of primate lentiviruses. <i>Journal of General Virology</i> , 2002, 83, 1809-1829.	1.3	185
2365	Occupancy and mechanism in antibody-mediated neutralization of animal viruses. <i>Journal of General Virology</i> , 2002, 83, 2091-2108.	1.3	247
2366	Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India. <i>Journal of General Virology</i> , 2017, 98, 1879-1891.	1.3	25
2367	C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. <i>Journal of General Virology</i> , 2013, 94, 1-19.	1.3	33
2368	Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120. <i>Journal of General Virology</i> , 2008, 89, 2597-2604.	1.3	12
2377	A method for tethering single viral particles for virus-cell interaction studies with optical tweezers. , 2018, 10723, .		2

#	ARTICLE	IF	CITATIONS
2378	Designing HIV gp120 Peptide Vaccines: Rhetoric or Reality for Neuro-AIDS. , 0, , 105-119.		3
2379	The Relationship of T-Cell Epitopes and Allergen Structure. , 0, , 123-159.		1
2380	Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
2381	Current Concepts in Human Immunodeficiency Virus Infection and AIDS. Vaccine Journal, 1999, 6, 295-305.	2.6	13
2382	Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys. Journal of Virology, 1998, 72, 8437-8445.	1.5	42
2383	T-Tropic Human Immunodeficiency Virus Type 1 (HIV-1)-Derived V3 Loop Peptides Directly Bind to CXCR-4 and Inhibit T-Tropic HIV-1 Infection. Journal of Virology, 1998, 72, 9763-9770.	1.5	53
2384	Nuclear Magnetic Resonance Analysis of Solution Conformations in C4-V3 Hybrid Peptides Derived from Human Immunodeficiency Virus (HIV) Type 1 gp120: Relation to Specificity of Peptide-Induced Anti-HIV Neutralizing Antibodies. Journal of Virology, 1999, 73, 746-750.	1.5	11
2385	â€œHiddenâ€-dUTPase Sequence in Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 1999, 73, 751-753.	1.5	19
2386	Adaptation of a CCR5-Using, Primary Human Immunodeficiency Virus Type 1 Isolate for CD4-Independent Replication. Journal of Virology, 1999, 73, 8120-8126.	1.5	145
2387	Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 gp120 Involved in CCR5 Utilization. Journal of Virology, 1999, 73, 8216-8226.	1.5	112
2388	Lymphotropic Virions Affect Chemokine Receptor-Mediated Neural Signaling and Apoptosis: Implications for Human Immunodeficiency Virus Type 1-Associated Dementia. Journal of Virology, 1999, 73, 8256-8267.	1.5	125
2389	Determinants of Neutralization Resistance in the Envelope Glycoproteins of a Simian-Human Immunodeficiency Virus Passaged In Vivo. Journal of Virology, 1999, 73, 8873-8879.	1.5	59
2390	Minimal Incidence of Serum Antibodies Reactive with Intact Primary Isolate Virions in Human Immunodeficiency Virus Type 1-Infected Individuals. Journal of Virology, 1999, 73, 9638-9641.	1.5	18
2391	Determinants of CD4 Independence for a Human Immunodeficiency Virus Type 1 Variant Map outside Regions Required for Coreceptor Specificity. Journal of Virology, 1999, 73, 10310-10319.	1.5	111
2392	Use of a gp120 Binding Assay To Dissect the Requirements and Kinetics of Human Immunodeficiency Virus Fusion Events. Journal of Virology, 1999, 73, 10346-10358.	1.5	113
2393	CCR5-Mediated Human Immunodeficiency Virus Entry Depends on an Amino-Terminal gp120-Binding Site and on the Conformational Integrity of All Four Extracellular Domains. Journal of Virology, 1999, 73, 1645-1648.	1.5	43
2394	Effect of Mutations in the Second Extracellular Loop of CXCR4 on Its Utilization by Human and Feline Immunodeficiency Viruses. Journal of Virology, 1999, 73, 2576-2586.	1.5	85
2395	Opposite Effects of SDF-1 on Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 1999, 73, 3608-3615.	1.5	51

#	ARTICLE	IF	CITATIONS
2396	Host-Specific Modulation of the Selective Constraints Driving Human Immunodeficiency Virus Type 1 <i>env</i> Gene Evolution. <i>Journal of Virology</i> , 1999, 73, 3764-3777.	1.5	34
2397	Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, gp120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5. <i>Journal of Virology</i> , 1999, 73, 4145-4155.	1.5	205
2398	Cyanovirin-N Binds to gp120 To Interfere with CD4-Dependent Human Immunodeficiency Virus Type 1 Virion Binding, Fusion, and Infectivity but Does Not Affect the CD4 Binding Site on gp120 or Soluble CD4-Induced Conformational Changes in gp120. <i>Journal of Virology</i> , 1999, 73, 4360-4371.	1.5	122
2399	Subdomain Folding and Biological Activity of the Core Structure from Human Immunodeficiency Virus Type 1 gp41: Implications for Viral Membrane Fusion. <i>Journal of Virology</i> , 1999, 73, 4433-4438.	1.5	56
2400	Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope. <i>Journal of Virology</i> , 1999, 73, 4640-4650.	1.5	46
2401	Effects of Soluble CD4 on Simian Immunodeficiency Virus Infection of CD4-Positive and CD4-Negative Cells. <i>Journal of Virology</i> , 1999, 73, 5373-5380.	1.5	60
2402	Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains. <i>Journal of Virology</i> , 1999, 73, 5707-5713.	1.5	34
2403	Peptide Ligands to Human Immunodeficiency Virus Type 1 gp120 Identified from Phage Display Libraries. <i>Journal of Virology</i> , 1999, 73, 5795-5802.	1.5	78
2404	Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants. <i>Journal of Virology</i> , 1999, 73, 6271-6281.	1.5	182
2405	Replication-Competent Rhabdoviruses with Human Immunodeficiency Virus Type 1 Coats and Green Fluorescent Protein: Entry by a pH-Independent Pathway. <i>Journal of Virology</i> , 1999, 73, 6937-6945.	1.5	64
2406	CD4-Chemokine Receptor Hybrids in Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 1999, 73, 7453-7466.	1.5	14
2407	Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 1999, 73, 7489-7496.	1.5	77
2408	Expanded Tropism of Primary Human Immunodeficiency Virus Type 1 R5 Strains to CD4 + T-Cell Lines Determined by the Capacity To Exploit Low Concentrations of CCR5. <i>Journal of Virology</i> , 1999, 73, 7842-7847.	1.5	49
2409	Challenges in Designing HIV Env Immunogens for Developing a Vaccine. , 2008, , 327-379.		1
2410	Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. <i>Journal of Clinical Investigation</i> , 2000, 106, 1039-1052.	3.9	76
2411	Cell Death in HIV Infection. , 2005, , 95-108.		1
2412	A Novel Cell-Free Translation/Glycosylation System Prepared from Insect Cells.. <i>Journal of Bioscience and Bioengineering</i> , 2000, 90, 508-514.	1.1	1
2413	Whole Cell Cryo-Electron Tomography Reveals Distinct Disassembly Intermediates of Vaccinia Virus. <i>PLoS ONE</i> , 2007, 2, e420.	1.1	69

#	ARTICLE	IF	CITATIONS
2414	Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotypic Monoclonal Antibodies Mimicking the CD4-Binding Site. PLoS ONE, 2008, 3, e3423.	1.1	21
2415	Functional, Non-Clonal IgMa-Restricted B Cell Receptor Interactions with the HIV-1 Envelope gp41 Membrane Proximal External Region. PLoS ONE, 2009, 4, e7215.	1.1	20
2416	Limitations of Ab Initio Predictions of Peptide Binding to MHC Class II Molecules. PLoS ONE, 2010, 5, e9272.	1.1	45
2417	Restricted Genetic Diversity of HIV-1 Subtype C Envelope Glycoprotein from Perinatally Infected Zambian Infants. PLoS ONE, 2010, 5, e9294.	1.1	36
2418	Novel Peptides Based on HIV-1 gp120 Sequence with Homology to Chemokines Inhibit HIV Infection in Cell Culture. PLoS ONE, 2011, 6, e14474.	1.1	6
2419	Inhibition of HIV-1 Infection in Ex Vivo Cervical Tissue Model of Human Vagina by Palmitic Acid; Implications for a Microbicide Development. PLoS ONE, 2011, 6, e24803.	1.1	13
2420	Llama Antibody Fragments Recognizing Various Epitopes of the CD4bs Neutralize a Broad Range of HIV-1 Subtypes A, B and C. PLoS ONE, 2012, 7, e33298.	1.1	56
2421	Association of Enhanced HIV-1 Neutralization by a Single Y681H Substitution in gp41 with Increased gp120-CD4 Interaction and Macrophage Infectivity. PLoS ONE, 2012, 7, e37157.	1.1	20
2422	Structural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop. PLoS ONE, 2012, 7, e37530.	1.1	42
2423	Insights into the Structure, Correlated Motions, and Electrostatic Properties of Two HIV-1 gp120 V3 Loops. PLoS ONE, 2012, 7, e49925.	1.1	20
2424	Structural Plasticity and Conformational Transitions of HIV Envelope Glycoprotein gp120. PLoS ONE, 2012, 7, e52170.	1.1	23
2425	A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1. PLoS ONE, 2013, 8, e72054.	1.1	20
2426	Stabilizing Exposure of Conserved Epitopes by Structure Guided Insertion of Disulfide Bond in HIV-1 Envelope Glycoprotein. PLoS ONE, 2013, 8, e76139.	1.1	19
2427	Critical Amino Acids within the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein V4 N- and C-Terminals Contribute to Virus Entry. PLoS ONE, 2014, 9, e86083.	1.1	12
2428	Deletion of the Highly Conserved N-Glycan at Asn260 of HIV-1 gp120 Affects Folding and Lysosomal Degradation of gp120, and Results in Loss of Viral Infectivity. PLoS ONE, 2014, 9, e101181.	1.1	26
2429	HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor. PLoS ONE, 2015, 10, e0124839.	1.1	8
2430	A Transmembrane Domain GGxxG Motif in CD4 Contributes to Its Lck-Independent Function but Does Not Mediate CD4 Dimerization. PLoS ONE, 2015, 10, e0132333.	1.1	19
2431	HIV-1 Tropism Determines Different Mutation Profiles in Proviral DNA. PLoS ONE, 2015, 10, e0139037.	1.1	4

#	ARTICLE	IF	CITATIONS
2432	Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. <i>PLoS ONE</i> , 2015, 10, e0143245.	1.1	7
2433	Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene. <i>PLoS ONE</i> , 2016, 11, e0167690.	1.1	3
2434	Differentiating founder and chronic HIV envelope sequences. <i>PLoS ONE</i> , 2017, 12, e0171572.	1.1	3
2435	Probing the compartmentalization of HIV-1 in the central nervous system through its neutralization properties. <i>PLoS ONE</i> , 2017, 12, e0181680.	1.1	20
2436	Experimental Estimation of the Effects of All Amino-Acid Mutations to HIV™s Envelope Protein on Viral Replication in Cell Culture. <i>PLoS Pathogens</i> , 2016, 12, e1006114.	2.1	96
2437	Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response. <i>PLoS Pathogens</i> , 2017, 13, e1006614.	2.1	58
2438	An Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. <i>Receptors & Clinical Investigation</i> , 2017, 4, .	0.9	7
2439	Plasmonic Nanoparticles and Their Conjugates: Preparation, Optical Properties and Antimicrobial Activity. <i>Journal of Nanotechnology and Materials Science</i> , 2015, 2, 1-18.	0.1	3
2440	Primate models for human immunodeficiency virus infection. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2004, 51, 1-29.	0.4	5
2441	Novel approach to computer modeling of seven-helical transmembrane proteins: current progress in the test case of bacteriorhodopsin.. <i>Acta Biochimica Polonica</i> , 2001, 48, 53-64.	0.3	36
2442	Therapeutic Potential of Aptamer-siRNA Conjugates for Treatment of HIV-1. <i>BioDrugs</i> , 2012, 26, 393-400.	2.2	17
2443	Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions. <i>Current Pharmaceutical Design</i> , 2014, 20, 1293-1301.	0.9	41
2444	Current Computational Approaches for the Development of Anti-HIV Inhibitors: An Overview. <i>Current Pharmaceutical Design</i> , 2019, 25, 3390-3405.	0.9	13
2445	Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1599-1620.	1.0	7
2446	Recent Advances on the Use of Structural Biology for the Design of Novel Envelope Immunogens of HIV-1. <i>Current HIV Research</i> , 2014, 11, 464-472.	0.2	4
2447	HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development. <i>Current HIV Research</i> , 2013, 11, 427-438.	0.2	25
2448	Protein-Based HIV-1 Microbicides. <i>Current HIV Research</i> , 2014, 11, 576-594.	0.2	9
2449	Bioinformatic Analysis of HIV-1 Entry and Pathogenesis. <i>Current HIV Research</i> , 2014, 12, 132-161.	0.2	22

#	ARTICLE	IF	CITATIONS
2450	Discovery of Novel Candidate Therapeutics and Diagnostics Based on Engineered Human Antibody Domains. <i>Current Drug Discovery Technologies</i> , 2014, 11, 28-40.	0.6	20
2451	Exposing HIV-1 Env: Implications for therapeutic strategies. <i>Clinical and Investigative Medicine</i> , 2019, 42, E2-E6.	0.3	3
2452	Immunopathogenesis of HIV Infection. , 2002, , 11-92.		1
2453	Immune Control of HIV. <i>Journal of Life Sciences (Westlake Village, Calif)</i> , 2019, 1, .	1.8	13
2455	Synthesis of Novel Urea Bridged Macrocyclic Molecules Using BTC. <i>Heterocycles</i> , 2007, 73, 617.	0.4	13
2456	Journal of AIDS & Clinical Research. <i>Journal of AIDS & Clinical Research</i> , 2012, S8, 3.	0.5	45
2457	Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine. <i>Journal of AIDS & Clinical Research</i> , 2012, 01, .	0.5	9
2458	Synthetic Studies on Cyclic Guanidine Natural Products for the Elucidation of Their Controlling Mechanism of Protein-protein Interaction. <i>Yuki Gosei Kagaku Kyokaiishi/Journal of Synthetic Organic Chemistry</i> , 2006, 64, 539-547.	0.0	3
2459	Conservation, Compensation, and Evolution of N-Linked Glycans in the HIV-1 Group M Subtypes and Circulating Recombinant Forms. <i>Isrn Aids</i> , 2012, 2012, 1-9.	2.5	27
2460	HIV-1 envelope accessible surface and polarity: clade, blood, and brain. <i>Bioinformatics</i> , 2011, 6, 48-56.	0.2	6
2461	To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. <i>Frontiers in Immunology</i> , 2021, 12, 708227.	2.2	26
2462	How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. <i>Viruses</i> , 2021, 13, 2106.	1.5	7
2463	Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. <i>Retrovirology</i> , 2021, 18, 31.	0.9	3
2464	Mechanisms and in-vivo Significance of HIV-1 Neutralisation. , 2000, , 99-132.		0
2465	Biochemical Defense Mechanisms. , 2001, , 1831-1877.		1
2466	ã,»ãf³ãfÊã,ã, ã,ãf«ã,1è†œã,¿ãf³ãf'ã,`è³ãã@æ^ç†ÿã:ã^†ãã,ãf£ãfšãfãf³. <i>Uirusu</i> , 2001, 51, 95-100.	0.1	0
2472	AIDS Vaccines. , 2002, , 1-9.		0
2473	HIV-1 Receptor Interactions. , 2003, , 99-104.		0

#	ARTICLE	IF	CITATIONS
2474	Antibodyâ€™Antigen Recognition and Conformational Changes. , 2003, , 33-38.		1
2476	Role of Rafts in Virus Fusion and Budding. , 2005, , 127-142.		0
2477	Cell Death in HIV Infection: gp120. , 2005, , 111-124.		0
2478	Local structure for the HIV-1 gp120 V3 loop. Comparative analysis of the fragment conformations in HIV-MN and HIV-Thailand isolates. Biopolymers and Cell, 2005, 21, 536-547.	0.1	0
2479	Evaluation of current strategies to inhibit HIV entry, integration and maturation. , 2006, , 213-254.		0
2480	Characteristics of Allosterism in Drug Action. , 2006, , 19-37.		2
2481	HIV-1 infection: Is it time to reconsider our concepts?. International Journal of Molecular Medicine, 0, , .	1.8	5
2482	A brief history of AIDS. BMJ, The, 2006, 333, 0612450.	3.0	1
2483	Adaptative Immune Responses in HIV-1 Infection. , 2007, , 333-378.		0
2485	HIV-1 Infection and Drug-Abuse in IndiaÃ¢â€šâ€œAn Emerging Challenge. American Journal of Infectious Diseases, 2007, 3, 191-194.	0.1	0
2486	Virus Receptor Wars: Entry Molecules Used for and Against Viruses Associated with AIDS. , 2008, , 271-277.		0
2493	FELINE IMMUNODEFICIENCY VIRUS AND ITS RECEPTORS. Virus Reviews & Research: Journal of the Brazilian Society for Virology, 2010, 15, .	0.1	0
2494	HIV-1â€™Receptor Interactions. , 2010, , 97-101.		0
2495	Chapter 7. Structural Studies of Viral Proteins â€™ X-ray Crystallography. RSC Biomolecular Sciences, 2010, , 121-134.	0.4	0
2496	Chapter 12. Attachment and Entry: Receptor Recognition in Viral Pathogenesis. RSC Biomolecular Sciences, 2010, , 220-242.	0.4	0
2497	Chapter 15. Development of Anti-HIV Drugs. RSC Biomolecular Sciences, 2010, , 291-318.	0.4	0
2499	Single-Molecule Analysis of Cell-Virus Binding Interactions. , 2011, , 153-166.		0
2502	The Potential and Current Progress of Internalizing Molecules in Targeted Drug Delivery. Fundamental Biomedical Technologies, 2011, , 97-123.	0.2	0

#	ARTICLE	IF	CITATIONS
2503	Chapter 12. Managing the HIV Epidemic in the Developing World – Progress and Challenges. RSC Drug Discovery Series, 2011, , 322-365.	0.2	0
2504	17 The protein epitope mimetic approach to protein-protein interaction inhibitors. , 2011, , 295-324.		0
2505	Anti-HIV Therapy: Pipeline Approaches and Future Directions. South Asian Journal of Experimental Biology, 2011, 1, 1-8.	0.1	1
2509	An Introduction to the Current State of HIV Vaccine Research. Journal of AIDS & Clinical Research, 2012, 01, .	0.5	1
2510	Genetic Diversity and the Human Immunodeficiency Virus Type-1: Implications and Impact. , 0, , .		0
2511	Synthesis of Functional and Variable HIV-1 Envelope Glycoproteins. , 2013, , 75-122.		0
2513	Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy. Current Medicinal Chemistry, 2013, 20, 751-771.	1.2	4
2514	Computer-Aided Search for Novel Anti-Hiv-1 Agents Presenting Peptidomimetics of Neutralizing Antibodies and Evaluation of their Potential Inhibitory Activity by Molecular Modeling. Mathematical Biology and Bioinformatics, 2013, 8, 119-134.	0.1	2
2515	Characterization of Binding Mode of the Heterobiaryl gp120 Inhibitor in HIV-1 Entry: A Molecular Docking and Dynamics Simulation Study. Bulletin of the Korean Chemical Society, 2013, 34, 2466-2472.	1.0	0
2516	Anti-Carbohydrate HIV Vaccine Design. , 2014, , 143-176.		1
2517	CD4 Count of Art and Non-Art Hiv Positive Patients Attending Living Word Mission Hospital Abayi Aba, Abia State, Nigeria. IOSR Journal of Dental and Medical Sciences, 2014, 13, 41-46.	0.0	1
2519	The Protein Data Bank. , 1999, , 251-264.		1
2520	Designing a Vaccine Against HIV. Handbook of Experimental Pharmacology, 1999, , 357-396.	0.9	0
2521	The Potential Role of HLA Mimicry in the Pathogenesis of AIDS. , 1999, , 173-187.		0
2522	Physiological coreceptor use by dual-tropic HIV-1: one plus one equals one. Journal of Clinical Investigation, 1999, 104, 531-532.	3.9	0
2525	Virtual Screening of Novel Hiv-1 Entry Inhibitors Blocking Cd4-Binding Site of the Virus Envelope Gp120 Protein. Mathematical Biology and Bioinformatics, 2014, 9, 359-372.	0.1	3
2526	CCR5: A Cellular Doorway for HIV-1 Entry. Journal of Human Virology & Retrovirology, 2015, 2, .	0.1	0
2527	A COMPLETE HIV-1 Env CODING SEQUENCES FROM HIV ISOLATED IN CENTRAL JAVA, INDONESIA. KnE Life Sciences, 2015, 2, 27.	0.1	0

#	ARTICLE	IF	CITATIONS
2528	Contemporary HIV Vaccines: Tissue Resident T-Cells and Strategies to Prevent Mucosal Infection. Current Topics in Medicinal Chemistry, 2015, 16, 1107-1117.	1.0	3
2530	The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission. PLoS ONE, 2016, 11, e0161596.	1.1	4
2532	HIV/Oppportunistic Infections. , 2017, , 359-372.		0
2533	HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance. , 2017, , 545-557.		1
2534	HIV-1 Entry Inhibitor Resistance. , 2017, , 499-521.		0
2538	Tropism and Properties of the HIV-1 Envelope Glycoprotein in Transmission. , 2018, , 2081-2091.		0
2540	Molecular dynamics for structural complexes of potential HIV-1 inhibitors with the viral envelope gp120 protein. , 2018, 62, 576-584.	0.0	0
2542	Development of Potential HIV-1 Inhibitors by In Silico Click Chemistry And Molecular Modeling Methods. Mathematical Biology and Bioinformatics, 2018, 13, 507-525.	0.1	1
2543	Limitations to the Structure-Based Design of HIV-1 Vaccine Immunogens. , 2019, , 143-159.		0
2544	Antibody Complexes. Sub-Cellular Biochemistry, 2019, 93, 23-51.	1.0	1
2546	The Rational Design of Biological Complexity: A Deceptive Metaphor. , 2019, , 87-102.		0
2547	Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine. , 2019, , 163-188.		0
2548	Basic Research in HIV Vaccinology Is Hampered by Reductionist Thinking. , 2019, , 103-126.		0
2549	Reductionism and the Search for Structure: Function Relationships in Antibody Molecules. , 2019, , 59-70.		0
2550	Futuristic Methods for Determining HIV Co-receptor Use. , 2019, , 625-663.		0
2552	Virtual screening and identification of potential HIV-1 inhibitors based on the cross-reactive neutralizing antibody N6. , 2019, 63, 445-456.	0.0	2
2553	In silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6. Mathematical Biology and Bioinformatics, 2019, 14, 430-449.	0.1	2
2555	Identification of functional mimetics of anti-hiv antibody n6 by methods of virtual screening and molecular modeling. , 2019, 63, 561-571.	0.0	1

#	ARTICLE	IF	CITATIONS
2558	Evolutionary Temporal Footprint of an HIV-1 Envelope Protein in an Epidemiologically Linked Cluster. <i>Open AIDS Journal</i> , 2020, 14, 41-49.	0.1	0
2561	Domain Organization of Lentiviral and Betaretroviral Surface Envelope Glycoproteins Modeled with AlphaFold. <i>Journal of Virology</i> , 2022, 96, JVI0134821.	1.5	4
2562	Contributions of single-particle cryoelectron microscopy toward fighting COVID-19. <i>Trends in Biochemical Sciences</i> , 2022, 47, 117-123.	3.7	6
2563	HIV-associated neurodegenerative disorders: role of endoplasmic reticulum in Gp120-mediated neurotoxicity. <i>Aids</i> , 2020, 34, 2333-2334.	1.0	1
2564	Single Amino Acids G196 and R198 in hr1 of Subgroup K Avian Leukosis Virus Glycoprotein Are Critical for Tva Receptor Binding. <i>Frontiers in Microbiology</i> , 2020, 11, 596586.	1.5	10
2565	Anti-HIV Mechanism of Sulfated Poly and Oligosaccharides. <i>Journal of Fiber Science and Technology</i> , 2020, 76, 387-402.	0.2	3
2567	Binding Thermodynamics to Intrinsically Disordered Protein Domains. <i>Methods in Molecular Biology</i> , 2020, 2141, 449-462.	0.4	4
2568	Development of a generative adversarial neural network for identification of potential HIV-1 inhibitors by deep learning methods. <i>Informatika</i> , 2020, 17, 7-17.	0.1	1
2569	The development of a predictive model to identify potential HIV-1 attachment inhibitors. <i>Computers in Biology and Medicine</i> , 2020, 120, 103743.	3.9	1
2572	Synthetic peptide-based reagents for blocking the entry and inactivation of HIV. , 2002, , 258-259.		0
2573	Rational engineering of a miniprotein inhibitor of HIV-1 infectivity. , 2002, , 516-518.		0
2574	HIV gp41: A Viral Membrane Fusion Machine. , 2005, , 35-47.		2
2575	Proteomics of HIV-1 Virion. , 2004, , 339-365.		0
2576	Chemokine Receptors and HIV/AIDS. , 2007, , 259-293.		0
2579	Application of Deep Learning and Molecular Modelling Methods to Identify Potential HIV-1 Entry Inhibitors. , 0, , .		0
2612	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. <i>Human Antibodies</i> , 2005, 14, 59-67.	0.6	109
2613	Sources of variation in ancestral sequence reconstruction for HIV-1 envelope genes. <i>Evolutionary Bioinformatics</i> , 2007, 2, 53-76.	0.6	2
2615	Rational design of vaccines for AIDS and influenza. <i>Transactions of the American Clinical and Climatological Association</i> , 2012, 123, 9-15; discussion 15-6.	0.9	5

#	ARTICLE	IF	CITATIONS
2616	Preparation of biologically active single-chain variable antibody fragments that target the HIV-1 gp120 V3 loop. <i>Cellular and Molecular Biology</i> , 2012, 58, 71-9.	0.3	5
2617	Biomedical approaches to HIV prevention. <i>Alcohol Research</i> , 2010, 33, 195-202.	1.0	3
2621	Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development. <i>World Journal of Gastroenterology</i> , 2000, 6, 465-469.	1.4	4
2623	Immune Control of HIV. <i>Journal of Life Sciences (Westlake Village, Calif)</i> , 2019, 1, 4-37.	1.8	7
2624	Human Immunodeficiency Virus 1 (HIV-1): Viral Latency, the Reservoir, and the Cure. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 549-560.	0.2	7
2625	Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses. <i>American Journal of Cancer Research</i> , 2021, 11, 2430-2455.	1.4	1
2626	Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus. <i>Cardiology Clinics</i> , 2022, 40, 45-54.	0.9	3
2627	The Gp120 Alters its Conformation to Enhance Evasiveness and Infectivity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2628	Recent research results have converted gp120 binders to a therapeutic option for the treatment of HIV-1 infection. A medicinal chemistry point of view. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114078.	2.6	7
2629	Viral dUTPases: Modulators of Innate Immunity. <i>Biomolecules</i> , 2022, 12, 227.	1.8	2
2630	Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment. <i>Journal of Molecular Biology</i> , 2022, 434, 167395.	2.0	1
2631	Identification of HIV Rapid Mutations Using Differences in Nucleotide Distribution over Time. <i>Genes</i> , 2022, 13, 170.	1.0	3
2632	Functional nucleic acids in glycobiology: A versatile tool in the analysis of disease-related carbohydrates and glycoconjugates. <i>International Journal of Biological Macromolecules</i> , 2022, 201, 592-606.	3.6	9
2634	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer. <i>Nature Communications</i> , 2022, 13, 732.	5.8	19
2635	Infectious RNA: Human Immunodeficiency Virus (HIV) Biology, Therapeutic Intervention, and the Quest for a Vaccine. <i>Toxins</i> , 2022, 14, 138.	1.5	6
2637	Conformational plasticity of the HIV-1 gp41 immunodominant region is recognized by multiple non-neutralizing antibodies. <i>Communications Biology</i> , 2022, 5, 291.	2.0	3
2638	Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation. <i>Journal of Virology</i> , 2022, 96, e0166821.	1.5	13
2639	Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities. <i>Vaccines</i> , 2022, 10, 384.	2.1	3

#	ARTICLE	IF	CITATIONS
2640	The HIV Env Glycoprotein Conformational States on Cells and Viruses. <i>MBio</i> , 2022, 13, e0182521.	1.8	11
2642	Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin. <i>Frontiers in Immunology</i> , 2022, 13, 842831.	2.2	6
2643	HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers. <i>Biomedicines</i> , 2022, 10, 768.	1.4	4
2644	Folding molecular dynamics simulation of Tâ€peptide, a <scp>HIV</scp> viral entry inhibitor: Structure, dynamics, and comparison with the experimental data. <i>Journal of Computational Chemistry</i> , 2022, 43, 942-952.	1.5	0
2645	Small-molecule HIV-1 entry inhibitors targeting the epitopes of broadly neutralizing antibodies. <i>Cell Chemical Biology</i> , 2022, 29, 757-773.	2.5	4
2646	Deep-Time Structural Evolution of Retroviral and Filoviral Surface Envelope Proteins. <i>Journal of Virology</i> , 2022, 96, e0006322.	1.5	6
2648	Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs. <i>European Journal of Medicinal Chemistry</i> , 2022, 233, 114217.	2.6	27
2649	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101819.	1.6	9
2650	Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 Bâ€2 subtype infected individual with broadly neutralization activity. <i>Molecular Immunology</i> , 2022, 145, 50-58.	1.0	0
2651	IgG1-b12â€HIV-gp120 Interface in Solution: A Computational Study. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 359-371.	2.5	1
2652	Multiple binding modes of an Nâ€terminal CCR5â€peptide in complex with HIVâ€1 gp120. <i>FEBS Journal</i> , 2022, 289, 3132-3147.	2.2	2
2653	CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target. <i>Cancers</i> , 2022, 14, 86.	1.7	14
2654	Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 27-43.	0.8	0
2655	Structural basis for llama nanobody recognition and neutralization of HIV-1 at the CD4-binding site. <i>Structure</i> , 2022, 30, 862-875.e4.	1.6	4
2677	AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy. , 0, , 1369-1384.		0
2678	ACE2 and COVID-19 Susceptibility and Severity. , 2022, 13, 360.		18
2680	One arrow for two targets: potential co-treatment regimens for lymphoma and HIV. <i>Blood Reviews</i> , 2022, , 100965.	2.8	1
2681	Targeting Câ€C Chemokine Receptor 5: Key to Opening the Neurorehabilitation Window After Ischemic Stroke. <i>Frontiers in Cellular Neuroscience</i> , 2022, 16, 876342.	1.8	6

#	ARTICLE	IF	CITATIONS
2682	Residues 140â€“142, 199â€“200, 222â€“223, and 262 in the Surface Glycoprotein of Subgroup A Avian Leukosis Virus Are the Key Sites Determining Tva Receptor Binding Affinity and Infectivity. <i>Frontiers in Microbiology</i> , 2022, 13, 868377.	1.5	1
2683	A Controlled Phase II Trial Assessing Three Doses of Enfuvirtide (T-20) in Combination with Abacavir, Amprenavir, Ritonavir and Efavirenz in Non-Nucleoside Reverse Transcriptase Inhibitor-Naive HIV-Infected Adults. <i>Antiviral Therapy</i> , 2003, 8, 279-287.	0.6	63
2684	The Safety and Tolerability of Z-100 in Patients Infected with HIV-1. <i>Antiviral Therapy</i> , 2006, 11, 297-303.	0.6	1
2685	Interacci3n de linfocitos T CD4 con el segmento V3 de la glicoproteÃna 120 presente en el Virus de Inmunodeficiencia Humana tipo 1. <i>Revista CientÃfica De La Facultad De Ciencias QuÃmicas Y Farmacia</i> , 0, , 41-65.	0.1	0
2686	Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env. <i>PLoS Pathogens</i> , 2022, 18, e1010531.	2.1	3
2688	Human Papillomavirus Minor Capsid Protein L2 Mediates Intracellular Trafficking into and Passage beyond the Endoplasmic Reticulum. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
2690	Carbohydrates based stimulus responsive nanocarriers for cancer-targeted chemotherapy: a review of current practices. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 623-640.	2.4	10
2691	Structural dynamics reveal isolate-specific differences at neutralization epitopes on HIV Env. <i>IScience</i> , 2022, 25, 104449.	1.9	16
2693	Triazolyl Ru(II), Os(II), and Ir(III) complexes as potential HIV-1 inhibitors. <i>BioMetals</i> , 0, , .	1.8	2
2694	Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability. <i>Current Protein and Peptide Science</i> , 2023, 24, 59-77.	0.7	4
2696	Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
2697	Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection. <i>Aids</i> , 0, Publish Ahead of Print, .	1.0	1
2699	Genetic adaptations to SIV across chimpanzee populations. <i>PLoS Genetics</i> , 2022, 18, e1010337.	1.5	0
2700	Structural and Mechanistic Evidence for Calcium Interacting Sites in the HIV Transmembrane Protein gp41 Involved in Membrane Fusion. <i>Biochemistry</i> , 2022, 61, 1915-1922.	1.2	2
2701	Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation. <i>Pathogens</i> , 2022, 11, 891.	1.2	1
2702	Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound. <i>Journal of Virology</i> , 0, , .	1.5	9
2704	A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. <i>Science Advances</i> , 2022, 8, .	4.7	11
2705	HIV-1 replication in CD4+ T cell lines: the effects of adaptation on co-receptor use, tropism, and accessory gene function. <i>Journal of Leukocyte Biology</i> , 2000, 68, 331-337.	1.5	13

#	ARTICLE	IF	CITATIONS
2706	Allosteric modulation. , 2022, , 233-267.		0
2708	Residues L55 and W69 of Tva Mediate Entry of Subgroup A Avian Leukosis Virus. <i>Journal of Virology</i> , 2022, 96, .	1.5	1
2710	Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression. <i>Biomedicines</i> , 2022, 10, 2172.	1.4	3
2713	Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods. <i>Biophysical Reviews</i> , 2022, 14, 1109-1140.	1.5	15
2714	Structural principles of B cell antigen receptor assembly. <i>Nature</i> , 2022, 612, 156-161.	13.7	26
2715	HIV-1 Vpu restricts Fc-mediated effector functions in vivo. <i>Cell Reports</i> , 2022, 41, 111624.	2.9	8
2717	Structural and Functional Characterization of Indane-Core CD4-Mimetic Compounds Substituted with Heterocyclic Amines. <i>ACS Medicinal Chemistry Letters</i> , 2023, 14, 51-58.	1.3	3
2718	Antiviral Effect of Saffron Compounds on the GP120 of HIV-1: an In Silico Study. <i>ChemistrySelect</i> , 2022, 7, .	0.7	2
2719	Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers. <i>Journal of Virology</i> , 2022, 96, .	1.5	4
2720	Molecular Complementarity of Proteomimetic Materials for Target-Specific Recognition and Recognition-Mediated Complex Functions. <i>Advanced Materials</i> , 2023, 35, .	11.1	1
2721	Structural Basis of the gp120 Superantigen-Binding Site on Human Immunoglobulins. <i>Journal of Immunology</i> , 1998, 161, 6681-6688.	0.4	54
2722	Selection of HIV-Specific Immunogenic Epitopes by Screening Random Peptide Libraries with HIV-1-Positive Sera. <i>Journal of Immunology</i> , 1999, 162, 6155-6161.	0.4	81
2723	Induction of Phosphorylation and Intracellular Association of CC Chemokine Receptor 5 and Focal Adhesion Kinase in Primary Human CD4+ T Cells by Macrophage-Tropic HIV Envelope. <i>Journal of Immunology</i> , 1999, 163, 420-426.	0.4	68
2724	Substitution of gp120 C4 region compensates for V3 loss-of-fitness mutations in HIV-1 CRF01_AE co-receptor switching. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	2
2725	Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity. <i>Cell Reports</i> , 2023, 42, 111983.	2.9	5
2726	Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry. <i>Molecules</i> , 2023, 28, 474.	1.7	3
2727	Mutation in the D1 domain of CD4 receptor modulates the binding affinity to HIV-1 gp120. <i>RSC Advances</i> , 2023, 13, 2070-2080.	1.7	1
2730	Adeno-associated virus receptor complexes and implications for adeno-associated virus immune neutralization. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	4

#	ARTICLE	IF	CITATIONS
2734	CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals. <i>Science Immunology</i> , 2023, 8, .	5.6	8
2735	A review on synthesis of antiviral drugs, in silico studies and their toxicity. <i>Journal of the Indian Chemical Society</i> , 2023, 100, 100936.	1.3	1
2736	Study on molecular mechanisms of CD4 dependency and independency of HIV-1 gp120. <i>RSC Advances</i> , 2023, 13, 6274-6286.	1.7	0
2738	The crystal structure of a simian Foamy Virus receptor binding domain provides clues about entry into host cells. <i>Nature Communications</i> , 2023, 14, .	5.8	1
2739	Monoclonal CCR5 Antibody: A Promising Therapy for HIV. <i>Current HIV Research</i> , 2023, 21, .	0.2	0
2740	Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120. <i>Cell Chemical Biology</i> , 2023, 30, 540-552.e6.	2.5	6
2741	Molecular imprinting and surface grafting of glycoprotein fragments in polymeric nanosystems: from cancer diagnosis to virus targeting. , 2023, , 787-841.		1
2742	Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	5
2744	Viral Diseases: Cellular Understanding of Diseases. , 2023, , 27-63.		1
2753	Structural dynamics of chemokine receptors. <i>Vitamins and Hormones</i> , 2023, , .	0.7	0
2768	PRACTICAL APPLICATIONS OF MACHINE LEARNING FOR ANTI-INFECTIVE DRUG DISCOVERY. <i>Medicinal Chemistry Reviews</i> , 0, , 345-375.	0.1	0
2786	Central nervous system complications of human immunodeficiency virus infection. , 2024, , 23-43.		0